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ABSTRACT 
DESIGN AND SYNTHESIS OF SELECTIVE ESTROGEN RECEPTOR β 
AGONISTS AND THEIR PHARMACOLOGY 
K. L. Iresha Sampathi Perera, B.Sc. (Hons), M.Sc. 
 
Marquette University, 2017 
Estrogens (17β-estradiol, E2) have garnered considerable attention in influencing 
cognitive process in relation to phases of the menstrual cycle, aging and menopausal 
symptoms.  However, hormone replacement therapy can have deleterious effects leading 
to breast and endometrial cancer, predominantly mediated by estrogen receptor-alpha 
(ERα) the major isoform present in the mammary gland and uterus.  Further evidence 
supports a dominant role of estrogen receptor-beta (ERβ) for improved cognitive effects 
such as enhanced hippocampal signaling and memory consolidation via estrogen activated 
signaling cascades.   
Creation of the ERβ selective ligands is challenging due to high structural similarity 
of both receptors.  Thus far, several ERβ selective agonists have been developed, however, 
none of these have made it to clinical use due to their lower selectivity or considerable side 
effects.  The research in this dissertation involved the design of non-steroidal ERβ selective 
agonists for hippocampal memory consolidation.  The step-wise process to achieve the 
ultimate goal of this research includes: (1) design and synthesis of (4-
hydroxyphenyl)cyclohexyl or cycloheptyl derivatives, (2) in vitro biological evaluation of 
synthesized compounds to identify highly potent and selective candidates, and (3) in vivo 
biological evaluation of selected candidates for hippocampal memory consolidation. 
Several (4-hydroxyphenyl)cyclohexyl or cycloheptyl derivatives were synthesized 
having structural alterations on both aromatic and cyclohexyl/heptyl ring scaffolds.  ERβ 
agonist potency was initially evaluated in TR-FRET ERβ ligand binding assay and 
compounds having high potency were re-evaluated in functional cell based assays for 
potency and ERβ vs. ERα selectivity.  Two compounds from each series, ISP 163-PK4 and 
ISP 358-2 were identified as most selective ERβ agonists.  Both compounds revealed high 
metabolic stability, solubility and no cross reactivity towards other nuclear receptors.  In 
vivo efficiency of ISP 358-2 was evaluated in ovariectomized mice (C57BL/6) with object 
recognition (OR) and object placement (OP) tasks.  The results indicate improved memory 
consolidation at 100 pg/ hemisphere and 0.5 mg/Kg via DH infusion and IP injection 
respectively.  The information learned from this project serves as a foundation for 
development of other cycloheptyl/hexyl based ERβ agonists or antagonists having 
acceptable pharmacological profiles.  
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CHAPTER 1 
BACKGROUND AND GOALS OF RESEARCH 
The goal of this research is the design, synthesis and biological evaluation of 
estrogen receptor β (ERβ) selective agonists for hippocampal memory consolidation for 
potential use by postmenopausal women. 
1.1 Discovery of Estrogen Receptors 
Estrogens, such as 17β-estradiol (E2, Figure 1.1), play an important role in the 
growth, development and maintenance of a variety of tissues which are mainly mediated 
by the estrogen receptor (ER), a ligand-activated transcription factor.1-2  There are two 
distinct subtypes of estrogen receptors, ERα and ERβ, which are found to diverge with 
respect to their transcriptional activities and tissue distribution.2-4  Since the first 
observations by Jensen and co-workers in 19685 that exogenous estrogen binds to a specific 
receptor protein in the rat uterus, this estrogen receptor protein (ERα) has been extensively 
studied.  The gene which encodes for ERα (ESR1 located on chromosome 6) was 
successfully cloned in 1986.4  Until 1995, it was believed that there was a single ER which 
was responsible for facilitating all the biological effects of estrogens.  Thus, it was a 
surprise when, in 1995, a second distinct estrogen receptor from rat prostate was reported 
by the Gustafson’s group.  This later estrogen receptor is known as ERβ and the gene which 
encodes for ERβ is located on chromosome 14.4, 6-8 
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Figure 1.1: Structure of 17β-estradiol (E2) 
The two receptors, ERα and ERβ, display overlapping but distinct patterns of tissue 
distributions as well as different types of transcriptional regulation.9-10  ERα is highly 
expressed in the breast, liver and uterus and contributes to the malignant growth in these 
tissues, whereas ERβ has counteractive anti-proliferative effects on breast cancer cell 
lines.11-13  In addition, ERβ is expressed in the lungs, prostate, colon, brain and 
gastrointestinal tract and upon binding of estradiol, it exerts beneficial effects in these 
organs/ tissues without the risk of breast cancer.9, 11, 14 These differential effects prompted 
researchers to develop novel ERβ selective ligands (agonists / antagonists)9 
1.2 Estrogen Receptors and Human Disease 
The prevalence of breast cancer remains highest among all the cancers in women 
and it is the leading cause of cancer-related mortality within the United States.15-16  While 
initiation and progression of breast cancer involves several environmental and genetic 
factors, estrogen and ERs plays a vital role in the progression and treatment of this disease.  
Approximately 70% of breast cancers are ERα positive and respond to the selective 
estrogen receptor modulator (SERMs) prodrug tamoxifen as part of anti-estrogen 
therapy.4, 17-18  While, tamoxifen has relatively low binding to either ERα or ERβ (7% and 
6% relative binding affinity (RBA) compared to estradiol), it is metabolized by cytochrome 
P450 enzymes into 4-hydroxytamoxifen (4-OHT) which has greatly increased binding 
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affinity (178% and 338% RBA compared to estradiol)(Scheme 1.1).19  Competitive binding 
of 4-OHT to ERα effects a decrease in expression of cyclin D1 (important for cell 
progression through the G1 phase), and c-myc (which regulates cell growth).  These 
changes eventually lead to repression of Bcl2, which regulates anti-apoptosis, thus leading 
to increased cell death.4, 20  In estrogen-sensitive malignancies ERα usually act as an 
oncogene whereas ERβ is a tumor suppressor which clearly reveals a divergent relationship 
(yin/yang relation) between the ER subtypes.4 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.1: The major metabolic pathway involves initial conversion of tamoxifen to N- 
desmethyl-tamoxifen and 4-hydroxy-tamoxifen followed by conversion to 
endoxifen via CYP450s21 
Estrogen and its receptors are essential for the development and branching 
morphogenesis of the prostate.  ERβ is predominantly expressed in both human and rodent 
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prostate in comparison to ERα.  So far, ERβ shows anti-proliferative effects for certain 
prostate cancer cell lines (DU145) by repressing key oncogenes such as 
phosphatidylinositol 3-kinase (PI3K), c-myc, cyclin E (which is involved in promotion of 
cells from the S phase to the G1 phase) and stimulating the expressions of anti-proliferative 
genes such as the phosphatase and tension homolog (PTEN), Forkhead box O3 protein 
(FOXO3) which functions as a trigger for apoptosis, and cyclin-dependent kinase inhibitor 
1 (CDKN1A) which regulates cell cycle progression at the G1 and S phases.4, 22-23 
Osteoporosis is defined as the loss of bone mass and strength, mainly due to 
increased bone resorption and this condition is associated with estrogen deficiency.3  In 
ERα knock-out (αERKO) mice, shorter bone lengths and reduced mineral density were 
observed in comparison to wild type mice.3, 24  Conversely, adult female ERβ knock-out 
(βERKO) mice were found to have slightly higher bone mineral density, signifying a 
regulatory role for ERβ in bone growth.3, 25  Similarly, male mice deficient in ERα, or both 
ERα and ERβ, (due to knock-out) exhibited reduced bone mineral density, bone diameter 
and length, while male mice with only ERβ knockout did not exhibit these reductions.3, 26  
These observations suggest the significance of ERα in bone mass regulation.  
ERs also have profound effects in the brain, mainly in brain injury, 
neurodegeneration and cognitive decline.27  Both ERs are distributed in numerous regions 
of the brain such as the hypothalamus, hippocampus, cerebral cortex, forebrain and 
midbrain.23  Dubal, et al., demonstrated that the removal of ERα completely abolished the 
protective role in brain injury, whereas the protection is preserved in the absence of ERβ 
in ovariectomized / ischemia mice models.23, 27  Another study, where stroke was induced 
from reversible middle cerebral artery (MCA) occlusion, found that no enhanced tissue 
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damage was observed in female αERKNO mice.28  This indicates the subtype independent 
nature of estrogen action towards brain injury prevention.  Impressively, Gustafsson, et al. 
showed an abundance of morphological abnormalities such as neuronal loss and 
proliferation of astroglial cells in the brains of βERKO mice and.no changes were observed 
in αERKO mice.29  Moreover, several researchers conclude that ERβ is crucial for neuron 
survival and its valuable influence on treatment of neurodegenerative diseases including 
Alzheimer disease, Parkinson disease, and schizophrenia.7, 23, 30 
1.2.1 Estradiol, the Hippocampus and Memory 
A plethora of literature accumulated over last twenty years has demonstrated that 
17β-estradiol (E2) is an important trophic factor that mediates the function of cognitive 
regions of the brain.31  “The importance of estrogen in cognitive function has been 
highlighted by examining cognition in relation to phases of the menstrual cycle, 
menopausal symptoms, circulating hormone levels and aging.”32  The decline in E2 
production as a result of menopause is linked with etiology of dementia, depression and 
cognitive decline in women, as well as rapid memory decline in animal models.31 
According to recent studies, it is evident that E2 governs the dendritic length in the 
basal forebrain and neuronal dendritic spine density in the somatosensory cortex, the 
amygdala, and the prefrontal cortex of the brain.33  Similarly, estradiol controls 
morphology and synaptic plasticity in the hippocampus; the major brain region responsible 
for cognitive activity.  So far, several mechanisms of action for the effects of estradiol on 
cognitive functions of the hippocampus have been recognized through several distinct 
pathways.  E2 promotes the formation of new dendritic spines and excitatory synapses, and 
stimulates the expression of N-methyl-D-aspartate (NMDA) mediated synaptic activity.  
6 
 
 
 
Moreover, E2 increases the phosphorylation of the cAMP response element binding 
protein (CREB) and long term potentiation (LP) which are highly responsible for the 
learning and long-term memory.32-34 
ERα and ERβ are confined in several compartments in hippocampal neurons, such 
as the nucleus, axon terminals and dendritic spine synapses.  In the nucleus, ERs mediate 
the estrogen effects on the classical genomic pathway leading to the gene transcription.  
However, the localization of ERs at distal sites, such as dendritic spines and axon terminals, 
proposed the possibility of a “non-genomic” or “non-classical” mechanism of estrogen 
receptors.  Indeed, binding of both ERs to the metabotropic glutamate receptor 1 (mGluR1) 
triggers the hippocampal extracellular signal-regulated kinase (ERK) signaling and 
promotes CREB phosphorylation.  The interaction of E2 with NMDA receptor also triggers 
ERK signaling as well as local protein synthesis.  Both ERK and CERB play pivotal role 
in hippocampal memory consolidation.  Besides intracellular ERs, several putative 
membrane bound ERs have been identified (e.g. GPER, ER-X and Gq-ER).  E2 binds to 
these receptors and enhances the memory consolidation by activating the c-Jun N-terminal 
kinase (JNK) cascade, which eventually facilitates gene transcription and protein 
translation (Figure 1.2)31, 33 
 
  
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 1.2: Schematic illustration of non-classical mechanisms required for E2 and ERs 
                     to enhance hippocampal memory consolidation33 
Though estrogen has been involved in influencing cognitive functions, the sub type 
of estrogen receptor responsible for these effects remain unclear.  However, accumulating 
biochemical, pharmacological and behavioral studies support the key role of ERβ for 
hippocampal memory and synaptic plasticity.  A few selected examples are discussed 
here.32-33 
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In general, hippocampal memory in rodents have been primarily evaluated in 
spatial tasks, including object placement, the Morris water maze and the radial arm maze, 
as well as through object recognition tasks.33  In 2002, Gustafsson and coworkers, 
demonstrated that removal of either receptor (by ERα or ERβ knockouts) impairs the 
spatial memory in the Morris water maze 31, 35-36  Semple-Rewland, et al., showed that 
spatial memory deficit induced by ERα knockouts can be restored by viral vector-mediated 
delivery of the ERα gene to the hippocampus.  However, the same delivery of the ERα 
gene to the hippocampus did not restore memory deficit in ERβ knockout mice.31, 37  
Moreover, both Walf, et al.31, 38-39and Brandon, et al.32showed that exogenously 
administrated E2 did not enhanced the hippocampal memory in female ERβ knockout 
mice.  
Besides the memory related studies, Brandon and coworkers examined the 
molecular events driven by ERβ in the hippocampus.32  Since estrogen exerts effects on 
synaptic physiology by activating non-genomic signaling cascades (MAPK), the 
abundance of pCREB levels were monitored in ovariectomized rats.  Dosing 
ovariectomized rats with ERβ selective agonist (WAY-200070) and estradiol significantly 
increased the phosphorylated cAMP response element binding (pCREB) levels; there were 
not pCREB level increases observed with administration of the ERα selective agonist PPT 
(Figure 1.3).32  
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Figure 1.3: Structure of ERα and ERβ selective agonists 
1.2.2 Estrogen Decrease in Menopause and Hormone Replacement Therapy  
Estrogen levels decrease in both sexes as humans age, but drop more precipitously 
in women during the menopausal transition.  Lower estrogen levels during menopause is 
correlated with “diseases of the skeleton (osteoporosis), cardiovascular system (coronary 
heart disease) and central nervous system (Alzhimer’s disease).”1  Hormone replacement 
therapy (HRT), the prolonged administration of estrogen and progesterone supplements, 
was initially developed to address the lower production of these important mediators.  HRT 
reduced the risk of dementia, mild cognitive impairment and prevented the spine and hip 
fraction in postmenopausal women.  However, the safety of continuous administration of 
estrogen supplements in HRT is currently under scrutiny due an increased risk of breast 
and endometrial cancer.40-43  The etiology of HRT carcinogenicity is complex, but an 
increasing amount of evidence supports the formation of catecholic estrogens via CYP450 
and their subsequent oxidation to tumor-initiative quinones (Scheme 1.2). 44-48 
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Scheme 1.2: Mechanism of quinone formation and DNA adduction 
Nevertheless, estradiol has garnered considerable attention over the past decades in 
influencing cognitive processes in relation to phases of the menstrual cycle, aging and 
menopausal symptoms.  Accumulating evidence supports the dominant role of estrogen 
receptor-beta (ERβ); the predominant isoform in the hippocampus for improved cognitive 
effects.32  ERβ mediates estradiol’s effects on neural plasticity, neuroprotection, enhanced 
hippocampal signaling and memory consolidation via estrogen activated signaling 
cascades, via the extracellular signal-regulated kinase/mitogen-activated protein kinase 
pathway (ERK/MAPK).49-50  Due to the deleterious effects of activating ERα compared to 
beneficial effects of activating ERβ, selective ERβ agonists are an exciting new direction 
in drug discovery for the treatment of cognitive deficits in postmenopausal women.  
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1.3 Estrogen Receptor Structure and Mechanism of Action  
“ERα and ERβ belong to the nuclear hormone receptor family whose members are 
ligand-controlled transcription factors.”7  ERα is a 66 kDa, 595-residue protein whereas 
ERβ is a 62 kDa, 530-residue protein.2  Both ERs exhibit similar architecture, having six 
regions of the primary amino acid sequence (A-F) and composed of three major functional 
domains: the N-terminal or A/B domain (NTD), the DNA-binding domain (DBD), and the 
C-terminal D/E/F or ligand-binding domain (LBD) (Figure 1.4).  The two human ERs 
share ~ 97% similarity between the DBD domains, 59% similarity in the LBD domains, 
but only 16% similarity in the NTD domain.  The two receptors are functionally not 
interchangeable.2, 4, 6 
 
 
 
 
 
 
 
Figure 1.4: Schematic representation of structural domain of human ERα and ERβ4 
The N-terminal domain (NTD) of ER consists of ligand-independent activation 
function (AF1) where it involves the protein-protein interactions and transcriptional 
activation.  In ERα, the AF1 domain shows higher activity in stimulation of reporter gene 
expression via estrogen response element (ERE) whereas AF1 activity of ERβ appeared to 
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be diminished under the same conditions.  This dissimilarity in N-terminal region accounts 
for the difference in activity of ERα and ERβ towards various exogenous ligands.6-7 
The DNA binding domain (DBD) of both receptors shares a high degree of 
sequence homology and each contains a zone called “zinc fingers”.  This region is rich in 
cysteine residues and four cysteine residues are coordinated to the zinc atom to form the 
finger structure, having a loop of 15 to 22 aminoacids.51   Zinc fingers are common to 
transcription factors and there are two zinc fingers for each receptor.  These play an integral 
role in receptor- DNA binding in that they offer “an optimum architecture for the mutual 
recognition between specific sequences of amino acids and nucleotides”51.  This eventually 
establishes the hydrogen bridges (via H-bonding) in order to form the stable ER-DNA 
complex.8, 51 
 
 
 
 
 
 
 
Figure 1.5: Formation of Zinc fingers in DNA binding domain.  (Adapted from Selective  
Estrogen Receptor Modulators, A. Cano, et al., Springer, 2006, pg 20)51 
The C-terminal ligand binding domain (LBD) governs the target gene expression 
via ligand binding, receptor dimerization and subsequent dimer-nuclear translocation.  The 
LBDs of both receptors have higher homology with respect to their amino acid sequences 
and have similar tertiary architecture.  LBD usually comprises of 12 helices (H1-H12) in 
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three anti parallel layers.  It incorporates an activation function 2 segment (AF2), whose 
structure and function are mainly mediated by incoming ligands.  AF2 interaction surface 
is composed of amino acids in helix 3, 4, 5, and 12 and the positioning of helix 12 is 
effected by incoming ligands based on their agonist or antagonist nature.  Overall, the 
ligand-binding domains of ERs have a net hydrophobic character, which is an essential 
prerequisite for attachment of low molecular weight organic molecules.2, 6-7  Small 
differences between the LBDs of ERα and ERβ influence the shape of their ligand binding 
pockets there by engendering unique affinities for ligands.6  These differences in the LBD 
will be discussed in more detail in Section 1.4. 
The ERs are mostly localized in the cytoplasm in complex with heat-shock proteins 
(Hsp) 50, 70 and 90 which stabilize the receptors in an inactive state.4  “The action of ERs 
is tripartite, as it involves the receptor, ligands (natural or synthetic) and coregulatory 
proteins.”52  In the classical mode of action, binding of estrogen to the LBD of ER induces 
receptor conformational changes (mainly dissociation of ER-Hsp chaperone complex), 
leading to receptor dimerization (ER2).  This dimer binds to a specific sequence of DNA 
in the promoter region known as the estrogen response element (ERE).  This binding 
promotes the recruitment and interaction with coregulators from the nucleus, and formation 
of a pre-initiation complex.  Finally, the receptor-DNA-coregulator complex undergoes 
DNA transcription to form mRNA and thereby desired proteins which lead to an alteration 
in cell function (Figure 1.6).4, 8, 51 
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Figure 1.6: Classical mechanism action of estrogen receptor53  
In addition to its classical mode of action, it is now accepted that ERs can mediate 
gene expression without directly binding to DNA.  One possible pathway is transcriptional 
cross-talk, where the E2-receptor complex is tethered to a transcription factor (TF) that 
interacts with the DNA, thus avoiding a direct ER-DNA interactions (Figure 1.7).4, 6, 8, 54  
Examples for transcriptional cross talk include interaction of ERs at activating protein 1 
(AP1), specificity protein 1 (Sp1), cAMP response element-binding protein (CREB), 
nuclear factor κB (NFκB), p53 binding sites.  Interaction of ER with the nuclear factor κB 
(NFκB) prevents the NFκB binding to interleukin-6 (IL-6) promoter leading to repression 
of cytokine IL-6 protein.  ERs regulate several genes by this mechanism and both AP1 and 
Sp1 mediated gene expression vary with the ligand, cell and receptor subtype.4, 6, 54-55  
Furthermore, “ERs stimulate transcriptional responses in the absence of estradiol.  
Epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor 
(IGF1R) can initiate the protein kinase cascade, thus phosphorylation and activation of ERs 
in the absence of the ligand.”8   
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Figure 1.7: a) classical mechanism of action.  b,c,d) “indirect effects of estrogen receptors 
on transcriptional activation”6 
 
Likewise, accumulating evidence supports for the rapid and non-genomic effects 
of membrane bound and cytoplasmic ERs where binding of estradiol activates the 
following proteins: mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-
kinase (PI3K), nitric oxide synthase 3 (NOS3), human epidermal growth factor receptor 2 
(HER2) and G proteins (GP).  Finally, these proteins can signal to regulate the gene 
expression via activation of other transcriptional factors.6, 8 
1.4 Important Interactions within the Ligand Binding Domain 
While the ligand binding domains (LBDs) of ERs share less than 60% of amino 
acid sequence, the ligand binding pockets (LBP) of the two isoforms have only minute 
variations in structure and composition.11  The crystal structure of estradiol bound to ERα 
revealed a hydrogen bonding network between the endogenous ligand and surrounding 
amino acid residues.56  The phenolic OH group interacts with a bound water molecule and 
two amino acid residues of the ER LBP (Glu353 and Arg394 in ERα, Glu305 and Arg346 
in ERβ, Figure.1.8) and the 17β-hydroxy group is involved in an additional hydrogen bond 
a b c d 
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interaction to His524 (ERα) or His475 (ERβ).57  The two LBPs are composed of 23 amino 
acid residues, 21 of which are conserved and only two of which are variant.  The residues 
Leu384 and Met421 in ERα are replaced with Met 336 and Ile373 in ERβ respectively.  
Furthermore, the interchanged Leu384/ Met336 residues are positioned above the B- and 
C-rings of estradiol whereas the interchanged Met421/Ile373 residues are positioned below 
the estradiol D-ring within the LBP.  These minute alterations in amino acid sequence plus 
other small variations in tertiary structure make the ERβ LBP smaller in volume (279 Å3) 
in comparison to the LBP of ERα (379 Å3).  However, the creation of ERβ selective ligands 
seems to be a real challenge due to higher structural similarity of LBP of both receptors.11, 
47, 57-60 
 
 
 
 
 
 
 
Figure 1.8: “Principal interactions of estradiol with ERα and ERβ conserved and 
nonconserved residues”60 
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1.5 Estrogen Receptor – Agonists, Antagonist and Selective Estrogen Receptor 
Modulators 
 
The molecules that bind to ERs possess significant variations in the process of 
uptake, binding, and/or recruitment of coregulator(s) leading to different transcriptional 
responses.  The conformational changes that occur at the LBD upon formation of ER-
molecular complex determine its transcriptional responses relative to the native estrogen.61   
Natural and synthetic ligands may be classified as agonists, antagonists or selective 
estrogen receptor modulators (SERMs).  Ligands that form complexes in a similar but not 
identical manner to those formed by estradiol are known as ER agonists.  They recruit a 
similar set of cofactors and eventually produce similar but not identical transcriptional 
responses.51, 61  On the contrary, ligands that form complexes at the LBD, but create 
different conformational changes compared to estradiol, are termed as ER-antagonists or 
antiestrogens.  These complexes fail to dimerize or recruit the same set of cofactors as 
estradiol or recruit different cofactors leading to a blocking of transcriptional responses.51, 
61   
ER agonists and antagonists bind at the same site of the LBD with different binding 
orientations or modes.  For this reason, agonist or antagonist activity is mainly due to the 
spatial repositioning of helix 12 (H12) after binding; the location of this helix is a key factor 
for the subsequent recruitment of the transcription cofactors.2, 62  Indeed, the binding of an 
agonist restructures the ligand binding domain, making helix 12 rotate in a way that it is 
positioned over the ligand binding pocket.  This facilitates the movement of coactivators 
while removing the corepressors from their original site.  In contrast, antagonist ligands 
lodge into the hydrophobic groove conferred by helices 3, 4, and 5 and disrupts helix 12 
conformation for coactivator interaction.  Figure 1.9 depicts the difference in positioning 
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of H12 of ERα upon binding of agonist (diethylstilbestrol) and antagonist (4-
hydroxytamoxifen) to the LBD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: a) The conformation of H12 of ERα due to diethylstilbestrol (agonist) binding 
(yellow) and tamoxifen (antagonist) binding (magenta) b) Ligand-dependent 
structural deviation between agonists (red) and antagonists (white) 
conformations. 2 
 
The folded yellow and extended pink portions represents the H12 helix in agonist 
and antagonist mode respectively and are readily discernable.  Moreover, the superposition 
of both agonist and antagonist forms of LBD without any modification clearly reveal the 
a) 
b) 
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conformationally conservative nature of the LBD (blue colored) aside from the H12 
orientation. 2, 6, 62  
ERα agonists (red in Figure 1.10a) primarily interact with Glu353, Arg394 and 
His524, whereas ERα antagonists (white) have an additional interaction with Asp351 
(upper left corner of Figure 1.10a).  This additional interaction is responsible for the 
antagonism which prevents the conformational change of helix 12.  Similar amino acid 
residues in ERβ are engaged in these interactions (Figure 1.10b); these differ only in 
residue numbering (Glu305, Arg346, His475, Asp303).2 
Selective estrogen receptor modulators (SERMs) are a structurally diverse class of 
therapeutic agents that interact with estrogen receptors but that exhibit a selective ER 
agonist vs antagonist profile which is tissue/organ specific. 63  To date several SERMs 
drugs are developed and some are approved for clinical use.  For an example, tamoxifen is 
used as an antagonist for the treatment of breast cancer, but shows agonist effects on bone 
mineral density and serum lipids on postmenopausal women.  Raloxifene, is used for 
treatment of osteoporosis and vertebral fractures, even though it is a failed breast cancer 
drug.17, 51, 63  Table 1.1 shows the classification of SERMs and Figure 1.11 shows some of 
their chemical structures.51   
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Figure 1.10: a) The binding interactions in the ERα for agonists (red) and antagonists 
(white). b) binding interactions in ERβ for agonist (blue) and antagonist 
(green) 2 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
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Table 1.1: “Classification of SERMs” (Adapted from Selective Estrogen Receptor 
Modulators, Cano, et. al, Springer, 2006, pg 51)51 
 
 
 
 
 
 
 
Chemical Class SERM       
Triphenylethylenes Tamoxifen* AstraZeneca   
 Toremifene* Orion    
 Droloxifene
# Pfizer    
 Idoxifene
# Smithkline Beecham  
      
Benzothiophenes Raloxifene*,†  Eli Lilly & Co   
 Arzoxifene†  Eli Lilly & Co   
      
Naphthylenes Lasofoxifene†  Pfizer    
 Trioxifene
#     
      
Indoles  Bazedoxifene†  Wyeth    
 Pipendoxifene†  Wyeth    
      
Benzopyrans EM-800†  Schering Plough   
 Acolbifene†  Schering Plough   
 Levormeloxifene* Novo-Nordisk   
           
      
  * Commercialized for different indications: breast cancer treatment, contraception,  
   Ovulation induction, prevention and treatment of postmenopausal osteoporosis. 
† Phase III clinical research     
# Clinical development cancelled       
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a) Triphenylethylene derivatives 
 
 
 
 
 
 
b)  Benzothiophenes  and Napththalene derivatives 
 
 
 
 
 
 
 
 
c) Indoles and Benzopyran derivatives 
 
 
 
 
 
 
 
Figure: 1.11: Selected chemical structures of SERMs 51 
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1.6 Review of ERβ Subtype Selective Ligands 
Estradiol has nearly equivalent binding affinity for ERβ and ERα.  While there are 
a considerable amount of compounds known which have greater selectivity for ERα, only 
a limited number molecules with greater selectivity for ERβ have been reported.60  Among 
natural products, coumestrol, genistein, liquiritigenin, naringenin and apigenin are some 
examples of ERβ-selective agonists (Figure 1.12).  They are found in many plants 
(phytoestrogen) and foods, especially in soybeans.  The isoflavone genistein shows nearly 
20 to 30-fold selectivity for ERβ over ERα and it was the first ERβ selective natural product 
characterized from X-ray crystallography (Figure 1.13).64  Coumestrol, liquiritigenin, 
naringenin, and apigenin also show considerable selectivities for ERβ in binding affinity 
assays (β/α 7, 11, 20, and 30 respectively).7, 10, 60, 65-67 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.12: Examples of natural ERβ-selective agonists60 
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Figure 1.13: a) “Schematic representations of hERβ–GEN complex. Helices are depicted 
as rods and H12 is colored in green.” b) “Comparison of ligand-binding 
mode of GEN (protein-light blue; ligand, green) in hERβ-LBD and E2 
(protein-red; ligand-purple) in hERα-LBD (PDB code: 1ERE) within the 
cavity. The ligands are viewed looking down from the β-face of the cavity 
and only those side chains that interact with the bound ligand or exhibit 
different orientations are shown. Hydrogen bonds are depicted as broken 
lines”64 
1.6.1 Design of Non-Steroidal ERβ Selective Agonists 
The design and development of non-steroidal ERβ selective agonists has piqued 
much interest due to their potential lower carcinogenic properties compared to steroidal 
molecules.60 To date, several non-steroidal selective ERβ agonists have been synthesized 
and a few selected examples are discussed here. 
In 2001, Katzenellenbogen and co-workers at the University of Illinois; discovered 
2,3-bis(4-hydroxyphenyl)propionitrile (DPN), a chiral molecule, as one of the most potent 
and selective ERβ agonists (Figure 1.14).60, 68  The racemic molecule has 70-fold higher 
relative binding affinity for ERβ compared to ERα and 170-fold higher relative potency in 
transcription assays (ERβ vs ERα).68  Due to its present commercial availability, several 
researchers have used (±)-DPN as a pharmacological probe to evaluate the unique biology 
a) b) 
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of ERβ in both in vivo and in vitro biological studies.60, 69-70  Subsequently; in 2009 Handa, 
et.al, separated the enantiomers by chiral HPLC.  They reported that (S)-DPN 
demonstrated a higher affinity for ERβ compared to (R)-DPN, and that (S)-DPN showed 
nearly 80-fold selectivity for ERβ.71  In 2012, the Katzenellenbogen group prepared the 
(S)-and (R)- DPN by enantioselective synthesis.  They confirmed the high affinity and 
potency preference of both enantiomers toward the ERβ (80-300), however, in this study, 
authors reported that (R)-DPN as the preferred agonist for ERβ activity.72  Computational 
docking of the (S)-stereoisomer with either ERα or ERβ shows that the hydroxyl group of 
the β - ring (see structures for aromatic ring designation) exerts a favorable H-bonding 
network with Glu353 and Arg394 in ERα (or Glu305 and Arg346 in ERβ) while the 
hydroxyl group of the α-ring interacts with His524 in ERα (or His475 in ERβ).  In this 
orientation, the CN group of DPN interacts with the sulfur atom of Met336 in ERβ in a 
more favorable manner than with the similarly positioned Leu384 residue of ERα.  In 
contrast, computational docking of (R)-DPN shows that the CN group projects in the 
opposite direction in comparison to the S-enantiomer and thus exerts a weaker interaction 
with the surrounding amino acid residues (Figure 1.14).  These docking studies suggest 
that the selectivity of DPN racemate towards ERβ mainly stems from the strongly 
interacting geometry of S-DPN and not from R-DPN at the ligand binding pocket.60, 68, 73 
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Figure 1.14: “Crossed stereo view of S-DPN (Panel A) and R-DPN (Panel B) docked and 
minimized in the ER and ER LBD Pockets, respectively. DPN and the ERβ 
pocket residues are shown with standard atom colors, whereas in the ERα 
complex, DPN and the pocket residues are shown in orange.”73 
 
In 2004, the Wyeth research group reported a series of ERβ selective agonists 
belonging to the benzoxazoles family.60  The ERB-041, WAY-292, WAY-659, WAY-818, 
and WAY-200070 are some examples from the Wyeth compound library (Figure 1.15). 9, 
60, 74  Among these, ERB-041 showed a 250-fold highest selectivity for ERβ having binding 
affinities (IC50) of 1200 nM and 5.4 nM for ERα and ERβ respectively.  Both docking and 
X-ray crystallographic studies reveal that the hydroxyl group of the 3-fluoro-4-
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hydroxyphenyl moiety forms H-bonds with nearby Glu305 and Arg346 of ERβ residues 
while the benzoxazole hydroxyl group hydrogen bonds to His475.  These interactions are 
common to both estrogen receptors (Figure 1.16).  Notably, the benzoxazole vinyl 
substituent is positioned in close proximity to Ile373 of ERβ while in ERα the vinyl group 
interacts with the Met421 residue (Figure 1.17).  It was suggested that the increased steric 
interaction of the vinyl group with the larger Met residue, as compared to the more compact 
Ile373 was responsible for the higher selectivity of ERB-041 with ERβ compared to ERα.9, 
60, 74-75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Examples of ERβ-selective agonists from Wyeth library60 
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Figure 1.16: Schematic representation of ERB-041 complexed with ERα and ERβ,  
showing key interactions within the ligand binding domain9 
 
 
 
 
 
 
 
Figure 1.17: ERB-041 binding interactions with ERα and ERβ60 
In 2006, Eli Lilly group developed a series of polycyclic benzopyran (PBP) 
derivatives as selective ERβ agonists (Figure 1.18).  
 
 
 
 
 
Figure 1.18: Racemic unadorned and racemic all-cis 3,4-cyclofused- (n= 1-3)  
                      benzopyrans60, 76 
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The racemic cyclopentyl annulated benzopyran (n = 1) exhibited good activity 
(0.47nM for ERβ and 4.34nM for ERα) and modest selectivity (β/α = 9).  The enantiomers 
were separated by chiral chromatography and named as SERBA1 and SERBA-2.  SERBA-
1 demonstrated the higher affinity for both ERβ and ERα (ERβ, Ki = 0.19 nM; ERα Ki = 
2.68 nM) compared to the enantiomer SERBA-2 (ERβ, Ki = 1.54 nM; ERα Ki = 14.5 nM).  
Moreover, the ERβ/ERα selectivity was greater for SERBA-1 (14.1) compared to SERBA-
2 (9.4).  This selectivity is mainly attributed to the two different binding orientations of 
SERBA-1 in both receptors.  According to the X-ray crystal structures (Figure 1.19), the 
most efficient interactions arise with ERβ, where the hydroxy of the phenol group is 
hydrogen bonded to Arg346/Glu305 while the benzopyran hydroxyl forms a H-bond with 
His475.  The fused cyclopentane ring lodges a small hydrophobic pocket, near to Ile373 
residue in ER β complex.  In ERα, the presence of Met421 makes the pocket too small to 
accommodate the cyclopentane ring.  Thus, binding of SERBA-1 in ERα forces a rotation 
of 180° along its central axis.  This orientation preserves the Arg/Glu H-bonding network, 
but the OH-His524 H-bonding interaction is weakened due to the greater distance between 
these groups (Figure 1.20).60, 76-77 
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Figure 1.19: “Surface diagram of the X-ray structure of SERBA-1 complexed to ERα (1A) 
and ERβ (1B)”77 
 
 
 
 
 
 
 
 
 
Figure 1.20: SERBA-1 binding interactions with ERα and ERβ60 
In 2011, the Katzenellenbogen group prepared estrogen analogs lacking the B ring 
(i.e. ACD- pseudosteroids), as ERβ selective agonists (Figure 1.21).47  While these authors 
initially reported78 the preparation of a trans-hydrindane skeleton, this was later corrected79 
to a cis- hydrindane (ACD-1, Figure 1.21) on the basis of X-ray crystallography.  The 
trans-hydrindane structure was eventually prepared80 and binding assays were performed 
on these compounds as well as on selected A-ring substituted variants.  From their ACD 
library, all compounds showed lower overall affinity but more importantly greater 
selectivity towards ERβ.   
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Figure 1.21: Design of ACD-pseudosteroids as ERβ selective agonists 
In addition to the aforementioned compounds, several other ERβ agonists with 
varied structural scaffolds (naphthalenes, quinolines, aromatic aldoximes, sulfonamides, 
salicylaldoximes, and carboranes etc.) have been developed by several research groups.58-
60  However, only limited number of compounds display comparable selectivity and 
potency simultaneously with the acceptable pharmacological profile.  Therefore, the 
challenge faced by ERβ targeted drug design process is to develop novel molecules with 
improved ERβ selectivity, potency, as well as reduced side effects. 
1.7 Design of 4-Cyclohexyl or Cycloheptyl Phenolic Derivatives as Selective ERβ  
      Agonists 
The basic requirements for any pharmacophore depends on size, shape and specific 
interactions with the surrounding residues of the target receptor.  While there is a variety 
of structural classes of molecules that possess greater affinity for the ERβ, there are some 
ACD-1 
RBA α = 1.5±0.26 
RBA β = 21.5±4.6 
β/α = 14.6 
 
ACD-2 
RBA α = 1.04±0.09 
RBA β = 8.7±1.5 
β/α = 8.4 
 
ACD-3 
RBA α = 2.38±0.19 
RBA β = 10±1.3 
β/α = 4.2 
 
ACD-4 
RBA α = 1.7±0.15 
RBA β = 6.84±0.41 
β/α = 4.1 
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significant prerequisites in guiding the development of ER β selective pharmacophores.  A 
phenolic OH is essential to establish the hydrogen bond network involving Arg346, Glu305 
and water triad in the ERβ binding cavity.  A second hydroxyl group, should be positioned 
nearly 11.0 ± 0.5 Å relative to the phenolic OH in order to exert hydrogen bonding 
interaction with His475 as well as Thr 299 in ERβ.  This Thr299-OH interaction is specific 
to ERβ and might contribute to the ERβ subtype selectivity.  Further, the presence of 
Met336 and Ile373 residues seems significant since they determine the size of a 
substituents that can be accommodated within the cavity and thereby ERβ selectivity. 60  
Based on these prerequisites, our research group focused on the design of non-
steroidal ERβ selective agonists for hippocampal memory consolidation in post-
menopausal women.  In this regards, the Donaldson laboratory developed a unique 
structural class of compound, cis-4-(4-hydroxyphenyl)cycloheptane methanol from 
organoiron methodology (Scheme 1.3).  The compound is comprised of a phenolic and 
cycloheptane-hydroxymethyl core; the 1st generation synthesis is outlined in Scheme 1.3.81 
 
 
 
 
Scheme 1.3: 1st generation synthesis of cis-4-(4hydroxyphenyl)cycloheptane methanol 
[reagents: a, vinylmagnesium chloride/THF/CH2Cl2 (57%); b, 4-
acetoxystyrene (2 eq), 5% Grubbs’ 1st generation catalyst (64%); c, H2O2/HO-
, d, LiAlH4, then 140˚C. (32%); e, H2,10% Pd/C (50%)] 
The cis-4-(4-hydroxyphenyl)cycloheptane methanol proved to be a potent agonist 
in cell-based ERβ agonist assays with an IC50 of 5.4 ± 0.3 nM and nearly 1000-fold 
selectivity for ERβ over ERα, making (±)-1.5 the most selective ERβ agonist reported.81  
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Figure 1.22: Predicted binding orientation of the lead compound A) in ERβ agonist 
conformation B) in antagonist conformation C) Overlay of estradiol (black) 
and lead compound (yellow)81 
 
In Figure 1.22 is shown the lowest energy docking representation into human ERα 
and ERβ in agonist and antagonist conformations of our lead compound.  Initial docking 
studies were conducted with estradiol crystal structure to confirm the method validity and 
obtained results were as expected.  Docking pose predictions indicate a higher ERβ affinity 
in agonist conformation where it forms two hydrogen bonds, one with tightly bound water 
and the other with His 475.  On the contrary, a different binding mode is shown in the ERβ 
antagonist conformation where hydrogen bonding of the phenolic hydroxyl is to Thr299 
rather than His 475.  Moreover, molecular overlay of estradiol and our lead compound 
reveals the well-aligned nature of both oxygen atoms of the two molecules in the ERβ 
pocket.81 
Using 4-(1-hydroxyphenyl)-1-hydroxymethylcycloheptane as a starting point, the 
research described in this dissertation seeks to expand on these results.  A second scaffold 
has been developed which exhibits high ERβ vs ERα selectivity, as evidenced by cell-
based functional assays.  Compounds from these two scaffolds were taken forward into 
34 
 
 
 
animal model studies for the consolidation of memory acquisition, and information on 
interactions with hERG, cytochromes and other nuclear receptors was obtained. 
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CHAPTER 2 
DEVELOPMENT OF 4-(4-HYDROXYPHENYL)CYCLOHEPTANEMETHANOL 
AND ANALOGUES 
 
2.1 Background and 1st Generation Synthesis of 4-(4-
(hydroxyphenyl)cycloheptanemethanol 
 
As part of initial efforts in the Donaldson laboratory to prepare estradiol analogs, 
an iron- mediated synthesis of 2,6-cycloheptadiene-1-methanols was adapted with olefin 
cross-metathesis.82-83  The first generation synthesis of 4-(4-
hydroxyphenyl)cycloheptanemethanol, as carried out by Dr. Rajesh Pandey, is presented 
in Scheme 2.1.  The precursor, 1-methoxycarbonylpentadienyl) Fe(CO)3
+ cation I, was 
prepared from furan in 5 steps (32.8% yield) according to the previously published 
procedure.84  Addition of vinyl magnesium chloride to cation I, in CH2Cl2 as reaction 
medium, gave the 2-vinyl-3-pentene-1,5-diyl complex II in moderate yield (57%, 
Scheme 2.1).  The cross-metathesis reaction of II with 4-acetoxystyrene (2 equivalents) 
gave complex III, along with the self-metathesis products, in 64% yield.  Oxidatively 
induced-reductive elimination of III, followed by ester reduction and thermal Cope [3,3] 
rearrangement afforded (±)-(4-(hydroxymethyl)cyclohepta-2,5-dien-1-yl)phenol 
RKP35C in 32% yield over two steps.  Finally exhaustive hydrogenation of RKP35C 
yielded desired (±)-4-(4-(hydroxyphenyl)cycloheptanemethanol in 50% unoptimized 
yield.81  Thus the 1st generation synthesis gave 2.0 in 10 steps, 1.9% yield from 
commercially available furan.  While this approach gave initial access to 2.0 for ER 
binding assays, it has several limitations.  These include low overall chemical yield (ca. 
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2%), preparation of racemic material, use of stoichiometric iron, access to only the cis-
stereoisomer and difficulties in translation to other analogs.  In addition, attempts to 
prepare additional samples of 2.0 by this pathway were problematic as the cross-
metathesis reaction did not prove robust in a subsequent student’s hands.  Therefore, a 
second-generation route to 2.0 was pursued. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1: 1st Generation synthesis of 4-(4-hydroxyphenyl)cycloheptanemethanol 
from organoiron methodology  
2.2 2nd Generation Synthesis of 4-(4-hydroxyphenyl)cycloheptanemethanol 
In order to circumvent a number of the low yielding steps, it was decided to 
pursue the preparation of 2.0 from a non-organoiron approach.  This strategy involved 
preparation of a protected analog of 4-(4-hydroxyphenyl)cycloheptanone (2.7), followed 
by introduction of the hydroxymethyl substituent (Scheme 2.2). 
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Scheme 2.2: Retrosynthetic analysis for preparation of 4-(4-hydroxyphenyl)-1-
hydroxymethylcycloheptane 
To this end, esterification of commercially available para-anisic acid 2.1 with 
thionyl chloride in the presence of methanol led to the formation of methyl 4-
methoxybenzoate (2.2, Scheme 2.3), which was identified by comparison of its 1H and 
13C NMR spectral data with the literature values.85  The Grignard reaction of 2.2 with in 
situ generated 3-butenyl magnesium bromide in 1:4 ratio under dry conditions gave the 
3° alcohol 2.3a as a major product (85%).  Obtaining these yields was dependent on a 
number of crucial experimental conditions.  Use of 4-equivalents of Grignard reagent 
was necessary; use of only 2 equivalents of 3-butenyl magnesium bromide gave a lower 
yield (13%).  In addition, the length of time for exposure of the crude reaction mixture 
to the NH4Cl workup conditions must be kept short, since longer exposure led to the 
formation of triene 2.3b (Scheme 2.3) as a by-product.  The formation of compound 2.3b 
can be rationalized by slow dehydration of 2.3a in the presence of acidic ammonium 
chloride (pKa = 9.24) (Scheme 2.4). 
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Scheme 2.3: Preparation of tertiary alcohol intermediate 2.3a 
 
 
 
 
 
Scheme 2.4: Mechanism of formation of compound 2.3b 
The structures of 2.3a and 2.3b were assigned on the basis of their NMR spectral 
data.  In particular, the signals at δ 4.88 – 4.98 (m, 4 H) and 5.73 - 5.84 (m, 2 H) ppm in 
the 1H NMR spectra of each are characteristic for the vinyl protons while two doublets 
of doublets at  6.88 and 7.28 ppm are typical for a 1,4-disubstituted phenyl substituents.  
The peak at δ 76.9 ppm in the 13C NMR spectrum of 2.3a was assigned to the tertiary 
alcohol carbon.  A triplet signal at δ 5.8 ppm in the 1H NMR spectrum of 2.3b was 
assigned to the proton of the trisubstituted olefin. 
Reaction of 2.3a with Grubbs’ 1st generation catalyst (G-I) under optimum 
experimental conditions (0.01 M concentration, slow addition of 4% of G-I over 8 h via 
syringe pump, 45 °C, and G-I quench with 50 equiv. DMSO) led to 2.4a as a major product 
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in 70- 75% yield (Scheme 2.5).  However, in certain instances the formation of self- or 
cross metathesis (CM) product 2.4b from 2.3a was observed (Scheme 2.5).   
 
 
 
 
 
 
 
 
Scheme 2.5: Ring closing metathesis and ionic reduction 
The structural assignment for 2.4a was based on its NMR spectral data.  In 
particular, signals at δ 5.83-5.86 (m, 2 H) and at δ 1.82-1.90 (m, 2 H), 1.97–2.10 (m, 4 H), 
2.44-2.55 (m, 2 H) in the 1H NMR spectrum of 2.4a correspond to the hydrogens within 
the cycloheptenol ring, while signals at δ 113.5 and 76.5 ppm in the 13C NMR spectrum 
correspond to the cycloheptenol olefinic and alcohol carbons respectively. 
Ionic reduction86 2.4a with 5 equivalents of triethylsilane and 10 equivalents of 
trifluoroacetic acid, in dry CH2Cl2, gave 2.5 (90%).  The removal of the OH group was 
confirmed by the presence of a signal at δ 49.4 ppm in the 13C NMR spectrum and a triplet 
of triplets at  2.69 ppm in 1H NMR spectrum which correspond to the benzylic carbon and 
its attached proton. 
Our first strategy for olefin-to-ketone conversion relied on epoxidation of 2.4a with 
meta-chloroperoxybenzoic acid to provide a mixture of cis- and trans-epoxides 2.5a (I and 
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II, Figure 2.1) in good yield (74%).  The structure of 2.5a was assigned based on its 1H 
NMR spectral data; no olefinic proton signals were observed and instead two new triplets 
of triplets and three multiplets were observed in  2.14-3.19 ppm region.  The same 
behavior was observed in the 13C NMR spectrum where the eighteen signals appear as a 
doublet set of nine for each stereoisomer. 
 
 
 
 
Figure 2.1: Diastereomers of compound 2.5a (I and II) 
Lewis acid-mediated ring opening of epoxide 2.5a was carried out with boron 
trifluoride etherate in anhydrous benzene to give the known87 cycloheptanone 2.7, albeit in 
low yield (26%).  Moreover, an aldehydic by-product was observed which can be 
rationalized by the following mechanism (Scheme 2.6). 
 
 
 
 
 
 
 
 
Scheme 2.6: Possible mechanism for generation of 2.7 and aldehydic by-product 
2.5a - I 2.5a - II 
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Alternatively, hydroboration of compound 2.5 with BH3.THF followed by 
oxidation from 30% H2O2 and 1N NaOH gave alcohol 2.6 in 93% yield (Scheme 2.7).  
Notably, attempted oxidative workup with sodium borate gave 2.6 in lower yields (20-
30%).  The absence of the olefinic signals and the presence of two multiplets at δ 3.90-4.06 
ppm (1H) in 1H NMR spectrum of 2.6 and the presence of two new peaks at δ 72.7, 71.5 
ppm in its 13C NMR spectrum support the presence of this product as a mixture of 
diastereomers.  
 
 
 
 
Scheme 2.7: Transformation of olefin 2.5 into cycloheptanone 2.7 
Oxidation of the secondary alcohol 2.6 to the corresponding ketone 2.7 was effected 
using either pyridinium chlorochromate and silica or celite as an adsorbent (55% yield), or 
n-propylmagnesium bromide and 1,1’-(azodicarbonyl)dipiperidine (20% yield),88 or Dess-
Martin periodinane with addition of 2-5 drops of water (50% yield, Scheme 2.7).  The 
product was identified by comparison of its spectral data with the literature values.87 
Wittig reaction of 2.7 with two equivalents of the ylide generated from reaction of 
methyltriphenylphosphonium bromide with nbutyllithium provided the exocyclic olefin 2.8 
(79%, Scheme 2.8).  The structural assignment of 2.8 was supported by the presence of 
characteristic peaks for the exocyclic alkene at δ 4.77 (2H) ppm in the 1H NMR spectrum 
and δ113.8 and 110.9 ppm in the 13C NMR spectrum.   
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Hydroboration of 2.8 with BH3.THF, followed by oxidation with 30% H2O2 and 3N 
NaOH afforded alcohol 2.9 (48-60%) as a mixture of cis- and trans- diastereomers 
(Scheme 2.8). The doublet at δ 3.46 ppm (2H) in the 1H NMR spectrum of 2.9 and peaks 
at δ 68.6 and 68.4 in 13C NMR spectrum were evidence of this mixture.  
Finally, deprotection of the methyl ether was achieved under BBr3 conditions to 
give the desired 4-(4-(hydroxyphenyl)cycloheptanemethanol 2.10 (ISP163) (28%) as a 
mixture of cis- and trans-isomers (Scheme 2.8).  The cis-stereoisomer was identified by 
comparison of its NMR spectral data with the literature values,81 while the doubling of 
many of the peaks was taken as evidence of the trans-stereoisomer.  This assignment of 
the 13C NMR signals for the trans-stereoisomer was eventually corroborated by HPLC 
separation of the stereoisomers as well as X-ray crystallography (vide infra) 
 
 
 
 
 
 
Scheme 2.8: Conversion of 2.7 into 4-(4-(hydroxyphenyl)cycloheptanemethanol  
The overall route (summarized in Scheme 2.9) requires 9 steps from commercially 
available material, and while it proceeded in a slightly improved overall yield (2.1%), 
compared to the original synthesis, the harsh conditions of the final step dictated the need 
for a different phenolic protecting group. 
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2.3 3rd Generation Synthesis of 4-(4-hydroxyphenyl)cycloheptanemethanol 
Our next focus was to introduce a readily cleavable protecting group.  Protection of 
commercially available methyl 4-hydroxybenzoate 2.11 as the t-butyldimethylsilyl ether 
provided 2.12 (84%, Scheme 2.10).  Characteristic signals for the t-butyl and two methyl 
groups appear at δ 0.99 (9H) and 0.22 (6H) ppm in the 1H NMR spectrum and at δ 18.1/25.7 
and -4.3 ppm respectively in the 13C NMR spectrum of 2.12.  The same 7 step synthetic 
sequence (Grignard addition, RCM, ionic reduction, hydroboration/oxidation, Wittig 
olefination, hydroboration/oxidation) eventually led to 2.19 under optimized conditions.  
However, the ionic reduction of 2.14 under acidic conditions, proceeded in a lower 60% 
yield due to silyl ether cleavage to give the degraded by-product 2.15a.  The by-product 
2.15a could be recycled by further TBDMS protection.  Use of 3N NaOH in the oxidative 
workup for hydroboration/oxidation of 2.18 also resulted in cleavage of the TBDMS group 
and afforded lower yields (40%).  Alternatively, use of 1N NaOH for the workup gave the 
product 2.19 without silyl ether cleavage (66%).  Deprotection of 2.19 was carried out 
under TBAF conditions to give 2.10 (ISP163) in 88% yield as a clean product.  Following 
this procedure, the mixture of stereoisomers was obtained in 9 steps from commercially 
available methyl 4-hydroxybenzoate, and in 10.7% overall yield. 
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Scheme 2.9: 9-Step, 2nd generation synthesis of 4-(4-(hydroxyphenyl)cycloheptane 
                     methanol (2.1% yield) 
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Scheme 2.10: 3rd  Generation synthesis of 4-(4-(hydroxyphenyl)cycloheptanemethanol 
                       (10.7% yield) 
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2.4 4th Generation Synthesis of 4-(4-hydroxyphenyl)cycloheptanemethanol 
While the 3rd generation synthesis (Scheme 2.10) proceeded in 4.4% yield, the 
length of this route (9 steps) and the use of expensive precursors (4-bromo-1-butene, $ 
248/mol) and reagents (Grubbs’ 1st generation catalyst, Dess-Martin periodinane) 
necessitated the development of a shorter synthesis of intermediate 2.17.  This synthesis 
commenced from commercially available 4-(4-hydroxyphenyl)cyclohexanone 2.20 that 
was protected with TBDMSCl to give the silyl ether 2.21 (95%, Scheme 2.11).  The 
presence of peaks at δ 0.98 (9H) and 0.19 (6H) ppm in 1H NMR verifies the product 
formation.  Ring expansion of cyclohexanone ring to cycloheptanone ring (2.22) was 
achieved under Büchner–Curtius–Schlotterbeck conditions89 with the use of ethyl 
diazoacetate and boron trifluoride etherate in dry ether (81%).  Krapcho-
decarboethoxylation of keto-ester 2.22 with LiCl/ H2O in DMSO at 160 ˚C furnished the 
key intermediate 2.17 in 78% yield.  Subsequent transformation of 2.17 to 2.10, by the 
route previously developed in Scheme 2.10, resulted in an 6-step, 20% overall yield route 
to a mixture of cis- and trans isomers of 4-(4-(hydroxyphenyl)cycloheptanemethanol.  
Utilizing this route, a sample of 2 g of 2.10 was eventually prepared.  This mixture of 
stereoisomers was subjected to ER binding assays; the results of these assays are described 
in Chapter 4. 
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Scheme 2.11: Preparation of 4-(4-(hydroxyphenyl)cycloheptanone intermediate by ring 
expansion 
2.5 Separation of Stereoisomers of 4-(4-(hydroxyphenyl)cycloheptanemethanol 
Since the 2nd, 3rd, and 4th generation syntheses furnished the target compound as a 
mixture of four stereoisomers, the next aim was to separate these isomers in order to 
identify the most potent candidate.  Figure 2.2 depicts the analytical HPLC chromatogram 
of ISP163 using a chiral cellulose 2(OZH) column with isopropanol : hexanes (1:4) as 
eluent and UV detection at 254 nm. This clearly reveals the presence of 4 stereoisomers at 
different retention times.  
 
 
 
 
 
 
 
Figure 2.2: Identification of presence of four isomers of ISP163 
PK
1 
PK
2 
PK
3 
PK
4 
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Due to the prohibitive cost of a preparative HPLC column, it was decided to 
contract a preparative separation of the mixture, to access the individual isomers.  This 
would provide sufficient quantities of the stereoisomers for ER binding assay as well as 
absolute configuration determination. The company Phenomenex (Torrence, CA) was 
contracted for these chromatographic services. 
Initial analytical method development by Phenomenex revealed that a Lux 
Cellulose-35 µm column and isocratic mobile phase of ethanol: 2-propanol: hexanes 
(4.33:8.66:87) was optimal, with detection at 280 nM.  The isolation process utilized a 250 
x 30 mm preparative column and the aforementioned solvent system.  This method 
produced a 12 min HPLC run with the first desired peak eluting just before 8 minutes 
(Figure 2.3).  The blue color zones were collected as pure isomeric products. 
. 
 
 
 
 
 
 
 
 
Figure 2.3: Prep Chromatogram of ISP163 for a single injection (courtesy of Phenomenex) 
Since these conditions were isocratic, stacked injections were implemented to 
accelerate the process.  In this regards, subsequent injections were made 6 min after the 
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previous injection with the products from the first injection collected shortly after the 
second injection was made (Figure 2.4).  
 
 
 
 
 
 
 
Figure 2.4: Implemented Stacked Injections for ISP163 (courtesy of Phenomenex) 
Analytical QC was developed to assess the separation.  Two Lux Cellulose-35 µm 
150 x 4.6 mm columns were used in series with ethanol : 2-propanol : hexanes (2 : 7 : 91) 
as an isocratic solvent system (Figure 2.5).  The analytical QC chromatograms confirmed 
separation of the stereoisomers and indicated that each fraction was of > 94% enantiomeric 
excess. 
However, these chromatograms also indicated “system” impurity peaks at ca. 7.5 
and 9.5 min.  Furthermore, 1H NMR analysis of the fractions returned by Phenomenex 
indicated signals due to an unidentifiable contaminant.  Fortunately, this contaminant was 
considerably more soluble in CDCl3 than the desired compound, and thus extracting the 
solids with this solvent gave a solid product which was essentially contaminant free by 1H 
NMR spectroscopy (Figure 2.6). 
  
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Analytical QC chromatograms of all four isomers of ISP163 (courtesy of 
Phenomenex) 
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Figure 2.6: 1H NMR analysis of all four isomers of ISP163 
Comparison of the 13C NMR spectra of peaks 3 and 4 with that previously obtained 
for cis-4-(4-(hydroxyphenyl)cycloheptanemethanol (obtained from the 1st generation 
synthesis), indicated that these fractions corresponded to the cis-isomer, and by deduction 
the lack of correspondence of the 13C NMR spectra for peaks 1 and 2 with the previously 
obtained material indicated that they had the trans-stereochemistry.  These spectroscopic 
assignments were eventually corroborated by single crystal X-ray diffraction of three of 
the fractions.  Figure 2.7 contains the ORTEP projections of peak 3 and peak 4 isomers, 
including not only relative configuration (cis) but also absolute stereochemistry (7R, 10S 
for peak 3; 7S, 10R for peak 4, crystallographic numbering).  The 7-membered ring in each 
structure has a somewhat twisted long chair confirmation. 
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Figure 2.7:a) ORTEP projections of the stereoisomers of trans- 4-(4-
(hydroxyphenyl)cycloheptanemethanol; a) peak 3 (7R, 10S); b) peak 4 (7S. 
10R); c) 3D-crystal packing of peaks 3 and 4 (identical) in solvent 
 
The X-ray crystal structure of the peak 1 isomer contains two symmetrically 
independent molecules of the same chirality (Figure 2.8).  The ordered 7-membered ring 
in structure a has a long chair conformation with both substituents in an equatorial 
orientation.  However, the situation with structure b is more complex since it has a 
disordered 7-membered ring structure with an overlap of 7/10,11-chair over 10/7,13-chair.  
Thus, the absolute configuration of this isomer was indeterminate. 
a b 
c 
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Figure 2.8: a) and b) Two possible X-ray crystal structure of pk1 isomer c) 3D-crystal packing 
in solvent 
 
 
 
 
a 
b 
c 
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2.6 Synthesis of Other 4-Cycloheptylphenol Analogues for SAR Studies 
Having established ISP163 (compound 2.10) as a lead compound, our next 
approach was to design a series of 4-cycloheptylphenol based analogs with various 
functional moieties in order to test the SAR studies.   
 
 
 
 
 
Scheme 2.12: Synthesis of analog 2.23  
Treatment of the mixture of diastereomeric epoxides 2.5a with three equivalents of 
lithium aluminum hydride in dry THF, gave a mixture of two diastereomeric alcohols 2.6 
in low yield (35%) which were identified by comparison of their NMR spectra with that 
previously prepared. (Scheme 2.12).  Since the two diastereomers did not show clear 
separation by TLC, the mixture was carried forward in the next reaction step.  The mixture 
of diastereomers 2.6 was subjected to the ether cleavage using excess BBr3 in anhydrous 
CH2Cl2 to afford compound 2.23 (86%, ISP58).  The product was a mixture of 
diastereomers (1:1 ratio) and the presence of the phenol group was confirmed by a singlet 
at 4.84 ppm assigned to the phenolic hydrogen in its 1H NMR spectrum. 
Cycloheptanone 2.7 was demethylated with 48% HBr under refluxing conditions 
to afford phenol 2.24 (49%, ISP242, Scheme 2.13).  The use of BBr3 conditions was 
problematic, as the 1H NMR spectrum of the crude product did not show any peaks 
belonging to a ketone functionality.  The removal of the methyl ether in 2.24 was evidenced 
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by an absence of the signals for the OMe group.  Reaction of 2.24 with hydroxylamine 
hydrochloride in the presence of NaHCO3 gave oxime 2.25 (52%, ISP166) as a mixture of 
E-  and Z- stereoisomers.  The occurrence of characteristic signals at δ 140.4 and 141.3 
ppm in the 13C NMR spectrum of 2.25 corresponded to the C=N carbons of the 
diastereomers.  Alternatively, treatment of phenolic cycloheptanone 2.24 with 2.2 
equivalents of MeLi. LiBr complex provided the diastereomeric tertiary alcohol 2.26 (40%, 
ISP362).  The two singlets at δ 1.23 and 1.21 ppm in 1H NMR spectrum, integrating to 
three protons in total, correspond to the methyl group of the diastereomeric product. 
  
 
 
 
 
 
 
 
  
 
Scheme 2.13: Synthesis of analogs 2.24, 2.25 and 2.26 
Horner–Wadsworth–Emmons olefination of 2.7 with the anion generated from the 
reaction of trimethyl phosphonoacetate with NaH gave 2.27 as a mixture of E- and Z- 
stereoisomers (31%, Scheme 2.14).  Formation of the 3,3-disubstituted enoate was 
evidenced by the presence of a singlet at δ 5.74 ppm and two singlets at δ 3.69 ppm in the 
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1H NMR spectrum of this product, which correspond to the olefinic CH and the OMe 
protons of the two stereoisomers.  Reduction of the methyl ester with DIBAL furnished the 
primary allylic alcohols 2.28 (43%), again as a mixture of E- and Z- stereoisomers.  The 
multiplet at δ 5.42-5.50 ppm and the doublet at δ 4.19 ppm in 1H NMR spectrum of this 
product correspond to the olefinic C-H and alcohol methylene protons respectively.  
Subsequent hydrogenation of 2.28 followed by demethylation with BBr3 provided the 4-
(2-hydroxyethyl)cycloheptyl)phenol 2.30 (ISP248) in low yield over 2 steps (7%).  This 
low yield was primarily attributed to the harsh methyl ether cleavage conditions. 
 
 
 
 
 
 
 
 
 
 
Scheme 2.14: Synthesis of 4-(2-hydroxyethyl)cycloheptyl)phenol  
3-Methyl-4-hydroxybenzoic acid 2.31 was converted into its methyl ester 2.32 by 
reaction with thionyl chloride in methanol under refluxing conditions (88%, Scheme 2.15).  
Formation of the methyl ester was confirmed by the presence of two singlets at δ 2.27 (3H) 
and 3.89 (3H) ppm in the 1H NMR spectrum of 2.32, corresponding to the OMe and Ar-
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CH3 protons.  Protection of 2.32 with tert-butyldimethyl silyl chloride gave the silyl ether 
2.33 (84%).  Transformation of 2.33 to the cycloheptanol 2.37 utilized the sequence of 
steps developed in the 2nd and 3rd generation syntheses of 2.10 (i.e. Grignard addition, 
RCM, ionic reduction, and hydroboration/oxidation).  Deprotection of 2.37 was carried out 
using TBAF/THF at reflux to obtain the 4-(4-hydroxy-3-methylphenyl)cycloheptan-1-ol 
2.38 (53%, ISP275) as a mixture of diastereomers.  The six-step sequence gave 6.62 % 
overall yield over 6 steps.  The structures of 2.34-2.38 were assigned by comparison of 
their 1H NMR spectral data with that obtained for the parent compounds 2.13-2.16 and 2.23 
(see Schemes 2.10 and 2.13).  
 
 
 
 
 
 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
 
Scheme 2.15: Synthesis of 4-(4-hydroxy-3-methylphenyl)cycloheptan-1-ol 
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The primary differences appeared in the aromatic region (signals due to 1,2,4-trisubstituted 
benzene vs 1,4-disubstituted benzene) and the appearance of a singlet at ca. δ 2.2 ppm due 
to the aryl methyl group. 
Oxidation of the mixture of cis- and trans- 4-(4-
(hydroxyphenyl)cycloheptanemethanol (2.10) with DDQ in CH2Cl2 gave the tricyclic ether 
2.39 (66%, ISP360, Scheme 2.16).  The structural assignment for 2.39 was supported by 
its NMR data.  In particular, the presence of two multiplets at δ 3.84-3.90 and 3.96-4.07 
ppm in 1H NMR spectrum integrating to one proton each correspond to the diastereotopic 
ether protons, while signals at δ 69.9 and 76.5 ppm in the 13C NMR spectrum correspond 
to the secondary and quaternary aliphatic ether carbons respectively.  This cyclization is 
rationalized by oxidation of 2.10 to the benzyl carbocation intermediate 2.39# (Scheme 
2.16) which is trapped by intramolecular attack of the hydroxymethyl group, followed by 
deprotonation. 
 
 
 
 
 
Scheme 2.16: Oxidative cyclization of 2.10 to generate tricyclic ether 2.39 
In order to explore the effects of the aliphatic ring size on ER binding affinity and 
selectivity, six-and five membered analogs of 2.10 were prepared.  The synthesis of 4-(4-
(hydroxyphenyl)cyclohexanemethanol and other derivatives are discussed in Chapter 3.  
For the cyclopentyl analog, commercially available 4-(4-hydroxyphenyl)cyclohexan-1-one 
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2.20 was converted into the known90 methyl ether 2.40 (44% unoptimized, Scheme 2.17) 
using iodomethane and K2CO3 in DMF.  The key ring contraction of 2.40 was effected with 
diphenyldiselenide and 30% H2O2 in 
tBuOH91 to afford the carboxylic acid 2.41 in low 
yield (40%). The product was identified by comparison of its NMR spectral data with the 
literature values.92  Finally, reduction of 2.41 with lithium aluminium hydride, followed by 
demethylation under BBr3 conditions afforded the 3-(4-
(hydroxyphenyl)cyclopentanemethanol 2.43 (36%, ISP427) as a mixture of diastereomers.  
 
 
 
 
 
 
 
 
 
 
                        
 
 
 
 
 
Scheme 2.17: Synthesis of 3-(4-(hydroxyphenyl)cyclopentanemethanol 
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CHAPTER 3 
DEVELOPMENT OF 4-[4-(HYDROXYMETHYL)CYCLOHEXYL]PHENOL 
AND ANALOGUES 
 
3.1 Synthesis of 4-[4-(Hydroxymethyl)cyclohexyl]phenol 
Based on estrogen receptor literature,47 the binding site cavity for ERβ is smaller 
in volume (279 Å3) than that for ERα (379 Å3).  Thus, in addition to the lead compound 
4-(4-(hydroxyphenyl)cycloheptanemethanol, described in the previous chapter, it was 
desirable to prepare analogs with varying cycloalkane ring(s).  In particular, the 
differences in molecular flexibilities between a “rigid” cyclohexane ring and a “floppy” 
cycloheptane ring, as well as the O-O interatomic distance, upon ligand binding and 
functional activation would shed light on important pharmacophore parameters.  
Molecular mechanics calculations of the O-O interatomic distances in cis-4-(4-
(hydroxyphenyl)cycloheptanemethanol varied between 10.7-11.0 Å.  This range of 
distances is due to (i).the flexible nature of the seven-membered ring, and (ii), rotation 
about the ring-to-CH2OH bond.
  The calculated distances are similar to those observed in 
the crystal structures (10.63-11.15 Å, see Figure 2.7 and 2.8).  In comparison, the O-O 
interatomic distance calculated for trans-4-[4-(hydroxymethyl)cyclohexyl]phenol (10.7 
Å) is within the range for known ligands of the estrogen receptor.  In this regards, 
syntheses of 4-[4-(hydroxymethyl)cyclohexyl]phenol and its analogs were designed 
from commercially available 4-(4-hydroxyphenyl)cyclohexan-1-one (3.1, Scheme 3.1). 
Protection of the phenol hydroxyl moiety of 3.1 with tert-butyldiphenylsilyl 
chloride (TBDPSCl) in CH2Cl2 gave 3.2 (93%).  The formation of the silyl ether was 
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confirmed by the presence of peaks at δ 7.74-7.70 (m, 4H), 7.45-7.34 (m, 6H), and 1.09 
(s, 9H) ppm in 1H NMR spectrum of the product.  Attempted Wittig olefination of 3.2 
with the ylide generated from methoxymethyl triphenylphosphonium chloride and n-
butyllithium or t-BuOK as the base, was ineffective (Scheme 3.1).  In contrast, reaction 
of 3.2 with the ylide generated from methyltriphenylphosphonium bromide with n-
butyllithium afforded the product 3.3 (85%).  The presence of a peak at δ 107.4 ppm in 
the 13C NMR spectrum and a peak at δ 4.65 (narrow t, 2H) ppm in the 1H NMR spectrum 
of 3.3 is characteristic of the exocyclic olefinic carbon and its attached protons.  
Subsequent hydroboration of 3.3 with BH3.THF followed by oxidation with 30% H2O2 
and 3N NaOH in ethanol gave 4-[4-(hydroxymethyl)cyclohexyl]phenol 3.4a (ISP171) 
(28%).  Notably, the use of 3N NaOH led to cleavage of the TBDPS protecting group.  
This product was determined to be a mixture of cis- and trans-stereoisomers (ca. 3 : 1 
ratio) by integration of the alcoholic methylene protons at δ 3.60 (1.5H) and 3.39 (0.5H) 
in the 1H NMR spectrum.  These relative chemical shifts are characteristic of cis- and 
trans-4-substituted cyclohexanemethanols.93-95 
The lower yield of the last step led us to explore an alternative protecting group 
strategy. Protection of 3.1 with tert-butyldimethylsilyl chloride (TBDMSCl) provided 
compound 3.5 (95%, Scheme 3.2).  Signals at δ 0.99 (9H) and 0.20 (6H) ppm in the 1H 
NMR spectrum and δ  -4.2, 18.4 and 25.9 ppm in 13C NMR spectrum of 3.5 are 
characteristic of the t-butyldimethylsilyl ether.  In a fashion similar to that in Scheme 3.1, 
Wittig methenylation of 3.5 gave 3.6 (84%).  Hydroboration of 3.6 with BH3.THF, 
followed by oxidation with 30% H2O2, and 3N NaOH proceeded with concomitant 
cleavage of the TBDMS group afforded 3.4a (40%).   
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Scheme 3.1: 1st Generation synthesis of 4-(4-(hydroxymethyl)cyclohexyl)phenol 
Alternatively, the TBDMS protecting group was stable under workup conditions 
of 1N NaOH to afford 3.7 (66%).  Under the BH3.THF conditions, the product was found 
to be a 3:2 mixture of cis:trans stereoisomers by 1H NMR integration and LC/MS data.  
Alternatively, use of 9-BBN instead of BH3.THF, followed by 30% H2O2/1N NaOH 
produced 3.7 (74%) as a 2:3 mixture of cis:trans stereoisomers.  The use of these two 
borane reagents have been previously demonstrated as a method to tune the cis:trans 
outcome for 4-substituted methylenecyclohexanes.96  Finally, removal of the TBDMS 
group was achieved under TBAF conditions to give 3.4a (ISP171) as a mixture of cis- 
and trans-stereoisomers (Figure 3.1).  The synthesis of this mixture was achieved in 43% 
overall yield over a four-step sequence.  
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Scheme 3.2: 2nd Generation synthesis of 4-(4-(hydroxymethyl)cyclohexyl)phenol 
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Figure 3.1: 1H NMR spectra of 4-[4-(hydroxymethyl)cyclohexyl]phenol from a) produced 
using 9-BBN b) produced using BH3.THF as hydroboration reagent (solvent 
= CD3OD) 
Treatment of the mixture of cis- and trans-4-[4-(hydroxymethyl)cyclohexyl]phenol 
(ISP171) with 1.1 equivalent of DDQ in dichloromethane gave a separable mixture of the 
bicyclic ether 3.8 (ISP358-1, 40%, Scheme 3.2), and unreacted trans-3.4b (ISP358-2, 20% 
borsm).  The oxidative conditions were optimized using the 2:3 mixture of cis:trans 
stereoisomers produced from 9-BBN hydroboration, 0.5 equivalent of DDQ and 5 h 
reaction time resulting in 47% maximum recovery of 3.4b along with 37% of cyclic ether 
3.8.  The structure of 3.4b (ISP358-2), tentatively assigned on the basis of its 1H NMR 
spectral data, was eventually corroborated by single crystal X-Ray diffraction analysis 
(Figure 3.2).  The cyclohexane ring has a chair conformation with both substituents in an 
a) 
b) 
cis  
trans 
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equatorial orientation.  The O-O distance found in this X-ray crystal structure (10.658 Å) 
is quite similar to that calculated on the basis of molecular mechanics (10.7 Å).  
 
 
Figure 3.2: a) X-ray crystal structure of compound 3.4b (ISP358-2) b) Crystal packing 
nature of compound 3.4b in solution 
 
Oxidation of either the cis- or trans-stereoisomer of 4-[4-
(hydroxymethyl)cyclohexyl]phenol would result in the same benzylic carbocation 
intermediate 3.8# (Scheme 3.3).  Thus, the formation of the separable mixture of 3.8 
(ISP358-1) and the trans-isomer 3.4b (ISP358-2) is due to the faster rate of generation of 
intermediate 3.8# from the cis-isomer.  Since the cis-isomer is less stable, and therefore 
higher in energy, compared to the trans-isomer, the barrier to oxidation of cis-3.4a to 3.8# 
(plus the DDQ reduction anion) should be lower, and thus the rate of oxidation is faster, 
than for trans-3.4b (plus the DDQ reduction anion). 
 
a b 
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Scheme 3.3: Mechanistic rationale for bicyclic ether formation of cis-isomer over trans 
isomer 
 
With a route to the trans-isomer 3.4b secured, the ring opening of bicyclic ether 3.8 
was examined as a selective means for preparation of the cis-isomer.  Ionic reduction of 
3.8 with either sodium cyanoborohydride/BF3.Et2O or triethylsilane/CF3COOH gave a 
mixture of cis- and trans- 4-[4-(hydroxymethyl)cyclohexyl]phenol in 1:4 and 2:3 ratios 
respectively.  
3.2 Synthesis of 4-Cyclohexylphenol Analogs  
To explore structure activity relationship (SAR) further, and search for compounds 
with improved potencies, physiochemical and biological properties several other 4-
cyclohexylphenol analogs were synthesized. 
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Scheme 3.4: Synthesis of analogs 3.9, 3.10, and 3.11 
Reduction of 3.1 with sodium borohydride afforded the secondary alcohol 3.9 
(ISP33, 90%, Scheme 3.4).  Similarly, reaction of 3.1 with NH2OH.HCl in the presence of 
NaHCO3 gave oxime 3.10 (ISP36, 70%).  Finally, nucleophilic addition of MeLi to 3.1 
gave the tertiary alcohol 3.11 (ISP361, 37%) in moderate yield under unoptimized 
conditions.  The alcohol 3.9 was determined to be a mixture of isomers whereas alcohol 
3.11 was a single isomer from their 1H and 13C NMR spectral data. 
Removal of the protecting group from 3.6 with TBAF gave 4-(4-
methylenecyclohexyl)phenol 3.12 (ISP365, 83%) and subsequent hydrogenation over 
Pd/C furnished the 4-(4-methylcyclohexyl)phenol 3.13 (ISP366, 80%, Scheme 3.5).  
Dihydroxylation of 3.6 with OsO4 in the presence of N-methylmorpholine-N-oxide (NMO) 
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gave diol 3.14 in 86% yield.  The presence of peaks at δ 66.2 and 72.4 ppm in 13C NMR 
spectrum of 3.14 were assigned to the primary and tertiary alcohol carbons respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.5: Synthesis of analogs 3.12, 3.13, 3.15, 3.16 and 3.17 
Removal of TBDMS group gave 4-[4-hydroxy-4-
(hydroxymethyl)cyclohexyl]phenol 3.15 (ISP411, 78%).  Reaction of 3.12 with 
paraformaldehyde, MgCl2 and NEt3
97
 effected carbonylation ortho to the phenol group to 
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give 3.16 (ISP384, 44%).  Reaction of 3.16 with NH4OH.HCl in the presence of NaHCO3 
gave oxime 3.17 (ISP389, 69%) as an inseparable mixture of E- and Z- stereoisomers.  
Katzenellenbogen, et. al, have previously reported on similar salicylketoximes as potent 
ERβ agonists that display antiproliferative activities in a glioma model.98   
Ortho carbonylation of bicyclic ether 3.8 was attempted using the same protocol as 
mentioned previously (Scheme 3.6).  The anticipated product 3.18 (ISP394) was obtained 
in very low yield (17%) along with the unsaturated alcohol 3.19 (ISP393, 8%).  The 
structures of 3.18 and 3.19 were assigned on the basis of their 1H NMR spectral data.  For 
3.18, signals in its 1H NMR spectrum at δ 9.99 (s, 1H) and 4.06 (s, 2H) ppm correspond to 
the aldehyde and ether methylene protons respectively, while for 3.19 signals at δ 10.01 (s, 
1H), 6.10 (s, 2H) and 3.49 (d, 2H) ppm correspond to the aldehyde, olefinic and 
hydroxymethylene protons respectively.   
The unsaturated aldehyde 3.19 presumably arises via eliminative opening of the 7-
oxabicyclo[2.2.2] octane ring of 3.8 under the MgCl2/NEt3 reaction conditions.  To test this 
hypothesis, treatment of bicyclic ether 3.8 with MgCl2 and NEt3 in the absence of 
formaldehyde gave unsaturated product 3.20 (ISP402, 78%).  Peaks at δ 5.97-5.92 (m, 1H) 
and 3.48 (dd, 2H) ppm in the 1H NMR spectrum correspond to the vinylic and methylene 
protons respectively.  Hydrogenation of 3.20 over Pd/C gave a mixture of the cis- and 
trans-stereoisomers 3.4a (ISP171, 67%) in 3:2 cis : trans ratio. 
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Scheme 3.6: Synthesis of analogs 3.18, 3.19 and 3.20 
Horner–Wadsworth–Emmons olefination of 3.2 with trimethyl phosphonoacetate 
and NaH, afforded enoate 3.21 (95%, Scheme 3.7).  Peaks at δ 5.65 (s, 1H) and 3.69 (s, 
3H) ppm in the 1H NMR spectrum of 3.21 correspond to the olefinic and methyl ester 
protons respectively, while a signal in its 13C NMR spectrum at δ 51.1 ppm is characteristic 
of the methyl ester carbon.  Selective ester reduction of 3.21 was accomplished using 
excess DIBAL to give the allylic alcohol 3.22 (58%).  The triplet at δ 5.42 and doublet at 
δ 4.17 ppm in the 1H NMR spectrum of 3.22 correspond to the olefinic C-H and the 
hydroxymethylene protons.  Hydrogenation of 3.22 followed by removal of the TBDPS 
protecting group under TBAF conditions gave 4-[4-(2-hydroxyethyl)cyclohexyl]phenol 
3.24 (RKP231IIF, 20%).  The overall yield of the synthesis is 5% over 5 steps. 
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Scheme 3.7: Synthesis of 4-[4-(2-hydroxyethyl)cyclohexyl]phenol  
3.3 Synthesis of Fluorine Containing 4-Cyclohexylphenol Analogs 
The introduction of fluorine into drug-like molecules is promising since it generates 
new pharmaceutical candidates with potentially improved pharmacological profiles.  While 
fluorine mimics hydrogen with respect to steric requirements (van der Waals radius: H, 
1.20 Å; F, 1.35 Å), the presence of F alters electronic properties of the molecule due to its 
higher electronegativity.  Incorporation of fluorine into drug candidates also enhance their 
in vivo metabolic stability, lipophilicity and blood-brain barrier penetration.99-100  
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Scheme 3.8: Synthesis of analog 3.25b 
 
 
 
 
99 
 
Scheme 3.9: Synthesis of analogs 3.26a and 3.26b 
Attempts to generate 3.25a from 3.9 by substitution using diethylaminosulfur 
trifluoride [DAST] or bis(2-methoxyethyl)aminosulfur trifluoride [DeoxofluorTM] at room 
temperature was ineffective and instead afforded the elimination product 1',2',3',6'-
tetrahydro-[1,1'-biphenyl]-4-ol 3.25b (ISP346, 51-63%, Scheme 3.8).  Since secondary 
alcohols favor the elimination product, deoxyfluorination of primary alcohols was 
examined.101-102  Reaction of the mixture of cis- and trans-stereoisomers 3.4a with 
deoxofluor gave 3.26a as a mixture of diastereomers (40%, Scheme 3.9).  Encouraged by 
these results, the pure trans-stereoisomer, 3.4b was then subjected to the same conditions 
and afforded the desired fluoro product 3.26b (ISP441, 64%).  The structure of 3.26b was 
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based on its NMR spectral data.  In particular, doublets at δ 89.4 ppm (1JC-F = 166 Hz) in 
the 13C NMR spectrum and at δ 4.23 ppm (2JH-F = 47.8 Hz) in the 1H NMR spectrum 
correspond to the fluoromethylene substituent. 
Ortho-fluorination of compound 3.1 or 3.9 was attempted with 1-chloromethyl-4-
fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) [SelectfluorTM] or N-
fluorobenzenebenzenesulfonamide (NFSI) as fluorinating reagents103-105 (Scheme 3.10).  
Unfortunately, in each case only starting material was recovered. 
 
 
 
 
 
 
Scheme 3.10: Attempted synthesis towards analogs 3.27 and 3.28 
Consequently, an alternative approach was conceived.  Protection of phenol 3.29 
with benzyl bromide produced 3.30 (95%, Scheme 3.11).  The multiplet at δ 7.47-7.32 (5H) 
ppm and a singlet at δ 5.13 (2H) ppm in the 1H NMR spectrum of 3.30 corresponds to the 
benzyl group.  Addition of the Grignard reagent generated from 3.30 with 1,4-
dioxaspiro[4.5]decan-8-one afforded the tertiary alcohol 3.31 (82%).  Treatment of 3.31 
with 2-3 drops of concentrated H2SO4 acid in THF/water to effect hydrolysis of the cyclic 
ketal proceeded with concomitant dehydration to give 3.32 in moderate yield (52%).  
However, large scale synthesis was unreliable from this protocol.  Alternatively, use of 
trifluoroacetic acid, instead of sulfuric acid, in CH2Cl2 furnished the product 3.32 in 
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excellent yield (90%).  Reduction of 3.32 with H2 in the presence of 10% Pd/C proceeded 
with both hydrogenation of the alkene and hydrogenolysis of the benzyl ether to deliver 
the desired 3.33 (ISP452, 45%).   
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.11: Synthesis of intermediate 3.33 
The triplet of triplets at δ 3.00 (1H) ppm in 1H NMR spectrum of 3.33 corresponds 
to the benzylic hydrogen of the cyclohexanone ring while the peak at δ 214.1 ppm in 13C 
NMR spectrum corresponds to the carbonyl carbon.  Cyclohexanone 3.33 is the ortho-
fluoro analog of 4-(4-hydroxyphenyl)cyclohexan-1-one and as such can serve as a starting 
material for synthesis of fluorinated analogs using previously established routes.  
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Scheme 3.12: Synthesis of 3.38 and proposed routes to 3.39a and 3.39b 
Attempted reaction of 3.33 with either TBDMSCl or TBDMSOTf as previously 
demonstrated for 3.1 (see Scheme 3.2), was sluggish even at optimal conditions.  The lack 
of reactivity of 3.33 under these reaction conditions is most probably a consequence of the 
electron withdrawing nature of the ortho fluorine atom on the nucleophilicity of the 
phenolic hydroxyl group. 
Alternatively, benzyl protection of 3.33 proceeded in a fashion similar to 3.29 gave 
3.34 (79%, Scheme 3.12).  Subsequent Wittig methenylation of 3.34 followed by 
hydroboration/oxidation using 9-BBN led to 3.36 in 16% yield over 2 steps.  Finally, 
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cleavage of the benzyl protection was accomplished under hydrogenation conditions to 
give 2-fluoro-4-[4-(hydroxymethyl)cyclohexyl]phenol 3.37 (ISP470) as a mixture of cis- 
and trans-stereoisomers.  The overall yield of the synthesis is 1.8% over 8 steps.  Reduction 
of 3.33 with NaBH4 gave the corresponding cyclohexanol 3.38 (ISP450) as a mixture of 
cis- and trans-stereoisomers (61%).  Conversion of 3.37 to its corresponding bicyclic ether 
3.39a, thereby chemical separation of trans isomer 3.39b will be conducted in future.  
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CHAPTER 4 
BIOLOGICAL EVALUATION OF ERβ SELECTIVE COMPOUNDS 
4.1 In vitro and In vivo Biological Evaluation – Assay Summary 
Compounds prepared in the previous chapters were evaluated for in vitro ER 
activity, interaction with selected CYP enzymes, hERG activity, and nuclear receptor 
screening, and in vivo efficacy for memory consolidation.  The in vitro biological studies 
with respect to ERα and ERβ activity, conducted by Alicia Schultz and Lucky Lu from the 
Sem lab at Concordia University-Wisconsin, include: 
• TR-FRET (Time Resolved Fluorescence Resonance Energy Transfer) ERβ binding 
assay, which measures the displacement of a fluorescently labelled estradiol from 
the ligand binding domain protein; 
• Selected compounds were carried forward to a cell-based functional assay, which 
      depends upon cell membrane penetration, the ability of ligand binding to ER and   
      to effect dimerization and subsequent protein transcription.  These were  
      conducted for both ERβ and ERα, in both agonism as well as antagonism mode; 
• CYP inhibition/binding activity, which measures the inhibition of selected CYP 
liver enzymes toward the metabolism of luciferin releasing substrates 
 
No-stress/no-reward in vivo memory consolidation studies, conducted by Jaekyoon Kim 
from the Frick lab at University of Wisconsin Milwaukee, include: 
• Object placement (answers the “where” memory question) by direct hippocampal 
and intraperitoneal injections 
• Object recognition (answers the “what” memory question) by direct hippocampal 
and intraperitoneal injections 
 
 
 
 
 
78 
 
 
 
4.2 Description of In vitro Assays and Results 
4.2.1 TR-FRET ERβ Binding Assay 
A Lanthascreen TR-FRET ERβ binding assay was conducted to assess the binding 
affinity of synthesized ligands.  Assays were conducted using a commercially available 
ERβ assay kit from ThermoFisher and verified to work with the Spectramax M5 (white 
plates) plate reader.  The screen consists of ERβ ligand-binding domain (LBD) tagged with 
glutathione-S-transferase and a terbium-labeled anti-GST antibody.  A proprietary 
fluorescein-labeled ligand, Fluormone ES2 Green, is bound in the LBD.  Excitation of the 
terbium label causes fluorescence at 488 nm, which is transferred to the tagged ligand 
which fluoresces at 518 nm (Figure 4.1).  When the ligand is bound, the ratio of 
518nm/488nm is high; displacement of the fluorescent ligand by a competitor results in 
diminished fluorescence at 518 nm, and thus a lower 518 nm/488 nm ratio. Eight different 
concentrations were examined to obtain a Ki value.  Typical data, as represented for the 
stereoisomers of ISP163, are shown in Figure 4.2.  
 
Figure 4.1: Simplified schematic for TR-FRET ERβ binding assay 
(http://slideplayer.com/slide/8532001/26/images/32/Receptor+binding+
assay.jpg)  
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Figure 4.2: TR-FRET ERβ binding profile of ISP163 isomers 
4.2.2 ERα and ERβ Cell-Based Assay 
Cell based assays were carried out to investigate the agonist and antagonist activity 
of synthesized ligands.  Assays were conducted using a commercially available ERβ assay 
kits from Indigo Biosciences.  The assay involves non-human mammalian cells engineered 
to express human estrogen beta (NR3A2) incorporating both the N-terminal DNA binding 
domain and the C-terminal ligand binding domain.  Cells incorporate the cDNA encoding 
beetle luciferase.  Upon binding, the encoded protein forms homo- and heterodimers that 
interact with specific DNA sequences to activate transcription, including the production of 
luciferase (Figure 4.3).  Quantifying changes in luciferase expression (via relative 
luminescence) provides a surrogate measure of the changes in ERβ activity.  As compared 
to the TR-FRET assay, an increase in fluorescence indicates the increased agonism.  The 
assay can be used to detect either agonist activity or antagonist activity.  In the antagonist 
mode, where the addition of estradiol (EC75 = 3.2 nM) serves as an agonist and thus effects 
transcription and production of luciferase, a decrease in fluorescence signifies that the test 
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compound serves as an antagonist against the action of E2.  Similar kits are available to 
assess functional ERα activity.  The agonist assay was conducted under optimized 
biological conditions delineated in the kit manual, verified to work with the Spectramax 
M5 (white plates) plate reader, and performed in duplicate.  Seven different concentrations 
were examined to obtain an IC50 value.  Typical data for ERβ activity, as represented for 
the four isomers of ISP163, are shown in Figure 4.4. 
 
 
Figure 4.3: Schematic representation of ERα and ERβ cell-based assay 
(https://www.caymanchem.com/pdfs/15739.pdf) 
 
 
 
 
 
 
 
 
 
Figure 4.4: ERβ cell-based agonist assay profile of IS163 isomers  
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4.2.3 TR-FRET Results for 4-(4-(hydroxymethyl)cyclohexyl)phenol and its Analogs 
The binding affinity (Ki) values of lead 4-(4-(hydroxymethyl)cyclohexyl)phenol 
(ISP 171) and its analogs were first studied in Lanthascreen TR-FRET ERβ binding assay 
(Table 4.1).  In particular; compounds bearing a hydroxymethyl functionality attached to 
the cyclohexyl core showed higher affinities in the range 80-240 nM.  Of the two 
components in the mixture of cis- and trans-stereoisomers (ISP 171, IC50 = 240 nM), it 
was found that the trans-isomer was more potent (ISP 358-2, IC50 = 80 nM) than the 
mixture.  Introduction of unsaturation within the six-membered ring (ISP 402, IC50 = 89 
nM) did not greatly change the binding affinity compared to ISP358-2.  Attachment of the 
OH group directly to the cyclohexyl core (ISP33, ISP361) did reduce the affinity by 
approximately one to two orders of magnitude.  This is presumably due to the less than 
optimal distance between phenolic OH and hydroxyl group for proper binding to the 
receptor.  The combination of both a hydroxyl and hydroxymethyl group attached to the 
six-membered ring (ISP 411, 2,500 nM) exhibited a 30-fold reduction in affinity compared 
to ISP358-2.  This result might be attributed to the interaction of the second OH with 
neighboring water molecule inside the cavity thereby creating a disruption of the optimal 
conformation within the ligand binding pocket.  On the other hand, extension of the chain 
length to a hydroxyethyl group (RKP231IIF, 7 nM) increased the affinity, but this trend 
was reversed with the insertion of an exocyclic alkene moiety (RKP228, 521 nM).  This 
decrease in affinity may be due to the reduced flexibility of the side arm. 
Replacing the hydroxymethyl group with different polar groups such as ketone 
(SM01, 4500 nM), oxime (ISP36, 215 nM) or ethyl acrylate functionality (RKP230, 681 
nM) resulted in some decrease in ERβ binding.  The presence of the aliphatic hydroxyl 
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group was not crucial for binding affinity.  In fact, ligands with hydrophobic groups 
attached to the cyclohexyl ring revealed pronounced affinity (ISP366, 11 nM; RKP231IF, 
15 nM) or similar affinity (ISP365, 85 nM).  The ability of simple 4-alkyl phenols to bind 
to ERβ and ERα has previously been reported.106  For example, 4-adamantyl phenol (AdP, 
Figure 4.5) was found to have ERβ IC50 = 200 ± 1 nM and ERα IC50 = 1000 ±1000 nM 
respectively.106  While these binding affinities are considerably less than for E2, they 
highlight the relative importance of the hydrogen bonding between the phenol OH and 
Glu/Arg residues, along with the hydrophobic interactions of the alkyl portion, in 
comparison to hydrogen bonding interactions between His and an aliphatic OH group. 
 
 
 
 
Figure 4.5: Reported ERβ agonist 4-adamantyl phenol (AdP) 
The cyclic ether had diminished affinity (ISP358-1, 250 nM). Introduction of a 2-
methylenehydrazine-1-carboxamide (ML431, 16,000 nM) or 2-methylenehydrazine-1-
carbothioamide (ML432, 5,000 nM) to the cyclohexyl ring greatly reduced binding affinity 
due to rigid and longer chain lengths.  
Meanwhile, compound ISP389, bearing an oxime functionality ortho to the 
phenolic oxygen showed modest affinity whereas those bearing an aldehyde ortho to 
phenolic oxygen such as ISP384, ISP393, and ISP394 reflected significantly lower 
binding affinities ranging from 900 -2100 nM.  Furthermore, an introduction of fluorine  
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Table 4.1: TR-FRET ERβ binding data for six-membered analog 
Compound 
 
TR-FRET 
Data 
(nM) 
Compound 
 
TR-FRET 
 Data 
(nM) 
            
ISP33 
 
 
   960±700 
 
RKP228 
 
 
521±87 
              
ISP361 
 
 
6,000±1600 
     
ISP36 
 
 
215±129 
        
ISP171 
 
240±14 
              
SM01 
 
 
4500±2800 
     
ISP358-2 
 
80±21 
 
                                            
ISP346 
 
 
570±130 
            
                                               
ISP402 
 
89±22 
  
RKP231IF 
 
 
15±2 
     
ISP393 
 
 
900±300 
           
ISP365 
 
 
85±16 
       
ISP411 
 
 
2,500±500 
        
ISP366 
 
 
11±2.7 
 
RKP231IIF 
 
 
7±1 
          
ISP358-I 
 
 
250±56 
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ortho to the phenolic oxygen such as ISP450 and ISP452 decreased the affinity 
dramatically (4281 nM and 880 nM respectively) compared to their non-fluorinated 
analogs.  However, replacing the hydroxyl group in the side chain with fluorine as in 
 
Compound 
 
TR-FRET 
Data 
(nM) 
 
Compound 
 
TR-FRET 
 Data 
(nM) 
           
ISP384 
 
 
1,100±430 
 
                                    
                                     
RKP230 
 
 
681±240 
            
ISP389 
 
 
270±66 
  
                                       
ML431 
 
 
16,000±8,000 
               
ISP394 
 
 
21,000±5000 
 
                                       
ML432                                     
 
 
5,000±2400 
                                       
                                               
ISP441 
 
 
49.5±18.3 
                  
                                       
ISP450 
 
 
4,281±2,516 
 
 
                           
                                               
ISP452 
 
 
880±464 
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ISP441 showed slightly higher affinity (49.5 nM) compared to the parent molecule 
(ISP358-2, 80 nM). 
4.2.4 Cell-based Functional Assay Results for Selected 4-[(hydroxymethyl) 
         cyclohexyl)]phenol Analogs 
4-[4-(Hydroxymethyl)cyclohexyl]phenol and analogs having lower IC50 values 
ranging from 7 to 240 nM were further tested in cell based assays to evaluate both their 
binding affinity as well as ERβ selectivity (Table 4.2).  The mixture of cis- and trans-
stereoisomers (ISP171) and the trans-only isomer (ISP358-2) showed identical ERβ 
agonist potencies (IC50 31 nM) and these results indicated the compounds to be more potent 
in the functional based assay than the TR-FRET ligand displacement assay.  In contrast, 
compounds RKP231IIF, RKP230 and ISP365 resulted in poorer ERβ potencies (IC50 72, 
89, 101 nM respectively) compared to their TR-FRET assay results.  These differences 
may be due to the nature of the assays; the TR-FRET assay measures only displacement of 
a labelled estradiol from the ligand binding domain, while the cell-based assay depends 
upon effecting conformational changes in the ER such that homo-dimerization and DNA 
binding/transcription must occur.  Additional interactions between the aliphatic hydroxyl 
group and the His475 may play a role in these latter conformational changes.  All 
compounds showed no ERβ antagonist activity (> 10,000 nM), or ERα agonist or 
antagonist activity thus demonstrating their pronounced selectivity towards the ERβ.  Of 
those, ISP358-2 gave > 3000-fold selectivity for ERβ over ERα in the cell-based functional 
assay, making it the most selective agonist thus reported.  
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Table 4.2: Cell-based assay data for selected six-membered analogs and comparison to 
TR-FRET assay 
 
 
  
Compound TR-FRET 
ERβ Agonist 
(nM) 
ERβ 
Agonist 
(nM) 
ERβ 
Antagon. 
(nM) 
ERα 
Agonist 
(nM) 
ERα 
Antagon. 
(nM) 
 
ISP171 
 
 
240±14 
 
 
30±15 
 
 
>10,000 
 
 
700,000 
±80,000 
 
 
>10,000 
 
ISP358-2 
 
 
80±21 
 
 
31±7 
 
 
>10,000 
 
 
100,000 
±17,000 
 
 
>10,000 
 
 
RKP231IIF 
 
 
7±1 
 
 
72±16 
 
 
>10,000 
 
 
72,000± 
22,000 
 
 
>10,000 
 
RKP231IF 
 
 
15±2 
 
 
89±6 
 
 
>10,000 
 
 
25,000±13
00 
 
 
>10,000 
 
 
ISP365 
 
 
85±16 
 
 
101±10 
 
 
>10,000 
 
 
In 
progress 
 
 
In 
progress 
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4.2.5 TR-FRET and Cell-based Assay Results for 4-[4-(hydroxymethyl)  
         cycloheptyl]phenol and Analogs 
The ERβ binding affinity (Ki) of lead 4-[4-(hydroxymethyl)cycloheptyl]phenol 
(ISP163) and its analogs were determined in the TR-FRET assay as previously described 
(Table 4.3).  The lead molecule ISP163 showed higher affinity as IC50 = 44 nM.  Extension 
or shortening of the distance between the phenolic and aliphatic hydroxyl groups (ISP248 
or ISP58, IC50 = 37 and 31 nM respectively) has similar binding affinity (within the error 
limits); this change in potency was not as significant as shown in the six membered analogs 
(see Table 4.1) from TR-FRET assay. 
Introduction of a methyl group ortho to the phenolic oxygen (ISP275) decreased 
the affinity by > 100-fold, compared to ISP58, indicating adverse steric interactions in the 
ligand binding pocket.  Introduction of two alkenes to the cycloheptyl ring (RKP35C, IC50 
378 nM) or the bicyclic ether functionality (ISP365, IC50 400 nM) diminished the binding 
affinities by 9-fold compared to ISP163, thus emphasizing the need for flexibility in the 
ring system.  A change in oxidation state of the hydroxyl group, to the cycloheptanone ring 
(ISP242) decreased the binding affinity by 6-fold in comparison to ISP58. Compounds 
having lower IC50 values were further evaluated in cell-based functional assays (Table 4.4). 
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Table 4.3: TR-FRET ERβ binding data for seven-membered analogs 
 
 
 
  
Compound 
 
TR-FRET 
 DATA 
(nM) 
Compound TR-FRET 
 DATA 
(nM) 
      
                                            
ISP163 
 
 
44±16 
                 
                                  
ISP 242 
 
 
182±63 
   
                                          
RKP35C 
 
378±97 
 
                                   
ISP360 
 
 
400±100 
   
ISP248 
 
37±9 
   
ISP275 
 
3400±1500 
            
ISP58 
 
 
31±7 
  
ISP427 
 
 
3,370±3,560 
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Table 4.4: TR-FRET and cell-based assay data for selected seven-and five-membered 
analogs 
 
 
 
 
 
 
Compound TR-
FRET 
DATA 
(nM) 
ERβ 
Agonist 
(nM) 
ERβ 
Antagon. 
(nM) 
ERα  
Agonist 
(nM) 
ERα 
Antagon. 
(nM) 
 
                            
ISP163 
 
 
44±16 
 
 
30±9 
 
 
>100,000 
 
 
10,500 
±200 
 
 
>10,000 
          
                            
ISP248 
 
 
37±9 
 
 
104±27 
 
 
>10,000 
 
 
45,000 
±17000 
 
 
>10,000 
 
 
                              
ISP58 
 
 
31±7 
 
 
401±29 
 
 
>10,000 
 
 
1,400 
±400 
 
 
>10,000 
 
                            
ISP166 
 
 
Not 
done 
 
 
1,460 
±305 
 
 
>10,000 
 
 
350,000 
±250 000 
 
 
>10,000 
 
 
                            
ISP427 
 
 
3,370 
±3,560 
 
 
2,100 
±250 
 
 
>10 000 
 
 
>10,000 
 
 
>10,000 
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The lead molecule, ISP163, displayed similar potency for ERβ agonist activity as 
found in the TR-FRET assay.  The seven-membered analogs varying in distance between 
the hydroxyl groups (ISP248, and ISP58) resulted in lower potencies (IC50 > 100 nM) as 
ERβ agonists, while the oxime analog (ISP166) was nearly 50-fold less potent.  Similar to 
the cyclohexyl compounds, these analogs did not show any ERβ antagonist activity (> 
10,000 nM), or ERα agonist or antagonist activity, indicating their greater selectivity 
towards the ERβ agonist activity.  From those, ISP163 gave > 350-fold selectivity for ERβ 
agonist activity over ERα making it as the most selective agonist among the seven-
membered series.  The five-membered ring analog 4-[3-
(hydroxymethyl)cyclopentyl]phenol (ISP427) showed very poor potency in both the TR-
FRET ligand displacement and cell-based functional assays.  This may be due to the 
inability of this smaller ring to occlude water molecules from the binding site.  
4.2.6 TR-FRET and Cell-based Assay of the Stereoisomers of 4-[4-(hydroxymethyl)- 
          cycloheptyl]phenol 
Since ISP163 is a mixture of four stereoisomers it was crucial to evaluate the 
potency and selectivity of the individual isomers.  Toward this end, binding affinity from 
TR-FRET assay and agonist activity from cell based assay were evaluated (Table 4.5 and 
Figure 4.6).  The two trans-stereoisomers (PK1 and PK2) reflected greater affinity than 
the mixture (ISP163) whereas the cis-stereoisomers PK3 (1R,4S absolute configuration) 
and PK4 (1S,4R absolute configuration) reflected lower affinity in the TR-FRET assay.  In 
contrast, all four isomers revealed lower potency in the cell-based ERβ agonist assay (IC50 
47-119 nM) in comparison to the mixture of stereoisomers.  Of those, PK2 and PK4 
showed higher ERβ agonist activity than for PK1 or PK3.  All of the stereoisomers 
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exhibited no ERβ antagonist activity (> 10μM), and no agonist or antagonist activity (> 
10μM) toward ERα.  However, in search for the better ERβ agonist selectivity between 
isomers, percent ERα agonist activity at highest concentration was assessed.  In this study, 
PK4 (1S,4R absolute configuration) manifested 47% activity at 12μM compared to the 
PK2 (34% activity at 10μM). 
Table 4.5: TR-FRET and cell-based assay data for ISP163 stereoisomers 
 
 
 
 
 
 
 
Figure 4.6: ERβ cell-based assay profiles for individual ISP163 stereoisomers  
 
ISP 163 
Isomers 
TR-
FRET 
ERβ 
(nM) 
ERβ 
Agonist 
(nM) 
ERβ 
Antagon. 
(µM) 
ERα 
Agonist 
(µM) 
% Agonist 
Activity @ 
Highest 
 
Concentration 
(µM)  
ERα 
Antagon. 
(µM) 
 
Mixture 
 
44±16 30±9 >100 10.5±0.2  >10  
PK1 
 
>25 68±48 >36 5±3 150% @ 36 
 
>36 
PK2 
 
33±10 47±4 >23 >10 34% @ 10 
 
>10 
PK3 
 
90±36 119±13 >10 >10 10% @ 10 
 
>10 
PK4 
 
65±26 
 
53±10 >12 >12 47% @ 12 
 
>12 
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4.2.7 CYP450 Assay and Results for ISP358-2 and ISP163 
The four-main drug metabolizing cytochrome P450 isoforms are CYP1A2, 
CYP2D6, CYP2C9, and CYP3A4.107  The interaction of ligands with these CYP450 
isoforms may be evaluated using P450-GloTM inhibition assay kits available from Thermo 
Fisher.  Isoform-specific substrates (Luciferin-ME, Luciferin-MEEGE, Luciferin-H, 
Luciferin-PPXE for CYP1A2, CYP2D6, CYP2C9, and CYP3A4 respectively) are 
incubated with the appropriate CYP enzyme, NADPH regeneration system and the test 
compound.  Each CYP enzyme acts on a specific luminogenic P450-GloTM substrate 
(Reaction A) to produce a luciferin product that generates light (chemiluminescence) upon 
interaction with the luciferin detection reagent (Reaction B), which is added after the CYP 
reaction has been completed (Figure 4.7).  Light is used to monitor CYP activity since the 
amount of light produced is proportional to the amount of luciferin product formed after 
the CYP reaction.   
 
 
 
 
 
 
 
 
Figure 4.7: Schematic diagram for basis of CYP450 assay   
(http://www.lumflu.com/A_Info.asp?id=36)  
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Interaction of the ligand with the CYP, either by metabolism or by inhibition of the 
CYP, causes a decrease in the luminescence.  Typical data for inhibition of CYP2C9 by 
ISP358-2 are shown in Figure 4.8. 
 
 
 
 
 
 
 
 
Figure 4.8: CYP2C9 assay profile for ISP358-2  
The results for the best six-membered ring lead (ISP358-2) and the mixture of 
seven-membered ring stereoisomers (ISP163) are detailed in Table 4.6.  The 
concentrations at which the two lead substances either inhibit these CYP450s and/or are 
metabolized by these CYP450s are significantly greater than their effective ERβ binding 
concentrations, thus confirming their suitability as drug candidates for further 
development. 
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Table 4.6: CYP450 assay data for ISP358-2 and ISP163 
 
 
 
 
 
 
4.2.8 hERG Assay results for ISP358-2 
hERG (the human Ether-à-go-go-Related Gene) assay evaluates a compound’s 
inhibition activity towards the Kv11.1, the alpha subunit of a voltage-gated potassium ion 
channel.  This channel is involved in cardiac action potential repolarization (electrical 
activity) of the heart that regulates the heart's beating, inhibition of which is linked with 
the fatal disorder known as ventricular arrhythmias.108  Compound ISP358-2 was 
submitted to Thermo Fisher to evaluate (on a per-fee basis) the inhibition hERG ion 
channel (Figure 4.9).  The results indicate 13% inhibition at 100 μM, representing an IC50 
of > 100 μM. This results again indicates safety of this lead compound against irregular 
heartbeat at the effective ERβ agonist concentration. 
 
  
CYP Enzyme 
 
ISP358-2 
IC 50 (µM) 
ISP163 
IC 50 (µM) 
CYP 2D6 
 
Did not converge >62.5 
CYP 3A4 
 
>62.5 31±2.7 
CYP 1A2 
 
>62.5 >62.5 
CYP 2C9 
 
34±4.7 1.8±0.3 
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Figure 4.9: hERG profile of ISP358-2  
4.2.9 Nuclear Receptor Panel Screening 
Since ER is a nuclear receptor it is important to establish if potential agonists of 
ERβ are agonists towards other nuclear receptors.  A selected panel of receptors consisted 
of androgen receptor (AR, essential for normal female fertility and male skeletal integrity), 
glucocorticoid receptor (GR, a major component of the endocrine influence, specifically 
stress response), mineralocorticoid receptor (MR, important for expressing proteins which 
regulate ion and water transport), peroxisome proliferator-activator receptor delta (PPAR-
Δ, involved in development of diabetes, obesity, atherosclerosis and cancer), progesterone 
receptor (PR, involved in cell proliferation), thyroid hormone receptor beta (TR-β, 
mediates functions of thyroid hormone), and the vitamin D receptor (VDR, involved in 
mineral metabolism) were considered.  The panel screenings for ISP358-2 and ISP163-
PK4 were conducted by Thermo/Life (on a per-fee basis) from GeneBlazer Cell based 
assay and results are summarized in Tables 4.7 and 4.8.  Both compounds showed no 
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activity at 0.25, 2.5 and 25 μM concentrations thus confirming no cross-reactivity towards 
the aforementioned receptors at the effective ERβ agonist concentration. 
Table 4.7: Nuclear receptor panel screen data for ISP358-2 
 
 
 
 
 
 
Table 4.8: Nuclear receptor panel screen data for ISP163-PK4 
 
 
 
 
 
 
4.3 Description of In vivo Assays and Results 
4.3.1 Assessment of Memory Consolidation in Ovariectomized Mice 
The effects of lead compounds on memory consolidation were assessed.  In 
particular, two types of behavioral tasks were utilized and which diverge in terms of the 
protocol for testing.  The object recognition (OR) task tests the knowledge of object identity 
(“what”) and object placement task (OP) tests the knowledge of object location or spatial 
Nuclear 
receptor 
ISP 358-2 
@ 25 µM 
ISP 358-2 
@ 2.5 µM 
ISP 358-2 
@ 0.25 µM 
AR -6 -5 -6 
GR -1 0 2 
MR 0 0 -1 
PPAR-δ 2 3 2 
PR -2 0 -1 
TR-β -1 -1 -1 
VDR -1 -1 -1 
Nuclear 
receptor 
ISP 163-PK4 
@ 25 µM 
ISP 163-
PK4 
@ 2.5 µM 
ISP 163-
PK4 
@ 0.25 µM 
AR -4 -6 -5 
GR 1 -1 -1 
MR 0 0 1 
PPAR-δ 2 2 3 
PR -1 -2 -1 
TR-β -2 -1 0 
VDR 0 0 -1 
97 
 
 
 
memory (“where”).  These tasks are sensitive to E2, exert low stress on subjects and a 
single training trial is ideal for mediating rapid biochemical activations to memory 
formation.33, 69, 109   Prior to testing, female mice (C57BL/6) used in this study were 
ovariectomized.  For assay of administration directly to the brain, these mice were also 
implanted with a bilateral guide cannula aimed at the dorsal hippocampus.  After one week 
of recovery, mice were trained in a square arena and were allowed to accumulate 30 s 
exploring two identical objects placed near the adjacent corners.  Immediately after this 
training, mice were administered, either by dorsal hippocampal infusion (DH) or 
intraperitoneal injection (IP), with either vehicle (negative control); DPN, a known agonist 
(positive control), or the lead compound (ISP358-2) in different concentrations.  For OP 
retention, animals were retested after 24 h with one of the objects in a different position; 
for OR retention animals were tested after 48 h with one new/novel object in place of a 
familiar object (Figure 4.10).  
 
 
 
 
 
 
 
 
 
Figure 4.10: Illustration of object placement (OP) and object recognition (OR) protocols  
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Since mice are inherently drawn to novelty110 under unthreatened environment, 
mice who remember the training objects spend more time than chance (15 s) with either 
the new placement (OP assay) or novel object (OR assay) and less time than chance 
exploring the familiar object in these assays. 
4.3.2 Assessment of Memory Consolidation by Dorsal Hippocampal Infusion 
Due to its potency and high ERβ selectivity, as well as its ease of preparation, trans-
4-[4- (hydroxymethyl)cyclohexyl]phenol (ISP358-2) was selected for initial screening by 
single DH infusion.  Five groups of mice (10 mice per group) were tested with each group 
receiving either vehicle (1% DMSO in saline), or DPN (10 pg/hemisphere), or ISP358-2 
(10 pg/ hemisphere, 100 pg/hemisphere, 1 ng/hemisphere).  For the object recognition task, 
mice receiving vehicle or the 10 pg dose of ISP358-2 did not spend more than chance time 
with the novel object, while mice receiving the known ERβ agonist DPN, or ISP358-2 at 
the 100 pg or 1 ng/hemisphere dose spent statistically significant more time than chance 
with the novel object (Figure 4.11a).  Similar results were obtained for the object placement 
task; neither administration of the vehicle nor the 10 pg dose of ISP358-2 exhibited 
differences in exploring the familiar vs. the moved object, while treatment with DPN, 100 
pg and 1 ng/hemisphere of ISP358-2 did result in statistically significant more time spent 
with the moved object vs. the familiar object (Figure 4.11b).  These data were confirmed 
by one-sample t-test, one-way ANOVA, and Fisher’s LSD posthoc tests70, 109 and suggest 
that 100 pg and 1 ng of ISP358-2, administered by dorsal hippocampal infusion, enhances 
object recognition and object placement memory consolidation in the ovariectomized 
mouse model. 
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Figure 4.11: a) Amount of time (of 30 sec total) spent with the novel object in OR assay; 
b) Amount of time (of 30 sec total) spent with the novel in OP assay [DH 
infusion] 
4.3.3 Assessment of Memory Consolidation by Intraperitoneal Administration 
While the above results demonstrate the effectiveness of ERβ agonist ISP358-2 for 
memory consolidation in this animal model, dorsal hippocampal infusion is a less than 
ideal means of therapeutic administration.  Studies of CNS drugs indicate that optimal 
characteristics for crossing the blood-brain barrier correspond to molecular weight ≤ 400, 
clog P = 1.5-2.7, polar surface areas (PSA) = 60-70 Å3, number of (nitrogen + oxygen 
atoms) ≤ 5, and low molecular flexibility.111-112. ISP358-2 fits the majority of these criteria 
except that it has PSA ~ 40 Å3.  In order to determine if this compound is capable of passing 
the blood-brain barrier and arriving at the hippocampus, object recognition and object 
placement tasks were conducted after a single intraperitoneal administration (IP) of 
ISP358-2 (Figure 4.12 a and b).  Four groups (10 mice per group) of mice were tested: 
vehicle (1% DMSO in saline), positive control DPN (0.05 mg/kg) and two doses of ISP-
358-2 (0.5 mg/kg and 5 mg/kg).  These doses of ISP358-2 were based in relationship to 
a) b) 
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the known effective dose of DPN previously established by the Frick group.  For the object 
recognition task, mice receiving vehicle did not spend time more than chance with the 
novel object while mice receiving the 0.5 mg/kg or 5 mg/kg dose of ISP358-2 by IP 
injection spent more time with the novel object.  The same trend was observed in the object 
placement task, and both OR and OP data were confirmed by one-sample t-test, one-way 
ANOVA, and Fisher’s LSD posthoc tests.70, 109  These results suggest that 0.5 mg and 5 
mg of ISP358-2 enhanced the object recognition and object placement memory 
consolidation after intraperitoneal administration.  Gratifyingly, these results confirmed 
both effectivity and blood-brain barrier (BBB) permeability of ISP358-2 which is an 
essential requirement of central nervous system (CNS) drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: a) Amount of time (of 30 sec total) spent with the novel object in OR assay; 
b) Amount of time (of 30 sec total) spent with the novel in OP assay [IP 
injection] 
 
 
 
 
 
 
 
b) a) 
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CHAPTER 5 
CONCLUSIONS AND OUTLOOK 
5.1 Summary 
The overall goal of this research was the design, synthesis and biological evaluation 
of ERβ selective agonists for hippocampal memory consolidation in postmenopausal 
women.  Two major types of non-steroidal compounds were synthesized and evaluated for 
in vitro ERβ vs. ERα agonism, and in vivo effect on memory consolidation in an 
ovariectomized mouse model. 
After identifying important prerequisites from the literature and from docking 
studies, research was focused towards the design of (4-hydroxyphenyl)cyclohexyl or 
cycloheptyl derivatives as selective ERβ agonists.  Toward this end, cis-4-(4-
(hydroxymethyl)cycloheptyl)phenol was first prepared from organoiron methodology and 
found to be an ERβ agonist in the 50 nM range with >1000- fold selectivity for ERβ over 
ERα in cell-based assays.81  While these biological results were promising, the organoiron 
synthetic route was problematic and difficult to replicate.  Three alternative syntheses were 
established using cheaper starting materials and more robust synthetic protocols; the most 
efficient route proceeded in fewer steps and with greater yields (20% in six steps).  These 
new protocols gave a racemic mixture of diastereomers of 4-(4-
(hydroxymethyl)cycloheptyl)phenol (ISP163); the individual stereoisomers were obtained 
by preparative chiral HPLC.  The relative stereochemistry of the diastereomers was 
established by NMR spectroscopy, while the absolute configuration of the individual cis-
isomers were determined by single crystal X-ray diffraction analysis.  A second lead 
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molecule, 4-(4-(hydroxymethyl)cyclohexyl)phenol (ISP171) was synthesized by sharing 
common synthetic pathways as in ISP163.  The product was a mixture of cis- and trans-
stereoisomers and a chemical separation of the mixture, via faster oxidative cyclization of 
the cis-isomer, afforded the trans- isomer ISP358-2 in 47% yield under optimal conditions.  
Several other 4-cyclohexyl and cycloheptyl phenolic analogs were prepared with varying 
functional groups, chain lengths, and molecular rigidity in order to establish structure 
activity relationships (SARs).  
A TR-FRET ERβ binding assay was conducted as an initial screen for the binding 
affinity of the synthesized ligands.  The incorporation of an aliphatic hydroxyl functionality 
at the end of the side chain, but not directly to the ring core appeared to have a stronger 
effect on the binding affinity of both six- and seven-membered ring scaffolds (ISP163, 
ISP171, ISP358-2, ISP402, ISP248 and RKP231IIF).  In contrast, introduction of an 
alkene functionality, and thereby rigidity within the ring structure decreased the binding 
affinity of ligands (ISP346 and RKP35c).  To supplement the TR-FRET findings, cell-
based assays were conducted for selected compounds having higher binding affinity to 
investigate their potential for binding and ability to effect transcription.  Among the six-
membered series the trans isomer ISP358-2 revealed the highest potency as ERβ agonists 
(~ 30 nM).  The same trend was observed in the seven-membered series where ISP163 
exhibited the highest ERβ agonist activity (~ 30 nM).  In general, all compounds which 
were tested in cell based assay did not have any observable effect on ERβ antagonist, ERα 
agonist or ERα antagonist activity.  Of particular note is that ISP358-2 and ISP163 exhibit 
> 3000-fold and > 300-fold selectivity for ERβ over ERα, thus making these compounds 
the most selective ERβ agonists yet reported.  Finally, the cell based assay for the individual 
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ISP163 stereoisomers (PK1-PK4) revealed that ISP163-PK4 [4(S)-(4-hydroxyphenyl)-1-
(R)-hydroxymethylenecycloheptane] possessed the best combination of potency (~ 53 nM) 
and ERβ:ERα selectivity (226-fold).   
Having recognized ISP163 and ISP358-2 as best ERβ agonist from each series, 
their metabolic stability was evaluated.  Both compounds exhibited poor inhibitory activity 
(> 30 µM) against four known drug metabolizing CYP450s, thus confirming their stability 
inside the liver.  The exception was ISP163 which exhibited IC50 = 1.8 µM for CYP2C9.  
This value is still considerably poorer than the ERβ IC50 (30 nM).  Neither ISPI63-PK4 
nor ISP358-2 exhibited cross reactivity with other common nuclear receptors (<2% 
activation at 25 µM).  Additionally, ISP358-2 did not show any observable effect on hERG 
inhibition indicating its non-cardiotoxicity.  
Memory consolidation in ovariectomized mice (C57BL/6) was assessed for 
ISP358-2 via DH infusion and IP administration.  A statistically significant effect was 
observed for memory consolidation in both object placement and object recognition tests 
at the 100 pg/hemisphere (DH) and 0.5 mg/Kg (IP) dose level.  These are both 
approximately one order of magnitude less potent in comparison to the DPN; 10 
pg/hemisphere (DH) and 0.05mg/Kg (IP).  These relative efficacies are consistent with the 
relative ERβ agonist activity of ISP358-2 compared to DPN.  The IP data also provides 
strong evidence for the blood-brain-barrier (BBB) permeability of ISP358-2. 
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5.2 Conclusion 
The results presented in this dissertation demonstrate the development of two types 
of non-steroidal selective ERβ agonists.  Among those, [4(S)-(4-hydroxyphenyl)-1-(R)-
hydroxymethylenecycloheptane] (ISP163-PK4) and trans-4-(4-
(hydroxymethyl)cyclohexyl)phenol (ISP358-2) display > 225-fold and > 3000-fold 
selectivity for ERβ over ERα respectively.  ISP358-2 was shown to have a statistically 
significant effect on memory consolidation in ovariectomized mice by either DH and IP 
administration.  The lack of off-target nuclear receptor activity, as well as lack of hERG 
activity, and the high metabolic stability (compared to effective dose) highlight the 
potential for this compound as a potential therapeutic for hippocampal memory 
consolidation. 
5.3 Outlook 
It is evident that great deal of research over the past two decades has focused on the 
design of estrogen receptor beta selective ligands as drug candidates.  There is extensive 
literature on relationships between ERβ agonists and hippocampal physiology for the 
development of new CNS drugs.   
The (4-hydroxyphenyl)cyclohexyl or cycloheptyl based ERβ agonists, specifically 
ISP163 and ISP358-2, described herein serve as a foundation for the development of small 
non-steroidal molecules as ERβ agonists.  Nevertheless, scalable stereo-specific synthesis 
of those is essential for further biological studies.  Moreover, it is important to synthesize 
the cis-ISP171 to compare its potency with respect to trans-stereoisomer (ISP358-2). One 
potential route to this compound is outlined in Scheme 5.1.  
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The crystal structures of ISP358-2 with ERβ and ERα should provide valuable 
information into the origin of its selectivity.  It will be necessary to establish collaborations 
for these studies.  Additionally, while ISP358-2 interacts with the panel of four CYP 
enzymes at concentrations 1,000-fold greater than the ERβ IC50 value, it will be important 
to assess the metabolic products produced from this compound with human liver 
microsomes.  Furthermore, while the memory consolidation efficacy of ISP358-2 via 
intraperitoneal administration demonstrates the ability of this compound to pass the blood-
brain barrier, the ability of this compound to be transported across intestinal mucosa is, yet, 
unknown.  This will require assessment of this lead molecule to be transported across a 
Caco-2 cell monolayer.  A correlation between the Caco-2 monolayer permeability and in 
vivo absorption is well recognized.113-114  Additionally, OP and OR testing via oral (gavage) 
administration could provide evidence for intestinal adsorption.  
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Scheme 5.1: Proposed synthetic protocol for cis- and trans-ISP171 
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CHAPTER 6 
SYNTHESIS AND CHARACTERIZATION 
6.1 Chemicals and General Methods 
All the chemicals were purchased from Sigma-Aldrich, Matrix scientific, or Alfa 
Aesar and used as received.  Reactions with moisture- or air-sensitive reagents were 
conducted under an inert atmosphere of nitrogen in oven-dried glassware with anhydrous 
solvents.  Reactions were followed by TLC on precoated silica plates (60 Å, F254, EMD 
Chemicals Inc) and were visualized by UV lamp (UVGL-25, 254/365 nm).  Flash column 
chromatography was performed by using flash silica gel (32–63 μ).  NMR spectra were 
recorded on Varian UnityInova 400 MHz instrument.  CDCl3, [D6] dimethylsulfoxide and 
[D6] acetone were purchased from Cambridge Isotope Laboratories.  1H NMR spectra were 
calibrated to  = 7.26 ppm for residual CHCl3,  = 2.50 ppm for d5-DMSO and  = 3.30 
ppm for residual d3-CD3OD.  
13C NMR spectra were calibrated from the central peak at  
= 77.23 ppm for CDCl3,  = 39.52 ppm for d6-DMSO and  = 49.00 ppm for CD3OD.  
6.2 Experimental Details  
 
 
 
 
Methyl 4-methoxybenzoate (2.2).  Para anisic acid 2.1 (8.010 g, 52.56 mmol) was 
dissolved in methanol (200 mL) and SOCl2 (10 mL, 6.8 mmol) was added dropwise with 
stirring at 0 °C over 30 min.  The system was heated at 65 ˚C for 12 h under N2.  The 
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resulting mixture was cooled to room temperature and diluted with water (50 mL).  
Methanol was evaporated and the pH was adjusted to pH = 7 with saturated sodium 
bicarbonate solution (5 mL).  The resulting solution was extracted with ethyl acetate (3 × 
30 mL).  The combined organic extracts were washed with brine (20 mL), dried (MgSO4), 
and concentrated to give 2.2 as a colorless solid (7.16 g, 82%).  
1H NMR (400 MHz, d6-
DMSO) δ 7.04 and 6.17 (AA’BB’, JAB = 8.7 Hz, 4H), 2.95 (s, 3H), 2.93 (s, 3H) ppm.  13C 
NMR (100 MHz, d6-DMSO) δ 165.9, 163.2, 131.2, 121.8, 114.0, 55.5, 52.0 ppm. The 
NMR spectral data for 2.2 are consistent with the literature values.115 
 
 
 
 
 
5-(4-Methoxyphenyl)-1,8-nonadien-5-ol (2.3a).  Dry magnesium turnings (3.654 g, 152.1 
mmol) were placed in a flame dried three-necked flask followed by THF (30 mL).  The 
system was connected to the N2 environment while stirring and fitted with a condenser and 
an addition funnel.  The addition funnel was loaded with a solution of 4-bromo-1-butene 
(7.72 mL, 76.1 mmol) in THF (20 mL).  A little amount of the bromobutene solution (2 
mL) was added slowly to the magnesium turnings, and the contents were heated to reflux.  
Once the Grignard formation had started, the remaining bromide solution was added 
dropwise maintaining a gentle reflux.  The reaction was stirred until most of the magnesium 
had reacted.  A solution of methyl 4-methoxybenzoate 2.2 (2.528 g, 15.20 mmol) in THF 
(30 mL) was loaded into the addition funnel and added dropwise over 30 min.  After stirring 
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overnight at ambient temperature, a saturated solution of NH4Cl (30 mL) was added to 
quench the reaction.  The resultant emulsion was stirred for 2 h and the solution was 
extracted with ether (3 x 40 mL).  The combined organic layers were washed with water 
(30 mL), then brine (2 x 20 mL) and dried (MgSO4).  The solvent was evaporated to give 
alcohol 2.3a as a yellow oil (3.182 g, 85%).  1H NMR (400 MHz, CDCl3) δ 7.29 and 6.88 
(AA’BB’, JAB = 8.9 Hz, 4H), 5.84-5.73 (m, 2H), 4.98–4.88 (m, 4H), 3.81 (s, 3H), 1.96–
1.84 (m, 8H) ppm.   13C NMR (100 MHz, CDCl3) δ 158.2, 139.0, 137.9, 126.6, 114.8, 
113.7, 77.1, 55.3, 42.4, 28.1 ppm. 
 
 
 
 
 
1-(4-Methoxyphenyl)-4-cyclohepten-1-ol (2.4a).  Alcohol 2.3a (1.015 g, 4.126 mmol) 
was dissolved in dry CH2Cl2 (415 mL, 0.01 M) to give a colorless solution.  A solution of 
Grubbs I catalyst (0.136 g, 0.165 mmol, 4%) in CH2Cl2 (15 mL) was added slowly through 
the syringe pump over 10 h and the mixture was heated at 40 °C with stirring for 12-18 h.  
The reaction mixture was cooled to room temperature, quenched with DMSO (50 eq, 0.600 
mL) and continued to stir for 12 h.  The mixture was concentrated to dryness and the crude 
material was purified by column chromatography (SiO2, hexanes-diethyl ether = 80:20) to 
give 2.4a (0.675 g, 75%) as a green oil.  1H NMR (400 MHz, CDCl3) δ 7.43 and 6.87 
(AA’BB’, JAB = 9.0 Hz, 4H), 5.86-5.83 (m, 2H), 3.80 (s, 3H), 2.55-2.44 (m, 2H), 2.10-1.97 
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(m, 4H), 1.90-1.82 (m, 2H), ppm.  13C NMR (100 MHz, CDCl3)  158.3, 142.3, 132.1, 
125.8, 113.5, 76.5, 55.2, 40.1, 23.0 ppm. 
 
 
 
 
 
 
5-(4-Methoxyphenyl)-1-cycloheptene (2.5).  Alcohol 2.4a (1.720 g, 7.880 mmol) was 
dissolved in dry CH2Cl2 (50 mL) to give a light green solution.  Triethylsilane (1.4 mL, 8.8 
mmol) was added followed by TFA (6.2 mL, 79 mmol).  The mixture was stirred at room 
temperature for 48 h while monitoring the reaction by TLC.  After complete disappearance 
of starting material, the solution was concentrated to a bilayer oil and purified by column 
chromatography (SiO2, hexanes-ethyl acetate = 50:50) to give 2.5 as a brown oil (1.433 g, 
90%).  1H NMR (400 MHz, CDCl3)  7.11 and 6.84 (AA’BB’, JAB = 8.6 Hz, 4H), 5.91-
5.87 (m, 2H), 3.79 (s, 3H), 2.69 (tt, J = 11.3, 3.2 Hz, 1H), 2.35-2.25 (m, 2H), 2.23-2.13 (m, 
2H), 1.91-1.83 (m, 2H), 1.54-1.43 (m, 2H) ppm.  13C NMR (100 MHz, CDCl3)  157. 9, 
141.8, 132.5, 127.7, 113.9, 55.5, 49.6, 35.2, 28.2 ppm. 
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1,2-Epoxy-5-(4-methoxyphenyl)cycloheptane (2.5a).  A solution of cycloheptene 2.5 
(0.551g, 2.73 mmol) in freshly distilled CH2Cl2 (20 mL) was stirred for 10 min.  To this 
solution was added dropwise a solution of m-chloroperoxybenzoic acid (mCPBA) (1.008 
g, 70% wt, 4.090 mmol) in freshly distilled CH2Cl2 (10 mL).  The solution was stirred 
under nitrogen and the reaction was followed by TLC.  The solvent was evaporated and 
residue was treated with saturated sodium bicarbonate solution (20 mL) with stirring for 
30 min.  The mixture was extracted with CH2Cl2 (3 x 20 mL), concentrated and purified 
by column chromatography (SiO2, hexanes-ethyl acetate = 50:50) to give 7 (0.441 g, 74%) 
as a yellow oil.  This was determined to be a mixture of cis- and trans-stereoisomers by 1H 
and 13C NMR spectroscopy.  1H NMR (400 MHz, CDCl3)  7.12-7.05 (m, 4H),  6.86-6.79 
(m, 4H), 3.78 (s, 3H), 3.77 (s, 3H), 3.20-3.16 (m, 2H), 3.13-3.07 (m, 2H), 2.55 (tt, J = 11.1, 
3.3 Hz, 1H), 2.41-2.28 (m, 4H), 2.13 (tt, J = 11.1, 2.2 Hz, 1H), 1.93-1.84 (m, 2H), 1.83-
1.77 (m, 2H), 1.75-1.67 (m, 2H), 1.66-1.57 (m, 4H), 1.51-1.39 (m, 2H) ppm.  13C NMR 
(100 MHz, CDCl3)  157.8/157.6, 141.2, 139.9, 127.6/127.3, 113.8/113.7, 56.1, 55.1, 49.2, 
48.0, 32.6, 32.0, 28.8, 27.5 ppm. 
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4-(4-Methoxyphenyl)cycloheptanol (2.6).  Epoxide 2.5a (0.100 g, 0.460 mmol) was 
dissolved in dry THF under N2.  To this solution was added LiAlH4 (0.048 g, 1.4 mmol) 
and AlCl3 (0.056 g, 0.46 mmol). The resulting mixture was stirred for 12 h, then treated 
with water (15 drops) and diluted with saturated aqueous KOH (3 mL) and water (10 mL).  
The mixture was filtered through celite and extracted with ether (3 × 20 mL).  The 
combined organic extracts were dried (MgSO4), and solvent was evaporated.  The residue 
was purified by column chromatography (SiO2, hexanes-ethyl acetate = 20:80) to give 2.6 
(0.032 g, 32%) as a light-yellow oil.  This product was determined to be a mixture of cis- 
and trans-stereoisomers on the basis of 1H and 13C NMR spectroscopy.  1H NMR (400 
MHz, CDCl3) δ 7.11 and 7.09 (2 × d, J = 8.3 Hz, 2H total), 6.83 (d, J = 8.2 Hz, 2H), 4.06-
4.00 and 3.99-3.90 (2 × m, 1H total), 3.78 (s, 3H), 2.72–2.56 (m, 1H), 2.15-2.05 (m, 1H), 
2.02–1.50 (m, 10H) ppm.  13C NMR (100 MHz, CDCl3)  157.6, 141.4, 127.5, 113.7, 72.7, 
71.6, 55.2, 46.2, 38.2, 37.6, 36.9, 35.7, 31.7, 29.6, 23.3, 21.3 ppm. 
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4-(4-Methoxyphenyl)cycloheptanol (2.6).  To a solution of cycloheptene 2.5 (1.24 g, 6.14 
mmol) in freshly distilled THF (25 mL) at 0 ˚C, was added dropwise a solution of borane-
tetrahydrofuran complex (1M in THF, 11.3 mL, 11.3 mmol).  The solution was gradually 
warmed to room temperature and stirred for 20 h under N2.  The reaction mixture was 
cooled to 0 ˚C, and water (440 mL) was added slowly followed by 30% hydrogen peroxide 
(8.50 mL) and 1N sodium hydroxide (14.5 mL).  The resulting solution was stirred at room 
temperature for 30 min and extracted with ethyl acetate (2 x 20 mL), concentrated and 
purified by column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to give 2.6 
(1.150 g, 85%) as a yellow oil.  This was determined to be a mixture of diastereoisomers 
by 1H and 13C NMR spectroscopy by comparison to a sample previously prepared. 
 
 
 
 
 
4-(4-Methoxyphenyl)cycloheptanone (2.7). A solution of epoxide 2.5a (0.038 g, 0.17 
mmol) in benzene (20 mL) was treated with borontrifluoride etherate (0.15 mL, 0.87 mmol) 
under N2.  The light yellow solution became darker in color and was stirred for 1 h.  The 
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mixture was treated with saturated aqueous sodium carbonate (25 mL), and the organic 
layer was separated and dried (MgSO4).  The solvent was evaporated under reduced 
pressure to give a yellow crude oil.  The residue was purified by column chromatography 
(SiO2, hexanes-ethyl acetate = 80:20) to afford 2.7 (0.010 g, 26%) as a colorless oil.  
1H 
NMR (400 MHz, CDCl3) δ 7.10 and 6.84 (AA’BB’, JAB = 8.7 Hz, 4H), 3.79 (s, 3H), 2.77–
2.53 (m, 4H), 2.16–1.52 (m, 7H) ppm.  13C NMR (100 MHz, CDCl3) δ 215.0, 157.9, 139.9, 
127.4, 113.9, 55.3, 47.9, 43.8, 42.9, 38.6, 32.2, 23.8 ppm.  The spectral data obtained for 9 
was consistent with the literature values.87 
 
 
 
 
 
 
4-(4-Methoxyphenyl)cycloheptanone (2.7).  Method A: To a solution of cycloheptane-
alcohol 2.6 (0.701g, 3.19 mmol) in CH2Cl2 (30 mL) at room temperature, were added 
pyridinium chlorochromate (1.39 g, 6.44 mmol) and silica (or celite) (1.52 g), and the 
resulting mixture was stirred at room temperature for 4 h.  The solution was filtered through 
a small pad of silica gel eluting with CH2Cl2.  The filtrate was concentrated in vacuo, and 
the residue was purified by column chromatography (SiO2, hexanes-ethyl acetate = 80:20) 
to afford 2.7 (0.389 g, 55%) as a colorless oil.  The 1H NMR spectrum of the product was 
identical to that previously obtained. 
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Method B: Dry magnesium turnings (0.152 g, 6.33 mmol) were placed in a flame dried 
three-necked flask followed by THF (10 mL).  A solution of propylbromide (0.200 mL, 
1.27 mmol) in THF (2 mL) was added dropwise while refluxing under nitrogen 
environment.  Once the Grignard formation was completed, the mixture was cooled to 
room temperature and a solution of 1,1’-(azodicarbonyl)dipiperidine (0.319g, 2.53 mmol) 
in THF (4 mL) was added dropwise over 15 min.  Then alcohol 2.6 (0.132 g, 0.600 mmol) 
was slowly added while stirring overnight at ambient temperature.  A saturated solution of 
NH4Cl (30 mL) was added to quench the reaction.  The resultant emulsion was stirred for 
30 min and the solution was extracted with ether (2 x 20 mL).  The combined organic layers 
were washed with water (30 mL), then brine (20 mL) and dried (MgSO4).  The solvent was 
evaporated and purified by column chromatography (SiO2, hexanes-ethyl acetate = 80:20) 
to afford 2.7 (0.027 g, 20%) as a colorless oil.  The 1H NMR spectrum of the product was 
identical to that previously obtained. 
Method C: To a solution of cycloheptane-alcohol 2.6 (0.787 g, 3.58 mmol) in CH2Cl2 (38 
mL) at room temperature, were added Dess–Martin periodinane (4.55 g, 10.7 mmol) and 
water (0.2 mL) and mixture was stirred at room temperature for 6 h.  The mixture was 
quenched with 1:1 mixture of saturated Na2S2O3 and NaHCO3 solution and continued to 
stir for 30 min.  The resulting solution was stirred at room temperature for 30 min and 
extracted with ethyl acetate (2 x 20 mL), dried (MgSO4) concentrated and purified by 
column chromatography (SiO2, hexanes ethylacetate = 80:20) to afford 2.7 (0.389 g, 50%) 
as a colorless oil.  The 1H NMR spectrum of the product was identical to that previously 
obtained. 
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1-(4-Methoxyphenyl)-4-methylenecycloheptane (2.8).  To a stirred solution of 
PPh3CH3Br (1.25 g, 3.50 mmol) in anhydrous THF (30 mL) at -10˚C under N2, was added 
a solution of n-butyl lithium (1.6 M in hexanes, 2.3 mL, 3.7 mmol) dropwise.  After 
complete addition, the deep yellow mixture was stirred for another 45 min at -10˚C before 
slowly adding a solution of 2.7 (0.380 g, 1.74 mmol) in THF (6 mL).  The solution changed 
from a deep to light yellow in color, and the mixture was gradually warmed to room 
temperature and stirred overnight.  The solution was diluted with water (20 mL) and 
aqueous layer was extracted with ethyl acetate (2 × 20 mL).  The combined organic extracts 
were washed with brine and dried (MgSO4).  The residue was purified by column 
chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 2.8 (0.296 g, 79%) as a light-
yellow oil.  1H NMR (400 MHz, CDCl3) δ 7.10 and 6.83 (AA’BB’, JAB = 8.4 Hz, 4H), 4.77 
(s, 2H), 3.79 (s, 3H), 2.61–2.45 (m, 2H), 2.32 (broad t, J = 12.2 Hz, 2H), 2.00–1.84 (m, 
3H), 1.71–1.48 (m, 4H) ppm.  13C NMR (100 MHz, CDCl3) δ 157.6, 151.9, 141.6, 127.7, 
113.8, 110.9, 55.5, 47.5, 37.9, 37.2, 36.1, 35.3, 27.4 ppm. 
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(4-(4-Methoxyphenyl)cycloheptyl)methanol (2.9).  To a solution of 2.8 (0.296 g, 1.37 
mmol) in freshly distilled THF (10 mL) at 0 ˚C, was added dropwise a solution of borane-
tetrahydrofuran complex (1M in THF, 2.75 mL, 2.7 mmol).  The resulting mixture was 
warmed to room temperature and stirred for 20 h.  The reaction mixture was cooled to 0 
˚C, and pure ethanol (115 mL) was added slowly followed by 30% hydrogen peroxide (2 
mL) and 3N sodium hydroxide (10 mL).  The mixture was heated at reflux for 1 h, extracted 
with ethyl acetate (2 × 20 mL), dried (MgSO4), and the solvent evaporated.  The crude 
material was purified by column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to 
give 2.9 (0.155 g, 48%) as a colorless gum.  This was determined to be a mixture of 
diastereoisomers by 1H and 13C NMR spectroscopy.  1H NMR (400 MHz, CDCl3) δ 7.11 
and 6.83 (AA’BB’, JAB = 8.8 Hz, 4H), 3.77 (s, 3H), 3.46 (d, J = 6.4 Hz, 2H), 2.69–2.55 (m, 
1H), 2.00–1.72 (m, 8H), 1.68–1.39 (m, 4H) ppm.  13C NMR (100 MHz, CDCl3) δ 157.6, 
142.1, 141.8, 127.7, 113.8, 68.6, 68.4, 55.4, 47.2, 46.0, 42.2, 41.0, 38.8, 36.8, 36.5, 33.0, 
31.5, 30.6, 29.9, 28.5 ppm. 
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4-(4-(Hydroxymethyl)cycloheptyl)phenol (2.10).  To a stirred solution of 2.9 (0.180 g, 
0.769 mmol) in anhydrous CH2Cl2 (10 mL) at -78 ˚C, was added dropwise a solution of 
boron tribromide  (1M in CH2Cl2, 2.31 mL, 2.31 mmol).  After complete addition, the 
reaction mixture was stirred for 30 min at -78˚C and gradually warmed to room temperature 
over a 2 h period.  The mixture was quenched with water (10 mL) and the aqueous layer 
was extracted with CH2Cl2 (3 × 20 mL).  The combined organic extracts were washed with 
brine and dried (MgSO4).  Evaporation of the solvent and purification from column 
chromatography (SiO2, hexanes-ethyl acetate = 50:50) gave 2.10 (0.048 g, 28%) as a 
colorless solid.  This product was determined to be a mixture of cis- and trans-
stereoisomers on the basis of 1H and 13C NMR spectroscopy.  mp 60-63 °C.  1H NMR (400 
MHz, CDCl3) δ 7.03 and 6.74 (AA’BB’, JAB = 8.5 Hz, 4H), 5.10 (s, 1H),3.48 (d, J = 6.6 
Hz, 2H), 2.67–2.49 (m, 1H), 1.97–1.32 (m, 11 H) ppm.  13C NMR (400 MHz, CDCl3) δ 
153.8, 142.0, 141.8, 127.9, 127.8, 115.4, 68.6, 68.5, 47.2, 46.1, 42.2, 41.3, 38.9, 36.7, 36.5, 
33.0, 31.5, 30.6, 29.9, 28.5, 27.4, 24.3 ppm. 
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Methyl 4-((tert-butyldimethylsilyl)oxy)benzoate (2.12).  To a stirred solution of methyl-
4-hydroxybenzoate 2.11 (8.000 g, 52.5 mmol) in anhydrous CH2Cl2 (80 mL) under N2 was 
added imidazole (10.7 g, 157 mmol) while stirring at 0 ˚ C.  After 45 min, tert-butyldimethyl 
silyl chloride (11.9 g, 78.9 mmol) was added and stirred at 0 ˚C for 2 h, and at room 
temperature overnight.  The resulting mixture was diluted with brine (70 mL) and 
partitioned with CH2Cl2 (3 x 30 mL).  The combined organic extracts were dried (MgSO4), 
concentrated and purified by column chromatography (SiO2, hexanes -ethyl acetate = 
90:10) to give 2.12 as a colorless gum. (11.73 g, 84%).  1H NMR (400 MHz, CDCl3) δ 7.93 
and 6.84 (AA’BB’, JAB = 8.9 Hz, 4H), 3.86 (s, 3H), 0.97 (s, 9H), 0.21 (s, 6H) ppm.  13C 
NMR (100 MHz, CDCl3) δ 170.0, 160.2, 131.5, 123.2, 119.9, 51.9, 25.7, 18.1, -4.3 ppm.  
The spectral data for this compound were consistent with the literature values.116 
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5-(4-((tert-Butyldimethylsilyl)oxy)phenyl)nona-1,8-dien-5-ol (2.13).  Dry magnesium 
turnings (6.75 g, 0.281 mmol) were placed in a flame dried three-necked flask followed by 
THF (25 mL).  The system was under N2 while stirring and fitted with a condenser and an 
addition funnel.  The addition funnel was loaded with a solution of 4-bromo-bute-1-ene 
(11.5 mL, 0.113 mol) in THF (20 mL).  A slight amount of bromobutene solution (3 mL) 
was added slowly to the magnesium turnings, and the contents were heated at 65 ˚C to 
reflux.  Once the Grignard formation was started, the remaining bromide solution was 
added dropwise.  The reaction was stirred until most of the magnesium had reacted and a 
solution of 2.12 (5.000 g, 18.8 mmol) in THF (25 mL) was loaded into the addition funnel 
and added dropwise over 45 min.  The mixture was stirred overnight at ambient 
temperature and a saturated solution of NH4Cl (30 mL) was added to quench the reaction.  
The resultant emulsion was stirred for 1 h and the solution was extracted with ether (3 x 30 
mL).  The combined organic extracts were washed with water (30 mL), followed by brine 
(2 x 20 mL) and dried (MgSO4).  The solvent was evaporated to give pure alcohol 2.13 as 
a colorless oil (5.208 g, 80%).  1H NMR (400 MHz, CDCl3) δ 7.23 and 6.82 (AA’BB’, JAB 
= 8.6 Hz, 4H), 5.85-5.73 (m, 2H), 5.01–4.86 (m, 4H), 2.13–1.80, (m, 9H), 1.01 (s, 9H), 
0.22 (s, 6H) ppm.   13C NMR (100 MHz, CDCl3) δ 154.2, 140.0, 138.4, 126.4, 119.6, 114.6, 
76.8, 42.2, 28.2, 25.8, 18.3, -4.3 ppm. 
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1-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cyclohept-4-en-1-ol (2.14).  To a solution of 
2.13 (0.313 g, 0.903 mmol) in dry CH2Cl2 (100 mL, 0.01 M) was added a solution of 
Grubbs I catalyst (0.029 g, 0.032 mmol, 4%) in CH2Cl2 (10 mL) via syringe pump over 10 
h and the mixture was stirred at 40 °C for 24 h.  Reaction mixture was cooled to room 
temperature, quenched with DMSO (50 eq, 0.15 mL) and continued to stir for another 12 
h.  The mixture was concentrated to a dark brown crude material and directly subjected to 
the column chromatography (SiO2, hexanes- diethyl ether = 80:20) to give 2.14 (0.247 g, 
86%) as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 7.35 and 6.79 (AA’BB’, JAB = 8.7 
Hz, 4H), 5.86-5.79 (m, 2H), 2.54-2.43 (m, 2H), 2.10–1.94 (m, 4H), 1.90-1.82 (m, 2H), 1.73 
(s,1H), 0.99 (s, 9H), 0.20 (s, 6H) ppm.  13C NMR (100 MHz, CDCl3)  154.5, 142.9, 132.3, 
125.9, 119.8, 76.7, 40.3, 25.7, 23.2, 18.3, -4.2 ppm. 
 
 
 
 
 
tert-Butyl(4-(cyclohept-4-en-1-yl)phenoxy)dimethylsilane (2.15).  To a solution of 2.14 
(1.601 g, 5.034 mmol) in anhydrous CH2Cl2 (20 mL) was added triethylsilane (0.8 mL, 5.0 
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mmol) followed by TFA (4.0 mL, 20 mmol).  The mixture was stirred at room temperature 
for 3 h while monitoring the reaction by TLC.  After detecting the decomposition of both 
starting material and product, the solution was concentrated to a dark brown oil and directly 
subjected to the column chromatography (SiO2, hexanes = 100%) to give 2.15 as a light-
yellow oil (0.906 g, 60%).  1H NMR (400 MHz, CDCl3)  7.05 and 6.78 (AA’BB’, JAB = 
8.7 Hz, 4H), 5.92-5.89 (m, 2H), 2.69 (tt, J = 11.2, 3.2 Hz, 1H), 2.36-2.27 (m, 2H), 2.24-
2.14 (m, 2H), 1.93-1.85 (m, 2H), 1.55-1.44 (m, 2H), 1.01 (s, 9H), 0.22 (s, 6H) ppm.  13C 
NMR (100 MHz, CDCl3)  153.6, 142.1, 132.7, 127.7, 120.0, 49.8, 35.2, 28.1, 25.9, 18.3, 
-4.2 ppm. 
 
 
 
 
 
tert-Butyl(4-(cyclohept-4-en-1-yl)phenoxy)dimethylsilane (2.15).  To a solution of 
phenol 2.15a (0.212 g, 1.13 mmol) in anhydrous CH2Cl2 (20 mL) was added imidazole 
(0.230 g, 3.38 mmol) while stirring at 0 ˚C under N2.  After 30 min tert-butyldimethyl silyl 
chloride (0.254 g, 1.69 mmol) was added at 0 ˚C and mixture was gradually warmed to 
room temperature overnight.  The resulting mixture was diluted with brine (20 mL) and 
extracted with CH2Cl2 (2 x 20 mL).  The combined organic extracts were dried (Na2SO4), 
concentrated and purified by column chromatography (SiO2, hexanes-ethyl acetate = 
90:10) to give 2.15 as a light-yellow oil (0.240, 70%).  The 1H NMR spectral data was 
identical to that previously obtained.  
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4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cycloheptan-1-ol (2.16).  To a solution of 
2.15 (0.906 g, 2.99 mmol) in freshly distilled THF (20 mL) at 0 ˚C under N2 was added 
dropwise a solution of borane-tetrahydrofuran complex (1M in THF, 6.0 mL, 6.0 mmol).  
The solution was gradually warmed to room temperature and stirred for 18 h.  The reaction 
mixture was cooled to 0 ˚C, and water (250 mL) was added slowly followed by 30% 
hydrogen peroxide (4.5 mL) and 1N sodium hydroxide (7.5 mL).  The resulting solution 
was stirred at room temperature for another 30 min  and extracted with ethyl acetate (2 x 
25 mL), concentrated and purified by column chromatography (SiO2, hexanes-ethyl acetate 
= 80:20) to give 2.16 (0.880 g, 92%) as a yellow oil.  This was determined to be a mixture 
of diastereoisomers by 1H and 13C NMR spectroscopy.  1H NMR (400 MHz, CDCl3) δ 7.01 
(m, 2H), 6.74 (m, 2H), 4.06-3.99 and 3.98-3.90 (2 x m, 1H total), 2.69-2.53 (m, 1H), 2.14-
1.49 (m, 11H), 0.97 (s, 9H), 0.18 (s, 6H) ppm.  13C NMR (100 MHz, CDCl3)  153.6, 142.1, 
127.5, 120.0, 73.0, 71.9, 46.4, 46.1, 38.3, 37.8, 37.3, 37.1, 37.0, 35.9, 31.8, 29.8, 25.9, 23.5, 
21.5, 18.4, - 4.2 ppm. 
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4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cycloheptan-1-one (2.17).  To a solution of 
2.16 (0.050 g, 0.16 mmol) in CH2Cl2 (10 mL) at room temperature, was added Dess–Martin 
periodinane (0.132 g, 0.312 mmol) and water (0.1 mL) and mixture was stirred at room 
temperature for 6 h.  The mixture was quenched with 1:1 mixture of saturated Na2S2O3 and 
NaHCO3 solution and continued to stir for another 30 min.  The resulting solution was 
extracted with CH2Cl2 (2 x 20 mL), dried (Na2SO4), concentrated and purified by column 
chromatography (SiO2, hexanes-ethyl acetate = 80:20) to afford 2.17 (0.036 g, 72%) as a 
colorless oil.  1H NMR (400 MHz, CDCl3) δ 7.01 and 6.75 (AA’BB’, JAB = 8.6 Hz, 4H), 
2.72–2.51 (m, 5H), 2.13–2.06 (m, 1H), 2.04–1.95 (m, 2H), 1.86–1.68 (m, 2H), 1.62–1.52 
(m, 1H), 0.97 (s, 9H), 0.18 (s, 6H) ppm.  13C NMR (100 MHz, CDCl3) δ 215.3, 153.9, 
140.6, 127.5, 120.1, 48.1, 44.0, 43.1, 38.7, 32.2, 25.9, 24.1, 18.3, -4.2 ppm. 
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tert-Butyldimethyl(4-(4-methylenecycloheptyl)phenoxy)silane (2.18).  To a stirred 
solution of PPh3CH3Br (0.476 g, 1.33 mmol) in anhydrous THF (20 mL) at -10˚C under 
N2, was added a solution of n-butyl lithium (1.6 M in hexanes, 0.83 mL, 1.3 mmol) 
dropwise.  After complete addition, the deep yellow mixture was stirred for another 45 min 
at -10˚C before slowly adding a solution of 2.17 (0.212 g, 0.667 mmol) in THF.  The 
solution changed from a deep to light yellow in color, and the mixture was gradually 
warmed to room temperature and stirred overnight.  The solution was diluted with water 
(20 mL) and aqueous layer was extracted with ethyl acetate (2 × 25 mL).  The combined 
organic extracts were washed with brine and dried (Na2SO4).  Removal of the solvent and 
purification from column chromatography (SiO2, hexanes–ethyl acetate = 90:10) gave 2.18 
(0.120 g, 57%) as a light-yellow oil.  1H NMR (400 MHz, CDCl3) δ 7.03 and 6.75 
(AA’BB’, JAB = 8.7 Hz, 4H), 4.76 (s, 2H), 2.59–2.45 (m, 2H), 2.37–2.26 (m, 2H), 2.01–
1.85 (m, 3H), 1.70–1.48 (m, 4H), 1.00 (s, 9H), 0.20 (s, 6H) ppm.  13C NMR (100 MHz, 
CDCl3) δ 153.4, 151.9, 142.3, 127.7, 120.0, 110.7, 47.6, 40.0, 37.2, 36.3, 35.4, 27.6, 25.9, 
18.4, -4.2 ppm. 
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4-(4-(Hydroxymethyl)cycloheptyl)phenol (2.10).  To a solution of 2.18 (0.320 g, 1.01 
mmol) in freshly distilled THF (10 mL) at 0 ˚C, was added dropwise a solution of borane-
tetrahydrofuran complex (1M in THF, 2.1 mL, 2.1 mmol).  The resulting mixture was 
warmed to room temperature and stirred for 18 h.  The reaction mixture was cooled to 0 
˚C, and pure ethanol (85 mL) was added slowly followed by 30% hydrogen peroxide (2.0 
mL) and 3N sodium hydroxide (2.5 mL).  The mixture was stirred for 1 h at room 
temperature, extracted with ethyl acetate (2 × 20 mL), dried (Na2SO4), and the solvent 
evaporated.  The crude material was purified by column chromatography (SiO2, hexanes-
ethyl acetate = 60:40) to give 2.10 (0.088 g, 40%) as a colorless solid.  This was determined 
to be a mixture of diastereoisomers by 1H and 13C NMR spectroscopy.  mp 60-63 °C.  1H 
NMR (400 MHz, CDCl3) δ 7.03 and 6.74 (AA’BB’, JAB = 8.7 Hz, 4H), 5.53 (s, OH), 3.48 
(d, J = 6.4 Hz, 2H), 2.65–2.49 (m, 1H), 1.97–1.30 (m, 12H).  13C NMR (100 MHz, CDCl3) 
δ 153.8, 142.0, 141.8, 127.7, 115.4, 68.8, 68.5, 47.2, 46.1, 42.2, 41.3, 38.9, 36.7, 36.5, 33.0, 
31.5, 30.6, 29.9, 28.5, 27.5, 24.3 ppm.  The NMR spectral data is consistent with previously 
observed values. 
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(4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cycloheptyl)methanol (2.19)  To a solution 
of 2.18 (0.821 g, 2.60 mmol) in freshly distilled THF (10 mL) at 0 ˚C, was added dropwise 
a solution of borane-tetrahydrofuran complex (1M in THF, 5.4 mL, 5.4 mmol).  The 
resulting mixture was warmed to room temperature and stirred for 18 h.  The reaction 
mixture was cooled to 0 ˚C, and 1N sodium hydroxide (3.2 mL) was added slowly followed 
by 30% hydrogen peroxide (1.5 mL).  The mixture was stirred for 1 h at room temperature, 
extracted with ethyl acetate (2 × 25 mL), dried (Na2SO4), and the solvent evaporated.  The 
crude material was purified by column chromatography (SiO2, hexanes-ethyl acetate = 
80:20) to give 2.19 (0.572 g, 66%) as a colorless oil.  This was determined to be a mixture 
of diastereoisomers by 1H and 13C NMR spectroscopy.  1H NMR (400 MHz, CDCl3) δ 7.02 
and 6.74 (AA’BB’, JAB = 8.3 Hz, 4H), 3.45 (d, J = 6.5 Hz, 2H), 2.67–2.53 (m, 1H), 1.98–
1.38 (m, 11H), 1.29-1.09 (m, 1H), 0.98 (s, 9H), 0.19 (s, 6H) ppm.  13C NMR (100 MHz, 
CDCl3) δ 153.5, 142.6, 142.4, 127.6, 127.5, 119.9, 68.7, 68.5, 47.3, 46.1, 42.2, 41.2, 38.9, 
36.8, 36.4, 33.1, 31.5, 30.7, 30.0, 28.5, 27.6, 26.1, 24.2, 18.3, -4.2 ppm. 
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4-(4-(Hydroxymethyl)cycloheptyl)phenol (2.10).  To a solution of 2.19 (0.873 g, 2.61 
mmol) in anhydrous THF (20 mL) was added a solution of TBAF (1M in THF, 10.0 mL, 
0.010 mol) while stirring.  The mixture was heated to reflux at 70 ˚C overnight and cooled 
to room temperature.  The solution was partitioned between ethyl acetate and water.  The 
organic layer was washed with brine, dried (Na2SO4) and concentrated.  Purification by 
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) gave 2.10 (0.508 g, 88%) 
as a colorless solid.  mp 60-63 °C.  The 1H NMR spectral data is consistent with that 
previously obtained.  
 
 
 
 
 
4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cyclohexan-1-one (2.21).  To a stirred 
solution of 4-(4-hydroxyphenyl)cyclohexanone 2.20 (4.0 g, 0.021 mol) in anhydrous 
CH2Cl2 (40 mL) at 0 ˚C was added imidazole (4.3 g, 0.063 mol) under N2.  After 30 min 
tert-butyldimethyl silyl chloride (4.6 g, 0.032 mol) was added at 0 ˚C and mixture was 
gradually warmed to room temperature overnight.  The resulting mixture was diluted with 
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brine (25 mL) and partitioned with CH2Cl2 (2 x 30 mL).  The combined organic extracts 
were dried (Na2SO4), concentrated and purified by column chromatography (SiO2, 
hexanes-ethyl acetate = 90:10) to give 2.21 (6.081 g, 95%) as a colorless solid. mp 39-42 
°C.  1H NMR (400 MHz, CDCl3) δ 7.08 and 6.78 (AA’BB’, JAB = 8.4 Hz, 4H), 2.96 (br t, 
J = 12.3 Hz, 1H), 2.56–2.40 (m, 4H), 2.25–2.14, (m, 2H), 1.97–1.82 (m, 2H), 0.98 (s, 9H), 
0.19 (s, 6H) ppm.  13C NMR (400 MHz, CDCl3) δ 211.6, 154.3, 137.7, 127.7, 120.1, 42.2, 
41.6, 34.6, 25.9, 18.4, -4.2 ppm. 
 
 
 
 
 
 
Ethyl 5-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-oxocycloheptane-1-carboxylate 
(2.22).  To a solution of ketone 2.21 (1.14 g, 3.74 mmol) in anhydrous diethyl ether (15 
mL) at 0 ˚C under N2 was added an aliquot of BF3.Et2O (0.92 mL, 7.5 mmol).  A solution 
of ethyl diazoacetate (0.77 mL, 7.47 mmol) in anhydrous ether (5 mL) was added dropwise 
over a period of 20 min and the resulting solution was stirred at room temperature for 12 
h.  The reaction mixture was cooled to 0 °C and neutralized with saturated sodium 
bicarbonate solution (20 mL).  The resulting mixture was extracted with CH3Cl3 (3 x 15 
mL), the combined organic extracts washed with brine (20 mL), dried (Na2SO4) and 
concentrated.  The dark yellow crude oil was purified by column chromatography (SiO2, 
hexanes-diethyl ether = 70:30) to give keto ester 2.22 (1.182 g, 81%) as a colorless oil.  
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The product is in equilibrium with its keto-enol tautomer.  1H NMR (400 MHz, CDCl3) δ 
12.74 (s, 0.4H), 7.02-6.97 (m, 2H), 6.77-6.72 (m, 2H), 4.27-4.16 (m, 2H), 3.64-3.56 (m, 
0.3H), 2.94–2.78 (m, 1H), 2.72-2.58 (m, 2H), 2.48-2.24 (m, 1H), 2.16-1.76 (m, 4H), 1.65-
1.54 (m, 1H), 1.32 and 1.29 (2 x t, J = 7.2 Hz, 3H total), 0.97 (s, 9H), 0.18 (s, 6H) ppm.  
13C NMR (100 MHz, CDCl3) δ 209.0, 208.8, 178.9, 173.0, 170.6, 154.0, 140.9, 139.9, 
127.7, 127.5, 120.2, 120.0, 101.5, 61.4, 60.7, 59.6, 58.5,49.6, 47.9, 47.2, 42.2, 36.8, 35.4, 
34.6, 32.8, 32.2, 27.8, 25.9, 23.9, 22.6, 18.4, 14.5, -4.2 ppm. 
 
 
 
 
 
 
4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cycloheptan-1-one (2.17).  To a stirred 
solution of 2.22 (1.74 g, 4.46 mmol) in DMSO (20 mL) at room temperature was added 
sequentially lithium chloride (1.3 g, 0.031 mol) and water (2.8 mL) at room temperature.  
The mixture was heated to reflux at 160 °C for 5 h, cooled to room temperature and poured 
into water.  The resulting solution was extracted with ether and ethyl acetate (3 x 20 mL), 
washed with brine, dried (Na2SO4) and evaporated in vacuo to provide desired product 2.17 
(1.114 g, 78%) as a colorless oil.  The NMR spectral data for the product is consistent with 
that previously obtained. 
 
 
131 
 
 
 
 
 
 
 
 
4-(4-Hydroxycycloheptyl)phenol (2.23).  To a stirred solution of 2.6 (0.028 g, 0.13 mmol) 
in anhydrous CH2Cl2 (30 mL) at -78˚C, was added dropwise a solution of boron tribromide 
in CH2Cl2 (1M, 0.3 mL, 0.03 mmol).  After complete addition, the reaction mixture was 
stirred for 30 min at -78˚C and gradually warmed to room temperature over a 2 h period.  
The mixture was quenched with water (10 mL) and aqueous layer was extracted with 
CH2Cl2 (3 × 20 mL).  The combined organic extracts were washed with brine and dried 
(MgSO4).  Evaporation of the solvent gave 2.23 (0.024 g, 86%) as a yellow crystalline 
solid.  This product was determined to be a mixture of cis- and trans-stereoisomers on the 
basis of 1H and 13C NMR.  1H NMR (400 MHz, CDCl3) δ 7.11-6.99 (m, 2H), 6.80-6.70 
(m, 2 H), 4.85 (s, OH), 4.56-4.48 and 4.42-4.34 (2 × m, 1H total), 2.78–2.59 (m, 1H), 2.53–
1.38 (m, 11H) ppm.  13C NMR (100 MHz, CDCl3)  153.5, 141.0, 127.7, 115.9, 56.1, 55.7, 
45.9, 45.3, 40.0, 39.4, 39.2, 37.7, 37.6, 36.3, 34.2, 31.3, 25.2, 23.5 ppm. 
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4-(4-Hydroxyphenyl)cycloheptanone (2.24).  A sample of 2.7 (0.074 g, 0.339 mmol) was 
dissolved in 48 % HBr (8 mL) and the mixture heated to reflux at 115 ˚C for 2 h.  Then the 
mixture was cooled to room temperature and portioned between ethyl acetate and water.  
The organic layer was washed with sodium bicarbonate solution, followed by brine, dried 
(Na2SO4) and concentrated.  The residue was purified by column chromatography (SiO2, 
hexanes-ethyl acetate = 20:80) to give 2.24 (0.057 g, 82%) as a brown syrup.  1H NMR 
(400 MHz, CD3OD) δ 6.98 and 6.70 (AA’BB’, JAB = 8.5 Hz, 4H), 4.98 (s, 1H), 2.77–2.39 
(m, 4H), 2.02–1.47 (m, 7H) ppm.  13C NMR (100 MHz, CD3OD) δ 218.1, 156.4, 140.3, 
128.5, 116.1, 49.0, 44.6, 43.7, 39.6, 33.1, 24.3 ppm. 
 
 
 
 
 
4-(4-Hydroxyphenyl)cycloheptanone oxime (2.25).  To a solution of 2.24 (0.048 g, 0.23 
mmol) in ethanol (10 mL), was added sodium bicarbonate (0.024 g) and hydroxylamine 
hydrochloride (0.023 g, 0.32 mmol).  The mixture was stirred at room temperature for 5 h 
and extracted with ethyl acetate (2 × 10 mL).  The combined organic extracts were dried 
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(MgSO4) and concentrated.  Purification of the residue by column chromatography (SiO2, 
hexanes-ethyl acetate = 65:35) gave 2.25 as a light brown gum (0.026 g, 52%).  1H NMR 
(400 MHz, CD3OD) δ 6.98 and 6.67 (AA’BB’, JAB = 8.5 Hz, 4H), 2.86-2.30 (m, 4H), 2.09-
1.20 (m, 8H) ppm.  13C NMR (100 MHz, CD3OD) δ 165.0, 164.8, 156.4, 156.3, 141.3, 
140.4, 128.5, 128.3, 116.1, 40.0, 39.7, 37.1, 34.1, 33.7, 33.3, 29.6, 28.4, 27.9, 24.8 ppm.   
 
 
 
 
 
 
4-(4-hydroxyphenyl)-1-methylcycloheptan-1-ol (2.26).  To a solution of 2.24 (0.158 g, 
0.773 mmol) in dry Et2O (15 mL) at -78 °C under N2, was added slowly a solution of 
methyllithium-lithium bromide complex (1.5 M in ether, 1.1 mL, 1.7 mmol).  The mixture 
was stirred for another 30 min at -78 °C, warmed to room temperature and stirred for 
another 1 h.  The mixture was cooled to 0 °C and quenched with water.  The mixture was 
extracted with diethyl ether (2 × 30 mL), dried (Na2SO4) and concentrated.  The residue 
was purified from column chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 
2.26 (0.068 g, 40%) as a colorless solid.  1H NMR (400 MHz, MeOD) δ 6.97 and 6.67 
(AA’BB’, JAB = 8.5 Hz, 4H), 2.63–2.44 (m, 1H), 1.97–1.30 (m, 10H), 1.23 (s, 1H) 1.21 (s, 
2H) ppm.  13C NMR (100 MHz, MeOD) δ 156.3, 141.7, 128.6, 128.4, 116.0, 74.6, 74.5, 
64.4, 44.2, 43.4, 42.8, 40.8, 40.4, 39.0, 38.5, 31.5, 31.2, 23.7, 23.6 ppm. 
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Methyl-2-(4-(4-methoxyphenyl)cycloheptylidene)acetate (2.27).  Sodium hydride (32 
mg, 55% in mineral oil, 0.80 mmol) was added to a stirring solution of trimethyl 
phosphonoacetate (0.130 mL, 0.80 mmol) in dry THF (3 mL) at 0 °C.  After 45 min, a 
solution 4-(4-methoxyphenyl)cycloheptanone 2.27 (0.147 g, 0.673 mmol) in dry THF (5 
mL) was added and the reaction mixture was stirred at room temperature for 12 h.  The 
mixture was diluted with water (15 mL) and the resulting mixture was extracted with ether 
(2 × 20 mL), dried (MgSO4) and concentrated.  The residue was purified by column 
chromatography (SiO2, hexanes–ethyl acetate = 90:10) to give 2.27 (0.057 g, 31%) as a 
colorless oil.  The product was determined to be a mixture of E and Z stereoisomers from 
1H and 13C NMR spectroscopy.  1H NMR (400 MHz, CDCl3) δ 7.08 and 6.82 (AA’BB’, 
JAB = 8.1 Hz, 4H), 5.74 (s, 1H), 3.78 (s, 3H), 3.69 (d, J = 3.6 Hz, 3H), 2.86 (broad t, J = 
14.9 Hz, 1H), 2.72-2.36 (m, 3H), 2.10-1.86 (m, 3H), 1.80-1.44 (m, 6H) ppm.  (Solvent 
peaks are overlapped in 1.30-2.20 ppm region).  13C NMR (100 MHz, CDCl3) δ 167.2, 
167.1, 166.8, 166.6, 157.9, 157.8, 141.1, 140.7, 127.6, 115.5, 113.9, 77.6, 55.4, 51.0, 47.7, 
47.1, 38.9, 38.2, 38.0, 37.4, 36.7, 35.3, 32.6, 31.3, 27.2, 25.9, 22.9, 14.3 ppm. 
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(Z)-2-(4-(4-Methoxyphenyl)cycloheptylidene)ethan-1-ol (2.28).  To a solution of 2.27 
(0.200 g, 0.730 mmol) in dry CH2Cl2 (5 mL) under nitrogen at –40 ˚ C was added a solution 
of diisobutylaluminum hydride in CH2Cl2 (1.58 mL, 1.2 M, 1.9 mmol). After 90 min, 
saturated aqueous potassium sodium tartrate was added and reaction mixture was gradually 
warmed to room temperature.  After 4 h the mixture was filtered through a pad of celite 
and extracted several times with water (2 × 15 mL).  The combined organic layers were 
dried (MgSO4), and concentrated to give 2.28 (0.078 g, 43%) as a colorless gum.  The 
crude product was used in the next step without any further purification.  1H NMR (400 
MHz, CDCl3) δ 7.09 and 6.83 (AA’BB’, JAB = 8.7 Hz, 4H), 5.50-5.42 (m, 1H), 4.19 (d, J 
= 7.2 Hz, 2H), 3.79 (s, 3H), 2.67-2.19 (m, 4H), 2.14-1.85 (m, 4H), 1.69-1.44 (m, 3H) ppm.  
13C NMR (100 MHz, CDCl3) δ 157.7, 145.1, 141.5, 141.3, 129.4, 127.6, 127.6, 124.2, 
124.1, 113.8, 59.2, 55.4, 47.6, 47.0, 38.3, 37.6, 37.4, 36.8, 36.1, 30.2, 29.2, 27.8, 26.5 ppm. 
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4-(4-(2-Hydroxyethyl)cycloheptyl)phenol (2.30).  To a solution of compound 2.28 (0.078 
g, 0.32 mmol) in methanol (10 mL) was added 10% Pd/C (0.040 g, 10 mol %).  The mixture 
was stirred under H2 balloon at room temperature for 12 h.  The reaction mixture was 
filtered through a pad of celite, concentrated and dried (MgSO4) to give the crude 
hydrogenated product (0.080 g, 0.323 mmol).  The crude product was dissolved in 
anhydrous CH2Cl2 (8 mL), cooled to -78˚C, and a solution of boron tribromide (1M in 
CH2Cl2, 0.97 mL, 0.97 mmol) was added dropwise.  After complete addition, the reaction 
mixture was stirred for 30 min at -78˚C and gradually warmed to room temperature over a 
2 h period.  The mixture was quenched with water (5 mL) and the aqueous layer was 
extracted with CH2Cl2 (3 × 10 mL).  The combined organic extracts were washed with 
brine and dried (MgSO4).  Evaporation of the solvent and purification by column 
chromatography (SiO2, hexanes-ethyl acetate = 65:35) gave 2.30 (0.005 g, 7%) as a light 
brown solid.  This was determined to be a mixture of diastereoisomers by 1H and 13C NMR 
spectroscopy.  1H NMR (400 MHz, CDCl3) δ 7.04 and 6.74 (AA’BB’, JAB = 8.7 Hz, 4H), 
3.71 (td, J = 6.9, 1.4 Hz, 2H), 2.66-2.48 (m, 1H), 1.96-1.13 (m, 13H) ppm.  13C NMR (100 
MHz, CDCl3) δ 153.6, 142.2, 127.8, 115.3, 61.5, 47.1, 45.9, 41.1, 40.9, 38.8, 36.8, 36.3, 
35.9, 35.4, 34.8, 34.5, 33.9, 33.0, 32.1, 27.3, 24.4 ppm. 
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Methyl 4-hydroxy-3-methylbenzoate (2.32).  To a solution of 4-hydroxy-3-
methylbenzoic acid 2.31 (5.000 g, 0.033 mol) in anhydrous methanol (80 mL) was added 
dropwise through an addition funnel SOCl2 (5 mL, 0.066 mol) over 1 h while stirring at 0 
°C.  After 30 min the system was heated at reflux overnight under N2.  The resulting 
mixture was cooled to the room temperature and diluted with water (50 mL).  Methanol 
was evaporated and the pH was adjusted to pH =7 with saturated sodium bicarbonate 
solution (15 mL).  The resulting solution was extracted with ethyl acetate (3 × 40 mL).  
The combined organic extracts were washed with brine (20 mL), dried (Na2SO4), and 
concentrated to give methyl ester 2.32 (4.80 g, 88%) as a light orange solid.  mp 124-125 
°C.  1H NMR (400 MHz, CDCl3)  7.84 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 6.83 (d, J = 8.4 
Hz, 1H), 6.48 (s, OH), 3.89 (s, 3H), 2.27 (s, 3H) ppm.  13C NMR (100 MHz, CDCl3)  
168.0, 158.9, 133.1, 129.6, 124.4, 122.0, 115.4, 52.4, 16.0 ppm.  The 1H and 13C NMR 
spectral data are consistent with the literature values.117-118 
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Methyl 4-((tert-butyldimethylsilyl)oxy)-3-methylbenzoate (2.33).  To a stirred solution 
of 2.32 (0.500 g, 3.01 mmol) in anhydrous CH2Cl2 (25 mL) at 0 ˚C under N2, was added 
imidazole (0.410 g, 6.02 mmol).  After 30 min tert-butyldimethyl silyl chloride (0.680 g, 
4.52 mmol) was added at 0 ˚C and mixture was gradually warmed to room temperature 
overnight.  The resulting mixture was diluted with brine (25 mL) and partitioned with 
CH2Cl2 (2 x 20 mL).  The combined organic extracts were dried (Na2SO4), concentrated in 
vacuo and purified by column chromatography (SiO2, hexanes-ethyl acetate = 10:90) to 
give 2.33 (0.712 g, 84%) as a colorless gum.  1H NMR (400 MHz, CDCl3)  7.84 (d, J = 
2.3 Hz, 1H), 7.77 (dd, J = 2.3, 8.4 Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H), 3.86 (s, 3H), 2.22 (s, 
3H), 1.01 (s, 9H), 0.23 (s, 6H) ppm.  13C NMR (100 MHz, CDCl3)  167.2, 158.4, 132.7, 
129.1, 128.8, 123.1, 118.1, 51.9, 25.9, 18.3, 16.9, -3.8 ppm. 
 
 
 
 
 
5-(4-((tert-Butyldimethylsilyl)oxy)-3-methylphenyl)nona-1,8-dien-5-ol (2.34).  Dry 
magnesium turnings (2.65 g, 0.110 mol) were placed in a flame dried three-necked flask 
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under N2 followed by THF (25 mL).  A solution of 4-bromo-1-butene (6.70 mL, 0.066 mol) 
in THF (20 mL) was loaded to the addition funnel and a small amount of bromobutene 
solution (2 mL) was added slowly to the magnesium turnings.  The solution was heated at 
65 ˚C to reflux.  Once the Grignard formation was started, the remaining bromide solution 
was added dropwise over 45 min.  The reaction was stirred until most of the magnesium 
had reacted and solution of 2.33 (3.086 g, 0.011 mol) in THF (15 mL) was filled into the 
addition funnel and added dropwise over 30 min.  The mixture was gradually cooled and 
stirred at ambient temperature overnight.  A solution of saturated NH4Cl (30 mL) was 
slowly added in order to quench the reaction and resultant emulsion was stirred for 1 h.  
The mixture was extracted with ether (3 x 30 mL) and the combined organic extracts were 
washed with brine (2 x 20 mL) and dried (Na2SO4).  The solvent was removed to give 
alcohol 2.34 (2.217 g, 56%) as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 
2.4 Hz, 1H), 7.03 (dd, J = 2.6, 8.4 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 5.85-5.74 (m, 2H), 
4.99–4.88 (m, 4H), 2.22 (s, 3H), 2.11–1.97 (m, 2H), 1.93-1.81 (m, 7H), 1.02 (s, 9H), 0.22 
(s, 6H) ppm.   13C NMR (100 MHz, CDCl3) δ 152.5, 139.2, 138.1, 128.5, 128.1, 123.6, 
118.1, 114.6, 77.1, 42.2, 28.3, 25.9, 18.4, 17.4, -4.0 ppm. 
 
 
 
 
 
1-(4-((tert-Butyldimethylsilyl)oxy)-3-methylphenyl)cyclohept-4-en-1-ol (2.35).  
Alcohol 2.34 (0.974 g, 2.70 mmol) was cyclized using Grubbs’ catalyst I (0.090 g, 0.108 
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mmol, 4%) in a fashion similar to the preparation of 2.14.  Purification of the crude product 
by column chromatography (SiO2, hexanes-diethyl ether = 80:20) gave 2.35 (0.573 g, 64%) 
as a light green oil.  1H NMR (400 MHz, CDCl3) δ 7.28 (br d, J = 2.3 Hz, 1H), 7.18 (dd, J 
= 2.5, 8.4 Hz, 1H), 6.72 (d, J = 8.5 Hz, 1H), 5.87-5.82 (m, 2H), 2.50 (br t, J = 13.3 Hz, 2H), 
2.22 (s, 3H), 2.11–1.97 (m, 4H), 1.91-1.83 (m, 2H), 1.68 (s, 1H), 1.02 (s, 9H), 0.22 (s, 6H) 
ppm.  13C NMR (100 MHz, CDCl3)  152.6, 142.7, 132.3, 128.4, 127.7, 122.9, 117.9, 77.1, 
40.3, 25.9, 23.3, 18.5, 17.2, -4.0 ppm. 
 
 
 
 
 
 
tert-Butyl(4-(cyclohept-4-en-1-yl)-2-methylphenoxy)dimethylsilane (2.36).  Ionic 
reduction of tertiary alcohol 2.35 (0.209 g, 0.623 mmol) in anhydrous CH2Cl2 (15 mL) 
with triethylsilane (0.1 mL, 0.626 mmol) and TFA (0.5 mL, 6.23 mmol) was carried out in 
a fashion similar to the preparation of 2.15.  Purification of the crude product by column 
chromatography (SiO2, hexanes = 100%) gave 2.36 (0.113 g, 57%) as a colorless oil.  
1H 
NMR (400 MHz, CDCl3)  7.00 (d, J = 2.2 Hz, 1H), 6.91 (dd, J = 8.1, 2.2 Hz, 1H), 6.72 
(d, J = 8.4 Hz, 1H), 5.94-5.90 (m, 2H), 2.68 (tt, J = 11.5, 3.4 Hz, 1H), 2.38-2.28 (m, 2H), 
2.27-2.16 (m, 5H), 1.95-1.87 (m, 2H), 1.58-1.44 (m, 2H), 1.06 (s, 9H), 0.26 (s, 6H)  ppm.  
13C NMR (100 MHz, CDCl3)  151.9, 142.1, 132.7, 129.5, 128.8, 125.1, 118.4, 49.7, 35.1, 
28.1, 25.9, 18.3, 17.2, -4.0 ppm. 
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4-(4-((tert-Butyldimethylsilyl)oxy)-3-methylphenyl)cycloheptan-1-ol (2.37).  The 
hydroboration-oxidation of cycloheptene 2.36 (0.334 g, 1.06 mmol) was carried out in a 
fashion similar to the preparation of 2.16.  Purification of the crude product by column 
chromatography (SiO2, hexanes-ethyl acetate = 80:20) gave 2.37 (0.116 g, 33%) as a 
colorless oil.  This was determined to be a mixture of diastereoisomers by 1H and 13C NMR 
spectroscopy.  1H NMR (400 MHz, CDCl3) δ 6.94 (d, J = 7.9 Hz, 1H), 6.84 (br t, J = 7.4 
Hz, 1H), 6.66 (d, J = 8.3 Hz, 1H), 4.06-3.99 and 3.98-3.89 (2× m, 1H total), 2.66-2.49 (m, 
1H), 2.18 (s, 3H), 2.13-2.05 (m, 1H), 2.02-1.48 (m, 10H), 1.00 (s, 9H), 0.20 (s, 6H) ppm.  
13C NMR (100 MHz, CDCl3) δ 151.9, 141.9, 141.8, 129.4, 128.7, 124.6, 118.3, 73.1, 71.9, 
46.4, 46.1, 38.3, 37.9, 37.3, 37.2, 37.0, 35.9, 31.9, 29.8, 26.0, 21.5, 18.4, 17.2, -4.0 ppm. 
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4-(4-Hydroxy-3-methylphenyl)cycloheptan-1-ol (2.38).  To a solution of 2.37 (0.100 g, 
0.299 mmol) in anhydrous THF (15 mL) was added a solution of tetrabutylammonium 
fluoride (1M in THF, 1.2 mL, 1.2 mmol).  The mixture was heated at 70 ˚C overnight and 
cooled to room temperature.  The solution was partitioned between ethyl acetate (2 x 15 
mL) and water (2 x 10 mL).  The organic layer was washed with brine, dried (Na2SO4) and 
concentrated.  Purification by column chromatography (SiO2, hexanes-ethyl acetate = 
50:50) gave 2.38 (0.035g, 53%) as a colorless solid.  1H NMR (400 MHz, CDCl3) δ 6.92 
(d, J = 8.2 Hz, 1H), 6.86 (br t, J = 7.3 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H), 5.84 (s, OH) 4.08-
4.01 and 4.00-3.90 (2 x m, 1H total), 2.66-2.44 (m, 1H), 2.22 (s, 3H), 2.16-1.48 (m, 11H) 
ppm.  13C NMR (100 MHz, CDCl3) δ 152.4, 141.4, 129.4, 124.9, 124.0, 114.9, 73.2, 72.1, 
46.4, 46.1, 38.4, 37.9, 37.1, 37.0, 36.9, 35.7, 31.9, 29.8, 23.5, 21.5, 16.2 ppm. 
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4-(6-Oxabicyclo[3.2.2]nonan-5-yl)phenol (2.42).  Cyclic ether formation of 4-(4-
(hydroxymethyl)cycloheptyl)phenol 2.10 (0.075 g, 0.34 mmol) was carried out  in a 
fashion similar to the preparation of 3.8.  Purification by column chromatography (SiO2, 
hexanes-ethyl acetate = 60: 40) gave 2.42 (0.049 g, 66%) as a light yellow viscous oil. 1H 
NMR (400 MHz, CDCl3) δ 7.15 and 6.58 (AA’BB’, JAB = 7.8 Hz, 4H), 6.30 (s, 1H), 4.07–
3.96 (m, 1H), 3.90–3.84 (m, 1H), 2.25–1.60 (m, 11H) ppm.  13C NMR (100 MHz, CDCl3) 
δ 154.3, 142.5, 125.6, 114.9, 76.5, 69.9, 42.9, 33.8, 32.5, 30.3, 22.6, 21.5 ppm.   
 
 
 
 
 
4-(4-methoxyphenyl) Cyclohexanone (2.40).  To a solution of 4-(4-
hydroxyphenyl)cyclohexanone (0.500 g, 2.63 mmol) in DMF (10 mL) was added K2CO3 
(0.545 g, 3.94 mmol) and iodomethane (0.21 mL, 0.485 g, 3.42 mmol).  The reaction was 
heated at reflux overnight.  The reaction was cooled, diluted with H2O and extracted with 
ethyl acetate.  The organic extracts were combined and washed with brine, dried (Na2SO4) 
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and concentrated.  The residue was purified by column chromatography (hexanes-ethyl 
acetate = 80:20) to give 2.40 (0.238 g, 44%) as a colorless solid.  mp 70-74 °C. [lit. mp 74 
°C].90  1H NMR (CDCl3) δ 7.17 and 6.87 (AA’BB’, JAB = 8.6 Hz, 4H), 3.79 (s, 3H), 2.98 
(tt, J = 11.9, 3.8 Hz, 1H), 2.56-2.44 (m, 4H), 2.24-2.15 (m, 2H) and 1.97-1.84 (m, 2H) ppm. 
The NMR data was consistent with the literature values.90 
 
 
 
 
3-(4-Methoxyphenyl)cyclopentane-1-carboxylic acid (2.41).  To a solution of 
cyclohexanone 2.40 (0.100 g, 0.490 mmol) in a heavy-walled reaction vessel was added 
diphenyldiselinide (0.002 g, 0.005 mmol), t-BuOH (4 mL) and 30% H2O2 (0.4 mL).  The 
reaction vessel was sealed and heated at 100 °C for 4 d.  After cooling the reaction vessel 
was opened and 10% Pd/C (20 mg) was added and solvent was distilled off.  The residue 
was treated with 10% aqueous Na2CO3 (40 mL) and extracted with CH2Cl2 (3 × 20 mL).  
The aqueous phase was adjusted to pH 1 with HCl and extracted with CH2Cl2 (3 × 25 mL).  
The combined extracts were dried (Na2SO4) and concentrated.  The residue was purified 
by column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to give 2.41 (0.044 g, 
41%) as a colorless oil.  This product was determined to be a mixture of cis- and trans- 
stereoisomers on the basis of 1H and 13C NMR spectroscopy.  1H NMR (400 MHz, CDCl3) 
δ 7.18, 7.06 and 6.84 (AA’BB’, JAB = 8.7 Hz, 4H total), 3.79 (s, 3H), 3.24–3.16 (m, 0.4H), 
3.15–2.92 (m, 1.6H), 2.72–2.63 (m, 0.3H), 2.42–2.33 (m, 0.7H), 2.21–1.69 (m, 5H) ppm.  
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13C NMR (100 MHz, CDCl3) δ 182.7, 179.9, 158.2, 136.5, 135.9, 128.9, 128.2, 114.0, 
113.9, 59.5, 55.5, 45.7, 43.6, 38.5, 37.6, 34.2, 29.3, 27.7 ppm. The 1H NMR data for this 
compound were consistent with the literature values.92 
 
 
 
 
(3-(4-Methoxyphenyl)cyclopentyl)methanol (2.42).  To a solution of 2.41 (0.083 g, 0.377 
mmol) in anhydrous THF (5 mL) at 0 °C under N2 was slowly added LiAlH4 (0.043 g, 1.13 
mmol).  After addition was completed the reaction was gradually warmed to room 
temperature and continued to stir for 3 h.  The mixture was cautiously quenched with water 
and extracted with ethyl acetate (3× 15 mL).  The combined extracts were dried (Na2SO4) 
and concentrated.  The residue was  purified by column chromatography (SiO2, hexanes-
ethyl acetate = 80:20) to give 2.42 (0.042 g, 54%) as a colorless oil.  This product was 
determined to be a mixture of cis- and trans- stereoisomers on the basis of 1H and 13C NMR 
spectroscopy.  1H NMR (400 MHz, CDCl3) δ 7.17 and 6.84 (AA’BB’, JAB = 8.7 Hz, 4H), 
3.79 (s, 3H), 3.61 (d, J = 6.7 Hz, 1.7H), 3.57 (d, J = 7.1 Hz, 0.3H), 3.08–2.97 (m, 1H), 
2.40–2.15 (m, 2H), 2.13–1.98 (m, 1H), 1.94–1.81 (m, 1H), 1.68–1.52 (m, 2H), 1.34–1.23 
(m, 1H) ppm.  13C NMR (100 MHz, CDCl3) δ 157.9, 137.7, 128.0, 113.8, 67.7, 67.6, 55.4, 
45.3, 43.9, 42.0, 41.4, 38.5, 37.1, 35.1, 33.7, 29.4, 28.4 ppm. 
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4-(3-(Hydroxymethyl)cyclopentyl)phenol (2.43).  To a solution of 2.42 (0.030 g, 0.145 
mmol) in anhydrous CH2Cl2 (8 mL) at -78 ˚C, was added dropwise a solution of boron 
tribromide (1M in CH2Cl2, 0.44 mL, 0.44 mmol).  After complete addition, the reaction 
mixture was stirred for 30 min at -78˚C and gradually warmed to room temperature over a 
2 h period.  The mixture was quenched with water (10 mL) and the aqueous layer was 
extracted with CH2Cl2 (3 × 15 mL).  The combined organic extracts were washed with 
brine, dried (MgSO4) and concentrated.  The residue was purified by column 
chromatography (SiO2, hexanes-ethyl acetate = 50:50) to give 2.43 (0.010 g, 36%) as a 
colorless solid.  This product was determined to be a mixture of cis- and trans- 
stereoisomers on the basis of 1H and 13C NMR spectroscopy.  1H NMR (400 MHz, CDCl3) 
δ 7.10 and 6.76 (AA’BB’, JAB = 8.2 Hz, 4H), 3.62 (d, J = 6.7 Hz, 1.6H), 3.58 (d, J = 7.2 
Hz, 0.4H), 3.06–2.93 (m, 1H), 2.40–2.14 (m, 2H), 2.11–1.94 (m, 1H), 1.93–1.71 (m, 1H), 
1.67–1.49 (m, 2H), 1.33–1.20 (m, 1H) ppm.  13C NMR (100 MHz, CDCl3) δ 153.9, 137.7, 
128.2, 115.3, 67.8, 67.7, 45.3, 44.0, 42.0, 41.4, 38.5, 37.2, 35.0, 33.7, 29.4, 28.4 ppm. 
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4-(4-((tert-Butyldiphenylsilyl)oxy)phenyl)cyclohexan-1-one (3.2).  To a solution of 4-
(4-hydroxyphenyl)cyclohexanone (0.815 g, 4.28 mmol) in dry CH2Cl2 (30 ml ) at 0 °C, 
was added imidazole (0.583 g 8.57 mmol).  After stirring for 30 min, a solution of t-
butyldiphenylsilyl chloride (1.60 mL, 5.57 mmol) in CH2Cl2 (9 mL) was added dropwise 
while maintaining the temperature at 0 °C.  The reaction mixture was slowly warmed to 
room temperature and stirred for 12 h.  The mixture was diluted with water (20 mL) and 
partitioned with CH2Cl2 (40 mL).  The organic portion was separated, washed with brine, 
dried (Na2SO4), and concentrated.  The residue was purified by column chromatography 
(SiO2, hexanes-ethyl acetate = 80: 20) to give 3.2 (1.70 g, 93%) as a colorless solid.  mp 
83-84 °C.  1H NMR (400 MHz, CDCl3) δ 7.74-7.70 (m, 4H), 7.45-7.34 (m, 6H), 6.96 and 
6.71 (AA’BB’, JAB = 8.6 Hz, 4H), 2.90 (tt, J = 12.1, 3.3 Hz, 1H), 2.49–2.42 (m, 4H), 2.19–
2.10 (m, 2H), 1.91–1.77 (m, 2H), 1.09 (s, 9H) ppm.  13C NMR (100 MHz, CDCl3) δ 211.6, 
154.3, 137.3, 135.7, 133.2, 130.1, 127.9, 127.5, 119.8, 42.1, 41.6, 34.3, 26.7, 19.7. 
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tert-Butyl(4-(4-methylenecyclohexyl)phenoxy)diphenylsilane (3.3).  A solution of 
nbutyllithium in hexane (1.6 M, 1.5 mL, 2.4 mmol) was added to a stirring solution of 
methyltriphenylphosphonium bromide (0.836 g, 2.34 mmol) in dry THF (20 mL) at -10 
°C.  After 30 min, a solution of 4-(4-butyldiphenylsilyloxyphenyl)cyclohexanone 3.2 
(0.502 g, 1.17 mmol) in dry THF (8 mL) was added dropwise.  The reaction mixture was 
slowly warmed to room temperature and stirred overnight.  After this time, the mixture was 
diluted with water (20 mL), extracted with ethyl acetate (2 ×25 mL), dried (Na2SO4) and 
concentrated.  The residue was purified by column chromatography (SiO2, hexanes-ethyl 
acetate = 80:20) to give 3.3 (0.423 g, 85%) as a colorless oil.  1H NMR (400 MHz, CDCl3) 
δ 7.75-7.71 (m, 4H), 7.46-7.34 (m, 6H), 6.93 and 6.69 (AA’BB’, JAB = 8.6 Hz, 4H), 4.65 
(t, J = 1.7 Hz, 2H), 2.55 (tt, J = 12.0, 3.3 Hz, 1H), 2.42–2.34 (m, 2H), 2.20–2.09 (m, 2H), 
1.95–1.87 (m, 2H), 1.50–1.38 (m, 2H), 1.10 (s, 9H) ppm.  13C NMR (100 MHz, CDCl3) δ 
153.8, 149.2, 139.5, 135.7, 133.3, 130.0, 127.9, 127.6, 119.5, 107.4, 43.4, 35.9, 35.4, 26.7, 
19.7 ppm. 
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4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a).  A solution of borane-THF complex in 
THF (1 M, 1.22 mL, 1.22 mmol) was added to a solution of 3.3 (0.261 g, 0.611 mmol) in 
THF (6 mL) at 0 °C.  The reaction mixture was slowly warmed to room temperature and 
stirred for 20 h.  The mixture was then cooled to 0 °C, followed by sequential addition of 
ethanol (50 mL), hydrogen peroxide solution (30% in water, 1.00 mL) and 3N NaOH 
solution (5.0 mL).  The mixture was warmed to room temperature and stirred for 30 min.  
The reaction mixture was extracted with ethyl acetate (2 ×20 mL).  The organic portion 
was washed with brine, dried (Na2SO4), and concentrated.  The residue was recrystallized 
from chloroform to give 3.4a (0.035 g, 28%) as a colorless solid.  mp 118-122 °C.  1H 
NMR (400 MHz, CD3OD) δ 7.04-6.98 (m, 2H), 6.70-6.65 (m, 2H), 3.60 (d, J = 7.6 Hz, 
1.5H), 3.39 (d, J = 6.6 Hz, 0.5H), 2.54–2.44 (m, 0.7H) and 2.37 (tt, J = 12.1, 3.4 Hz, 0.3H), 
1.93–1.70 (m, 3H), 1.61 (d, J = 6.3 Hz, 4H), 1.46–1.37 (m, 1H), 1.14–1.02 (m, 1H) ppm.  
13C NMR (100 MHz, CD3OD) δ 156.2, 139.6, 128.7, 116.0, 68.0, 64.4, 45.2, 44.0, 41.4, 
37.0, 35.4, 31.2, 30.5, 28.0 ppm. 
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tert-Butyldimethyl(4-(4-methylenecyclohexyl)phenoxy)silane (3.6).  Wittig 
methenylation of compound 3.5 (2.00 g, 6.57 mmol) was carried out in a fashion similar to 
the preparation of 3.3.  Purification of the crude residue by column chromatography (SiO2, 
hexanes-ethyl acetate = 90: 10) gave 3.6 (1.678 g, 84%) as a colorless oil.  1H NMR (400 
MHz, CDCl3) δ 7.06 and 6.77 (AA’BB’, JAB = 8.3 Hz, 4H), 4.68 (s, 2H), 2.62 (tt, J = 12.1, 
3.4 Hz, 1H), 2.42 (br d, J = 13.5 Hz, 2H), 2.18 (br t, J = 13.2 Hz, 2H), 2.00-1.93 (m, 2H), 
1.57-1.45 (m, 2H), 0.99 (s, 9H), 0.20 (s, 6H) ppm.  13C NMR (100 MHz, CDCl3) δ 153.9, 
149.2, 139.8, 127.8, 119.9, 107.4, 43.5, 36.0, 35.4, 25.9, 18.4, -4.2 ppm.  Anal. calcd. for 
C19H30OSi: C, 75.43; H, 9.99.  Found: C, 75.71; H, 10.02. 
 
 
 
 
 
 
4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a).  Hydroboration-oxidation of 3.6 (0.350 
g, 1.16 mmol) was carried out in a fashion similar to the hydroboration-oxidation of 3.3.  
Purification of the residue by column chromatography (SiO2, hexanes-ethyl acetate = 
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65:35) gave 3.4a (0.095 g, 40%) as a colorless solid.  The 1H NMR spectral data were 
consistent with previously obtained values. 
 
 
 
 
(4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cyclohexyl)methanol (3.7).  The 
hydroboration of 3.6 (0.821 g, 2.71 mmol) was carried out in a fashion similar to the 
hydroboration of 3.3.  After stirring for 18 h, the reaction mixture was cooled to 0 °C, 
followed by sequential addition of 1 N sodium hydroxide solution (3.2 mL) and hydrogen 
peroxide solution (30% in water, 1.50 mL).  The mixture was warmed to room temperature 
and stirred for 1.5 h.  The reaction mixture was quenched with saturated sodium 
bicarbonate solution (10 mL), diluted with water (20 mL) and extracted with ethyl acetate 
(2 ×20 mL).  The combined organic extracts were washed with brine, dried (Na2SO4,) and 
concentrated.  The residue was purified by column chromatography (SiO2, hexanes-ethyl 
acetate = 70:30) to give 3.7 (0.572 g, 66%) as a colorless oil.  1H NMR (400 MHz, CDCl3) 
δ 7.06 and 6.76 (AA’BB’, JAB = 8.5 Hz, 4H), 3.69 (d, J = 7.4 Hz, 1.3H), 3.50 (d, J = 6.5 
Hz, 0.7H), 2.59-2.51 (m, 0.5H), 2.42 (tt, J = 12.1, 3.8 Hz, 0.5H), 1.96-1.84 (m, 2H), 1.80-
1.37 (m, 7H), 0.98 (s, 9H), 0.19 (s, 6H) ppm.   13C NMR (100 MHz, CDCl3) δ 153.7, 140.4, 
140.0, 127.8, 119.9, 68.9, 64.6, 43.8, 42.6, 40.3, 36.2, 34.1, 30.0, 29.4, 27.0, 25.9, 18.4, -
4.2 ppm. 
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4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a).  To a solution of 3.7 (0.594 g, 1.85 
mmol) in anhydrous THF (10 mL) was added a solution of TBAF (1M in THF, 7.5 mL, 
7.5 mmol) while stirring.  The mixture was heated to reflux at 70 ˚C overnight and cooled 
to room temperature.  The solution was partitioned between ethyl acetate and water.  The 
organic layer was washed with brine, dried (Na2SO4) and concentrated.  Purification by 
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) gave 3.4a (0.280 g, 73%) 
as a colorless solid.  mp 118-122 °C.  The 1H NMR spectral data is consistent with that 
previously obtained.  
 
 
 
 
 
 
 
 
4-(2-Oxabicyclo[2.2.2]octan-1-yl)phenol (3.8) and trans-4-(4-
(Hydroxymethyl)cyclohexyl)phenol (3.4b).  To a solution of a mixture of cis- and trans-
4-(4-(hydroxymethyl) cyclohexyl)phenol 3.4a (0.050 g, 0.242 mmol) in anhydrous CH2Cl2 
(15 mL) at -10 °C, was slowly added a suspension of 2,3-dichloro-5,6-dicyano-1,4-
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benzoquinone (0.059 g, 0.262 mmol ) in CH2Cl2 ( 5 mL) over a period of 30 min.  The 
green solution continued to stir at 0 °C for 2 h and gradually warmed to room temperature 
and stirred for another 3 h.  The mixture was quenched by slow addition of saturated 
sodium bicarbonate solution at 0 °C.  After a few minutes, the layers were separated and 
the aqueous layer was extracted with CH2Cl2 (2 × 20 mL).  The combined organic extracts 
were washed with brine, dried (Na2SO4), and concentrated.  The residue was purified by 
column chromatography (SiO2, hexanes-ethyl acetate = 60: 40) to give 3.8 (0.020 g, 40%) 
followed by 3.4b (0.010 g, 20%) both as colorless solids.  3.8: mp 120-124 °C.  1H NMR 
(400 MHz, CD3OD) δ 7.18 and 6.64 (AA’BB’, JAB = 7.9 Hz, 4H), 4.04 (s, 2H), 2.01 (t, J = 
7.8 Hz, 4H), 1.94–1.73 (m, 5H) ppm.  13C NMR (100 MHz, CD3OD) δ 157.2, 138.9, 127.1, 
115.6, 73.0, 71.3, 34.5, 27.3, 25.9 ppm.  Anal. calcd for C13H16O2: C, 76.44; H, 7.89.  
Found: C, 76.39; H, 7.97.  3.4b: mp 115-120 °C.  1H NMR (400 MHz, CD3OD) δ 7.00 and 
6.68 (AA’BB’, JAB = 8.7 Hz, 4H), 3.39 (d, J = 6.7 Hz, 2H), 2.36 (tt, J = 12.1, 3.0 Hz, 1H), 
1.87 (br t, J = 15.4, 4H), 1.55–1.36 (m, 3H), 1.14–1.02 (m, 2H) ppm.  13C NMR (100 MHz, 
CD3OD) δ 156.3, 139.8, 128.6, 116.0, 68.8, 45.1, 41.4, 35.3, 31.2 ppm.  Anal. calcd for 
C13H18O2: C, 75.69; H, 8.79.  Found: C, 75.66; H, 9.09. 
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4-(4-Hydroxycyclohexyl)phenol (3.9).  Cyclohexanone 3.1 (0.200 g, 1.05 mmol) was 
dissolved in anhydrous methanol (15 mL) and NaBH4 (0.400 g, 10.6 mmol) was added 
while stirring at room temperature.  Reaction was continued for 3 h and mixture was 
extracted with ethyl acetate (3× 20 mL).  The combined extracts were concentrated to give 
product 3.9 (0.181 g, 90%) as a colorless solid.  mp 196-208 °C.  1H NMR (400 MHz, 
CD3OD) δ 7.00 and 6.67 (AA’BB’, JAB = 8.7 Hz, 4H), 3.61–3.53 (m, 1H), 2.38 (tt, J = 
11.8, 3.4 Hz, 1H), 2.05–1.98 (m, 2H), 1.87–1.78 (m, 2H), 1.56–1.30 (m, 4H) ppm.  13C 
NMR (100 MHz, CD3OD) δ 156.5, 139.1, 128.7, 116.0, 71.3, 49.3, 44.2, 36.8, 34.1 ppm.  
HRMS m/z 191.1077 [calcd for C12H15O2
– (M–H+) 191.1078]. 
 
 
 
 
 
 
 
4-(4-Hydroxyphenyl)cyclohexanone oxime (3.10).  To a solution of cyclohexanone 3.1 
(0.050 g, 0.26 mmol) in ethanol (10 mL), were added Amberlyst (0.060 g) and 
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hydroxylamine hydrochloride (0.039 g, 0.560 mmol).  The mixture was stirred at room 
temperature for 2 h and then filtered.  The filtrate was concentrated and extracted with ethyl 
acetate (2 × 10 mL) and water (2 × 10 mL).  The combined organic extracts were 
concentrated and dried (MgSO4).  Evaporation of the solvent gave 3.10 as a colorless solid 
(0.037 g, 70%).  mp 171-174 °C.  1H NMR (400 MHz, CD3OD) δ 7.00 and 6.69 (AA’BB’, 
JAB = 8.2 Hz, 4H), 3.39 (br d, J = 13.5 Hz, 1H), 2.67 (t, J = 12.8 Hz, 1H), 2.41 (br d, J = 
14.0 Hz, 1H), 2.20 (td, J = 14.6, 5.4 Hz, 1H), 1.93 (br t, J = 15.8 Hz, 2H), 1.81 (td, J = 14.0, 
5.2 Hz, 1H), 1.61–1.42 (m, 2H) ppm.  13C NMR (100 MHz, CD3OD) δ 160.8, 156.7, 138.3, 
128.6, 116.2, 44.1, 35.8, 34.6, 32.8, 25.1 ppm. 
 
 
 
 
 
 
4-(4-Hydroxy-4-methylcyclohexyl)phenol (3.11).  To a solution of 3.1 (0.100 g, 0.526 
mmol) in dry Et2O (20 mL) at -78 °C under N2, was added slowly a solution of 
methyllithium-lithium bromide complex (1.5 M in ether, 0.78 mL, 1.2 mmol).  The mixture 
was stirred for another 30 min at -78 °C, warmed to room temperature and stirred for 
another 1 h.  The mixture was cooled to 0 °C and quenched with water.  The mixture was 
extracted with diethyl ether (2 × 30 mL), dried (Na2SO4) and concentrated.  The residue 
was purified from column chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 
3.11 (0.040 g, 37%) as a colorless solid.  mp 126-131 °C.  1H NMR (400 MHz, CD3OD) δ 
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7.03 and 6.67 (AA’BB’, JAB = 8.3 Hz, 4H), 2.35 (tt, J =12.4, 3.6 Hz, 1H), 1.87–1.69 (m, 
4H), 1.61–1.44 (m, 4H), 1.21 (s, 3H) ppm.  13C NMR (100 MHz, CD3OD) δ 156.3, 139.9, 
129.6, 116.0, 69.3, 44.3, 39.9, 31.8, 30.9 ppm.  HRMS m/z 205.1234 [calcd for 
C13H17O2
– (M–H+) 205.1234].  
 
 
 
 
 
4-(4-Methylenecyclohexyl)phenol (3.12).  To a solution of 3.6 (0.739 g, 2.44 mmol) in 
anhydrous THF (20 mL) was added a solution of TBAF (1M in THF, 9.8 mL, 9.8 mmol).  
The mixture was heated to reflux at 70 ˚C for 5 h and cooled to room temperature.  The 
solution was partitioned between ethyl acetate (2 × 30 mL) and water (20 mL).  The 
combined organic layers were washed with brine, dried (Na2SO4) and concentrated.  
Purification of the crude material by column chromatography (SiO2, hexanes-ethyl acetate 
= 80:20) gave 3.12 (0.379 g, 82%) as a colorless solid.  mp 82-84 °C.  1H NMR (400 MHz, 
CD3OD) δ 6.99 and 6.67 (AA’BB’, JAB = 8.5 Hz, 4H), 4.63 (t, J =1.7 Hz, 2H), 2.57 (tt, J 
=12.3, 4.3 Hz, 1H), 2.41–2.33 (m, 2H), 2.22–2.11 (m, 2H), 1.94–1.85 (m, 2H), 1.45 (qd, J 
=12.3, 4.3 Hz, 2H) ppm.  13C NMR (100 MHz, CD3OD) δ 156.5, 150.2, 139.1, 128.6, 
116.0, 107.7, 44.7, 37.1, 36.2 ppm.  HRMS m/z 187.1128 [calcd for C13H15O
– (M–H+) 
187.1128]. 
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4-(4-Methylcyclohexyl)phenol (3.13).  To a solution of 3.12 (0.150 g, 0.797 mmol) in 
methanol (10 mL) was added 10% Pd/C (0.085 g, 10 mol %) and the mixture was stirred 
under a balloon filled with H2 at room temperature for 12 h.  The reaction mixture was 
filtered through a pad of celite, dried (Na2SO4) and concentrated.  The residue was purified 
by column chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 3.13 (0.121 g, 
80%) as a colorless solid.  mp = 93-99 °C.  [lit. mp 108°C].119  1H NMR (400 MHz, 
CD3OD) δ 7.05–6.96 (m, 2H), 6.70–6.64 (m, 2H), 2.48–2.28 (m, 1H), 1.83–1.34 (m, 8H), 
1.13–1.04 (m, 1H), 1.03 (d, J = 7.2 Hz, 1H), 0.92 (d, J = 6.6 Hz, 2H) ppm.  13C NMR (100 
MHz, CD3OD) δ 156.3, 140.0, 128.6, 116.0, 44.7, 36.9, 35.9, 33.7, 33.1, 30.0, 23.1 ppm.  
The NMR spectral data for this compound were consistent with the literature values.120 
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4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-1-(hydroxymethyl)cyclohexan-1-ol (3.14).  
To a solution of 3.6 (0.280 g, 0.926 mmol) and N-methylmorpholine-N-oxide (0.15 g, 1.3 
mmol) in acetone (6 mL) and distilled water (0.3 mL) was added a 2.5% solution of OsO4 
in tert-butanol (90 µL).  The mixture was stirred overnight and a saturated solution of 
NaHSO3 (10 mL) was added to quench the reaction.  The mixture was diluted with ether 
(20 mL) and extracted with water (2 × 10 mL).  The organic layer was dried (MgSO4) and 
concentrated.  Purification of the residue by column chromatography (SiO2, hexanes-ethyl 
acetate = 20:80) gave 3.14 (0.267 g, 86%) as a colorless solid.  mp 80-86 °C.  1H NMR 
(400 MHz, CDCl3) δ 7.04 and 6.76 (AA’BB’, JAB = 8.5 Hz, 4H), 3.69 (s, 1.7H), 3.47 (s, 
0.3H), 2.58-2.39 (m, 1H), 2.04–1.72 (m, 4H, solvent peak overlapped), 1.61–1.37 (m, 4H), 
0.97 (s, 9H), 0.18 (s, 6H) ppm.  13C NMR (100 MHz, CDCl3) δ 154.0, 138.9, 127.7, 120.0, 
72.4, 66.2, 42.8, 35.4, 31.3, 25.9, 18.4, -4.2 ppm. 
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4-(4-Hydroxy-4-(hydroxymethyl)cyclohexyl)phenol (3.15).  To a solution of 3.14 (0.230 
g, 0.683 mmol) in anhydrous THF (10 mL) was added a solution of TBAF (1M in THF, 
2.8 mL, 2.8 mmol).  The mixture was heated to reflux at 70 ˚C for 6 h and cooled to room 
temperature.  The solution was partitioned between ethyl acetate (2 × 20 mL) and water 
(20 mL).  The combined organic layers were washed with brine, dried (Na2SO4) and 
concentrated.  Purification of the crude material by column chromatography (SiO2, ethyl 
acetate-methanol = 90:10) gave 3.15 (0.118 g, 78%) as a colorless solid.  mp 182-188 °C.  
1H NMR (400 MHz, CD3OD) δ 7.02 and 6.68 (AA’BB’, JAB = 8.5 Hz, 4H), 3.62 (s, 2H), 
2.53–2.42 (m, 1H), 1.99–1.89 (m, 2H), 1.85–1.68 (m, 2H), 1.58–1.43 (m, 4H) ppm.  13C 
NMR (100 MHz, CD3OD) δ 156.5, 138.7, 128.6, 116.0, 73.0, 66.5, 44.2, 35.8, 32.5 ppm. 
Anal. calcd. for C13H18O3: C, 70.24; H, 8.16.  Found: C, 70.18; H, 7.78. 
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2-Hydroxy-5-(4-methylenecyclohexyl)benzaldehyde (3.16).  To a solution of 3.13 
(0.100 g, 0.532 mmol) in dry CH3CN (20 mL) was added magnesium chloride (0.076 g, 
0.797) and triethylamine (0.28 mL, 2.0 mmol), followed by paraformaldehyde (0.108 g, 
3.59 mmol).  The reaction mixture was heated at reflux for 6 h.  The mixture was cooled 
to room temperature and quenched with 10% HCl (10 mL) and extracted with ethyl acetate 
(2 × 25 mL). The combined extracts were washed with brine, dried (Na2SO4) and 
concentrated.  Purification of the residue by column chromatography (SiO2, hexanes-
diethyl ether = 80:20) gave 3.16 (0.046 g, 40%) as a colorless oil.  1H NMR (400 MHz, 
CD3OD) δ 9.96 (s, 1H), 7.50 (s, 1H), 7.39 (d, J = 8.5 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 
4.65 (t, J = 1.7 Hz, 2H), 2.68 (tt, J = 12.0, 3.4 Hz, 1H), 2.44–2.34 (m, 2H), 2.24–2.13 (m, 
2H), 1.97–1.89 (m, 2H), 1.49 (qd, J = 13.0, 4.0 Hz, 2H) ppm.  13C NMR (100 MHz, 
CD3OD) δ 197.3, 160.9, 149.6, 139.8, 136.9, 131.5, 122.3, 118.0, 108.1, 44.1, 36.7, 36.0 
ppm. 
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(E)-2-Hydroxy-5-(4-methylenecyclohexyl)benzaldehyde oxime (3.17).  To a solution of 
3.16 (0.050 g, 0.232 mmol) in pure ethanol (10 mL), were added sodium bicarbonate (0.024 
g, 0.278 mmol) and hydroxylamine hydrochloride (0.025 g, 0.348 mmol).  The reaction 
was heated at 80°C for 5 h, cooled and the mixture was extracted with ethyl acetate (2 × 
20 mL).  The combined organic extracts were dried (MgSO4) and concentrated.  
Purification of the residue by column chromatography (SiO2, hexanes-ethyl acetate = 
65:35) gave 3.17 (0.037 g, 69%) as a colorless solid.  This was determined to be a mixture 
of E- and Z-oxime stereoisomers by 1H NMR spectroscopy.  mp 120-125 °C.  1H NMR 
(400 MHz, CD3OD) δ 8.20 (s, 1H), 7.09–7.06 (m, 1H), 7.05 (d, J = 2.4 Hz, 1.8H), 6.99 (d, 
J = 7.9 Hz, 0.2H), 6.78 (d, J = 8.1 Hz, 0.8H), 6.68 (d, J = 8.6 Hz, 0.2H),  4.63 (t, J = 1.6 
Hz, 2H), 2.60 (tt, J = 12.2, 3.3 Hz, 1H), 2.42–2.33 (m, 2H), 2.22–2.10 (m, 2H), 1.94–1.85 
(m, 2H), 1.46 (qd, J =12.5, 4.0 Hz, 2H) ppm.  13C NMR (100 MHz, MeOD) δ 156.4, 152.2, 
150.0, 139.3, 130.1, 129.0, 128.6, 118.3, 117.0, 116.0, 107.8, 107.7, 44.6, 44.4, 37.1, 36.9, 
36.2, 36.1 ppm.  HRMS m/z 230.1187 [calcd for C14H16NO2
– (M–H+) 230.1186]. 
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5-(2-Oxabicyclo[2.2.2]octan-1-yl)-2-hydroxybenzaldehyde (3.18) and 4-Hydroxy-4'-
(hydroxymethyl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-3-carbaldehyde (3.19).  To a 
solution of 3.8 (0.050 g, 0.25 mmol) in dry CH3CN (15 mL) was added magnesium chloride 
(0.035 g, 0.367 mmol) and triethylamine (0.13 mL, 0.09 mmol) and the mixture was heated 
at reflux for 8 h.  The mixture was cooled to room temperature and quenched with 10% 
HCl (10 mL) and extracted with ethyl acetate (2 × 25 mL).  The combined organic extracts 
were washed with brine, dried (Na2SO4) and concentrated.  Purification of the crude 
material by column chromatography (SiO2, hexanes-ethyl acetate = 65:35) gave 3.18 
(0.010 g, 17%) followed by 3.19 (0.005 g, 8%) both as light-yellow oils.  3.18:   1H NMR 
(400 MHz, CD3OD) δ 9.99 (s, 1H), 7.69 (br s, 1H), 7.57 (br d, J = 8.7 Hz, 1H), 6.87 (d, J 
= 8.7 Hz, 1H), 4.06 (s, 2H), 2.12–1.75 (m, 9H) ppm.  13C NMR (100 MHz, CD3OD) δ 
197.3, 161.3, 140.0, 134.9, 130.1, 128.8, 117.7, 72.6, 71.3, 34.5, 27.3, 25.9 ppm.  3.19: 1H 
NMR (400 MHz, CD3OD) δ 10.01 (s, 1H), 7.69 (s, 1H), 7.62 (d, J = 8.5 Hz, 1H), 6.89 (d, 
J = 8.7 Hz, 1H), 6.10 (s, 1H), 3.49 (d, J = 6.1 Hz, 2H), 2.54–2.28 (m, 3H), 2.05–1.73 (m, 
3H), 1.47–1.35 (m, 1H) ppm.  13C NMR (100 MHz, CD3OD) δ 197.5, 161.4, 136.3, 135.6, 
134.6, 129.8, 123.9, 122.2, 118.0, 67.7, 37.2, 29.9, 27.9, 26.9 ppm.  HRMS m/z 231.1027 
[calcd for C14H15O3
– (M–H+) 231.1027]. 
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4'-(Hydroxymethyl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-ol (3.20).  To a solution of 
3.8 (0.103 g, 0.505 mmol) was in dry CH3CN (25 mL) was added magnesium chloride 
(0.072g, 0.756 mmol) and triethylamine (0.26 mL, 1.89 mmol).  The mixture was heated 
at reflux for 8.  The mixture was cooled to room temperature and quenched with 10% HCl 
(15 mL) and extracted with ethyl acetate (2 × 25 mL).  The combined extracts were washed 
with brine, dried (Na2SO4) and concentrated.  Purification of the crude material by column 
chromatography (SiO2, hexanes- ethylacetate = 65:35) gave 3.20 (0.080 g, 78%) as a 
colorless solid.  mp 177-184°C. 1H NMR (400 MHz, CDCl3) δ 7.20 and 6.69 (AA’BB’, 
JAB = 8.6 Hz, 4H), 5.97–5.92 (m, 1H), 3.48 (dd, J = 6.4, 2.6 Hz, 2H), 2.49–2.23 (m, 3H), 
2.01–1.71 (m, 4H), 1.43–1.31 (m, 1H) ppm.  13C NMR (100 MHz, CDCl3) δ 157.4, 137.5, 
135.0, 127.1, 122.0, 115.8, 67.8, 37.3, 30.0, 28.1, 27.1 ppm.  HRMS m/z 203.1078 [calcd 
for C12H15O2
– (M–H+) 203.1077]. 
 
 
 
 
164 
 
 
 
 
 
 
 
 
4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a).  Method A:  To a solution of 3.8 (0.020 
g, 0.098 mmol) dry CH2Cl2 (10 mL) was added triethylsilane (0.02 mL, 0.12 mmol) 
followed by trifluoroacetic acid (0.08 mL, 0.98 mmol).  The reddish mixture was stirred at 
room temperature overnight and the solution was extracted with ethyl acetate (2 × 10 mL).  
The combined organic extracts were washed with H2O (2 × 15 mL), dried (Na2SO4) and 
concentrated to give 3.4a (0.012 g, 59%) as a colorless solid.  The 1H NMR spectrum 
showed the formation of a 2:3(cis: trans) mixture of isomers.   
Method B: To a solution of 3.8 (0.050 g, 0.25 mmol) in dry THF (15 mL) cooled to -78 
°C was added NaCNBH3 (0.154 g, 2.48 mmol).  The mixture was stirred at this temperature 
for 1 h and BF3.Et2O (2.5 mL, 14 mmol) was added dropwise.  The mixture was warmed 
to room temperature overnight, quenched with water (10 mL) and extracted with ether (2 
× 20 mL). The combined organic extracts were washed with NaHCO3 solution, brine, dried 
(Na2SO4) and concentrated to give 3.4a (0.030, 60%) as a colorless solid.  The 
1H NMR 
spectrum showed the formation of a 1:4 (cis: trans) mixture of isomers.   
 
 
165 
 
 
 
 
 
 
 
 
4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a).  To a solution of compound 3.20 (0.046 
g, 0.23 mmol) in methanol (8 mL) was added 10% Pd/C (0.025 g, 10 mol %) and mixture 
was stirred under a balloon of H2 at room temperature for 12 h.  The reaction mixture was 
filtered through a pad of celite, and concentrated in vacuo to give 3.4a (0.031g, 65%) as a 
colorless solid.  The 1H NMR spectrum showed the formation of a 3:2 (cis: trans) mixture 
of isomers.   
 
 
 
 
 
 
 
Methyl 2-(4-(4-((tert-butyldiphenylsilyl)oxy)phenyl)cyclohexylidene)acetate (3.21).  
Sodium hydride (40 mg, 55% in mineral oil, 0.980 mmol) was added to a stirring solution 
of trimethyl phosphonoacetate (0.160 mL, 0.980 mmol) in dry THF (5 mL) at 0 °C.  After 
45 min, a solution of 4-(4’-t-butyldiphenylsilyloxyphenyl)cyclohexanone 3.2 (0.350 g, 
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0.818 mmol) in dry THF (5 mL) was added and the reaction mixture was stirred at room 
temperature for 8 h.  The mixture was diluted with water (25 mL) and the resulting mixture 
was extracted with ether (2 × 30 mL), dried (MgSO4) and concentrated.  The residue was 
purified by column chromatography (SiO2, hexanes–ethyl acetate = 90:10) to give 
compound 3.21 (0.376 g, 95%) as colorless gum.  1H NMR (400 MHz, CDCl3) δ 7.74- 7.68 
(m, 4H), 7.44-7.32 (m, 6H), 6.91 and 6.69 (AA’BB’, JAB = 8.6 Hz, 4H), 5.65 (s, 1H), 3.96-
3.88 (m, 1H), 3.69 (s, 3H), 2.66 (tt, J = 12.1, 3.4 Hz, 1H), 2.38-2.24 (m, 2H), 2.04-1.93 (m, 
3H), 1.59-1.46 (m, 2H), 1.08 (s, 9H) ppm.  13C NMR (100 MHz, CDCl3) δ 167.4, 162.7, 
154.0, 138.6, 135.7, 133.3, 130.0, 127.9, 127.5, 119.6, 113.3, 51.1, 43.3, 37.9, 35.9, 35.1, 
29.7, 26.7, 19.7 ppm.   
 
 
 
 
 
 
 
 
 
2-(4-(4-((tert-Butyldiphenylsilyl)oxy)phenyl)cyclohexylidene)ethan-1-ol (3.22).  To a 
solution of 3.21 (0.109 g, 0.225 mmol) in dry CH2Cl2 (2 mL) under nitrogen at –40 ˚C was 
added a solution of diisobutylaluminum hydride (0.50 mL, 1.2 M in CH2Cl2, 0.60 mmol).  
After 90 min, saturated aqueous potassium sodium tartrate was added and reaction mixture 
was warmed to room temperature.  After 4 h the mixture was filtered through a pad of celite 
and extracted several times with water (2 × 20 mL).  The combined organic layers were 
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dried (MgSO4), and concentrated to give 3.22 (0.059 g, 58%) as a colorless gum.  This was 
used without further purification in the next step.  1H NMR (400 MHz, CDCl3) δ 7.72 (d, 
J = 7.2 Hz, 4H), 7.45-7.33 (m, 6H), 6.91 and 6.68 (AA’BB’, JAB = 8.4 Hz, 4H), 5.42 (t, J 
= 7.2 Hz, 1H), 4.17 (d, J = 7.2 Hz, 2H), 2.72 (br d, J = 13.9 Hz, 1H), 2.58 (tt, J = 12.1, 3.2 
Hz, 1H), 2.37-2.26 (m, 1H), 2.23-2.13 (m, 1H), 1.97-1.85 (m, 3H), 1.51-1.34 (m, 2H), 1.08 
(s, 9H) ppm.  13C NMR (100 MHz, CDCl3) δ 153.8, 143.4, 139.2, 135.7, 133.3, 130.0, 
127.9, 127.5, 121.1, 119.6, 58.8, 43.8, 37.0, 35.9, 35.4, 28.7, 26.7, 19.6 ppm. 
 
 
 
 
 
 
 
 
2-(4-(4-((tert-Butyldiphenylsilyl)oxy)phenyl)cyclohexyl)ethan-1-ol (3.23).  To a 
solution of compound 45 (0.130 g, 0.285 mmol) in methanol (10 mL) was added, 10% 
Pd/C (0.012 g, 4 mol %). The reaction mixture was stirred under H2 (30 psi) for 12 h.  The 
reaction mixture was filtered through a pad of celite, and the solution was concentrated to 
give 3.23 (0.062 g, 48%) as a colorless oil.  The product was used in the next step without 
further purification.  1H NMR (400 MHz, CDCl3) δ 7.79-7.72 (m, 4H), 7.47-7.35 (m, 6H), 
6.99-6.92 (m, 2H), 6.76- 6.69 (m, 2H), 3.76-3.66 (m, 2H), 2.37 (t, J = 12.5 Hz,1H), 2.27 
(t, J = 6.4 Hz, 1H), 1.86 (d, J = 11.2 Hz, 3H), 1.73-1.56 (m, 3H), 1.56-1.49 (m, 1H), 1.48-
1.27 (m, 3H), 1.13 (s, 9H) ppm.  13C NMR (100 MHz, CDCl3) δ 153.7, 140.2, 135.7, 133.3, 
130.0, 127.9, 127.5, 119.4, 61.0, 43.7, 40.4, 34.5, 33.7, 30.3, 29.1, 26.7, 19.6 ppm. 
168 
 
 
 
   
 
 
 
 
 
 
4-(4-(2-Hydroxyethyl)cyclohexyl)phenol (3.24).  To a solution of 3.2 (0.063 g, 0.138 
mmol) in anhydrous THF (8 mL) was added a solution of TBAF (1M in THF, 1.2 mL, 1.2 
mmol) while stirring.  The mixture was heated to reflux at 70 ˚C overnight and cooled to 
room temperature.  The solution was partitioned between ethyl acetate and water.  The 
organic layer was washed with brine, dried (Na2SO4) and concentrated.  Purification by 
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) gave 3.24 (6 mg, 20%) as a 
colorless solid.  mp 120-125 °C.  1H NMR (300 MHz, (CD3)2CO) δ 8.02 (s, 1H), 7.08-7.01 
(m, 2H), 6.77-6.71 (m, 2H), 3.65- 3.56 and 3.43-3.37 (m, 3H total), 2.52-2.33 (m, 1H), 
1.91-1.00 (m, 11H) ppm. 
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1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-ol (3.25b).  Method A.   To a solution of 3.9 
(0.040 g, 0.21 mmol) in CH2Cl2 (10 mL) at room temperature under N2 was added 
Deoxofluor (0.08 mL, 0.43 mmol) in CH2Cl2 (5 mL).  The mixture was stirred for 20 h, 
after which saturated NaHCO3 (10 mL) was poured into the mixture.  After CO2 evolution 
ceased the mixture was extracted into CH2Cl2 (2 × 20 mL).  The combined extracts were 
dried (MgSO4) and concentrated.  The residue was purified by column chromatography 
(SiO2, hexanes-ethyl acetate = 70:30) to give 3.25b (0.023 g, 63%) as a colorless solid.  mp 
79-84 °C.  1H NMR (400 MHz, CDCl3) δ 7.12 and 6.80 (AA’BB’, JAB = 8.6 Hz, 4H), 5.79–
5.76 (m, 2H), 4.92 (s, 1H), 2.81–2.71 (m, 1H), 2.32–2.07 (m, 4H), 1.95–1.88 (m, 1H), 
1.78–1.66 (m, 1H) ppm.  13C NMR (100 MHz, CDCl3) δ 153.8, 139.9, 128.1, 127.2, 127.0, 
115.3, 39.4, 33.8, 30.2, 26.1 ppm. 
Method B.  To a solution of 3.9 (0.054 g, 0.28 mmol) in THF (20 mL) at room temperature 
under N2 was added DAST (0.08 mL, 0.61 mmol) in THF (3 mL).  The mixture was stirred 
for 20 h, then saturated NaHCO3 (15 mL) was poured into the mixture.  After CO2 evolution 
ceased the mixture was extracted into ethyl acetate (2 × 10 mL).  The combined extracts 
were dried (Na2SO4) and concentrated.  The residue was purified by column 
chromatography (SiO2, hexanes-ethyl acetate = 70:30) to give 3.25b (0.025 g, 51%) as a 
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colorless solid.  The NMR spectral data were consistent with the previously obtained 
values. 
 
 
 
 
 
 
4-(-4-(Fluoromethyl)cyclohexyl)phenol (3.26b).  To a solution of 3.4b (0.065 g, 0.315 
mmol) in CH2Cl2 (12 mL) at -78 ˚C under N2 was added a solution of Deoxofluor (0.09 
mL, 0.473 mmol) in CH2Cl2 (3 mL).  The mixture was gradually warmed to room 
temperature.  On completion, saturated aqueous NaHCO3 (10 mL) was poured in to the 
mixture and after CO2 evolution ceased the mixture was extracted into CH2Cl2 (2 × 20 mL).  
The combined extracts were dried (Na2SO4) and concentrated.  The residue was purified 
by column chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 3.26b (0.037 g, 
56%) as a colorless solid.  mp 103-109 °C.  1H NMR (400 MHz, CD3OD) δ 7.00 and 6.68 
(AA’BB’, JAB = 8.5 Hz, 4H), 4.23 (d, J = 48.1 Hz, 2H), 2.37 (tt, J = 12.3, 2.8 Hz, 1H), 
1.90–1.80 (m, 4H), 1.78–1.59 (m, 2H), 1.52–1.37 (m, 2H), 1.24–1.09 (m, 2H) ppm.  13C 
NMR (100 MHz, CD3OD) δ 156.5, 139.7, 128.6, 116.0, 89.4 (d, J = 166 Hz), 44.9, 39.6 
(d, J = 17 Hz), 35.0, 30.0, 29.9 ppm. 
 
 
 
171 
 
 
 
 
 
 
 
 
 
1-(benzyloxy)-4-bromo-2-fluorobenzene (3.3.).  To a solution of 4-bromo-2-
fluorophenol 3.29 (1.00 g, 5.24 mmol) in DMF (8 mL), benzyl bromide (1.16 g, 0.81 mL, 
6.81 mmol) and potassium carbonate (0.941 g, 6.81 mmol) were added and the mixture 
was heated at reflux for 6 h.  After cooling to room temperature the mixture was poured 
into ice-cold water.  The resulting mixture was partitioned with ethyl acetate (2 x 20 mL) 
and washed with brine (2 x 20 mL).  The combined organic extracts were dried (Na2SO4), 
concentrated and purified by column chromatography (SiO2, hexanes -ethyl acetate = 
90:10) to give 3.30 (1.397 g, 95%) as a colorless solid.  mp 55-60 ˚C.  1H NMR (400 MHz, 
CDCl3) δ 7.47-7.32 (m, 5H), 7.26 (dd, J = 10.6, 2.3 Hz, 1H), 7.19-7.13 (m, 1H), 6.88 (t, J 
= 8.7 Hz, 1H), 5.13 (s, 2H) ppm.  13C NMR (100 MHz, CDCl3) δ 152.9 (d, JC-F = 250 Hz), 
146.3 (d, JC-F = 10 Hz), 136.2, 128.9, 128.4, 127.6, 127.3, 120.0 (d, JC-F = 20 Hz), 117.1, 
(d, JC-F = 10 Hz), 112.8 (d, JC-F = 10 Hz), 71.7 ppm. The NMR spectral data for this 
compound are consistent with the literature values.121 
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8-(4-(Benzyloxy)-3-fluorophenyl)-8-hydroxy-1,4-dioxaspiro[4.5]decane (3.31).  Dry 
magnesium turnings (0.384 g, 0.016 mol) were placed in a flame dried three-necked flask 
followed by THF (10 mL).  The system was flushed with N2 and fitted with a REFLUX 
condenser and an addition funnel.  The addition funnel was filled with a solution of 3.30 
(0.900 g, 3.20 mmol) in THF (10 mL).  A little amount of the bromobenzene solution (3 
mL) was added slowly to the magnesium turnings, and the contents were heated at reflux.  
Once the Grignard formation had started, the remaining bromide solution was added 
dropwise and the mixture was stirred until most of the magnesium had reacted.  A solution 
of 1,4-cyclohexanedione monoethylene acetal (0.250 g, 1.60 mmol) in THF (10 mL) was 
added dropwise over 20 min.  After stirring overnight at room temperature, a saturated 
solution of NH4Cl (15 mL) was slowly added to quench the reaction.  The resultant 
emulsion was stirred for 15 min and the solution was extracted with ether (3 x 20 mL).  
The combined organic layers were washed with brine (20 mL), dried (MgSO4) and 
concentrated.  The residue was purified by column chromatography (SiO2, hexanes-ethyl 
acetate = 70:30) to give 3.31 (0.470 g, 82%) as a colorless solid.  mp 137-143 ˚C.  1H NMR 
(400 MHz, CDCl3) δ 7.46-7.28 (m, 5H), 7.26 (s, 1H), 7.18-7.12 (m, 1H), 6.95 (t, J = 8.4 
Hz, 1H), 5.13 (s, 2H), 4.03-3.93 (m, 4H), 2.16-2.01 (m, 4H), 1.83-1.75 (m, 2H), 1.71-1.63 
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(m, 2H), ppm.  13C NMR (100 MHz, CDCl3) δ 152.7 (d, JC-F = 245 Hz), 145.5 (d, JC-F = 13 
Hz), 142.6 (d, JC-F = 5 Hz), 136.8, 128.8, 128.3, 127.6, 120.3 (d, JC-F = 4 Hz), 115.4 (d, JC-
F = 2 Hz), 113.3 (d, JC-F = 20 Hz), 108.5, 72.1, 71.5, 64.5, 64.4, 36.7, 30.9 ppm. 
 
 
 
 
 
 
 
4-(4-Benzyloxy-3-fluorophenyl)-3-cyclohexanone (3.32).  Method A: Compound 3.31 
(0.100 g, 0.279 mmol) was dissolved in THF: Water-4:1 mixture (10 mL) to give a 
colorless solution.  Then 2-3 drops of Conc sulfuric acid was slowly added and the mixture 
was heated at reflux for 5 h.  After completion, the solution was diluted with brine and 
extracted with ethyl acetate (2 x 10 mL).  The combined organic layers were washed with 
brine (20 mL), dried (Na2SO4) and concentrated.  The residue was purified by column 
chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 3.32 (0.043 g, 52%) as a 
light yellow solid.  mp 74-82 ˚C. 1H NMR (400 MHz, CDCl3) δ 7.50-7.30 (m, 5H), 7.16 
(dd, J = 12.6, 2.1 Hz, 1H), 7.10-7.03 (m, 1H), 6.96 (t, J = 8.6 Hz, 1H), 6.02 (nr t, J = 3.9 
Hz, 1H), 5.15 (s, 2H), 3.05 (br s, 2H), 2.82 (t, J = 6.4 Hz, 2H), 2.67-2.59 (m, 2H) ppm.  13C 
NMR (100 MHz, CDCl3) δ 210.0, 152.8 (d, JC-F = 245 Hz), 146.1 (d, JC-F = 11 Hz), 136.6, 
136.3 (d, JC-F = 2 Hz), 134.6 (d, JC-F = 6 Hz), 128.8, 128.4, 127.6, 121.0 (d, JC-F = 3 Hz), 
120.7, 115.6 (d, JC-F = 2 Hz), 113.4 (d, JC-F = 19 Hz), 71.6, 40.0, 38.8, 27.9 ppm. 
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Method B:  To a solution of 3.31(1.189 g, 3.317 mmol) was dissolved in dry CH2Cl2 (20 
mL) was added TFA (3.5 mL, 0.046 mol) and the mixture was stirred at room temperature 
for 4h while monitoring the reaction by TLC.  Once completed, saturated aqueous NaHCO3 
(10 mL) was added and stirred for another 10 minutes.  The resulting solution was extracted 
with CH2Cl2, washed with brine (10 mL), dried (Na2SO4) and concentrated.  Purification 
of the crude material by column chromatography (SiO2, hexanes-ethyl acetate = 80:20) 
gave 3.32 (0.883 g, 90%) as a light yellow solid.   
 
 
 
 
 
 
 
4-(3-Fluoro-4-hydroxyphenyl)cyclohexanone (3.33).  To a solution of 3.32 (1.000 g, 
3.374 mmol) in ethyl acetate (15 mL), was added 10% Pd/C (0.360 g, 10 mol %) and the 
mixture was stirred under a balloon of H2 at room temperature for 12 h.  The reaction 
mixture was filtered through a pad of celite, concentrated, and the residue was purified by 
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to give 3.33 (0.315 g, 45%) 
as a colorless solid.  mp 137-145 °C.  1H NMR (400 MHz, CD3OD) δ 6.97 (dd, J = 12.4, 
2.1 Hz, 1H), 6.91-6.87 (m, 1H), 6.86-6.79 (m, 1H), 3.00 (tt, J = 12.1, 3.5 Hz, 1H), 2.58 (td, 
J = 14.0, 6.1 Hz, 2H), 2.41-2.33 (m, 2H), 2.19-2.10 (m, 2H), 1.86 (qd, J = 12.8, 4.2 Hz, 
2H) ppm.  13C NMR (100 MHz, CD3OD) δ 214.1, 152.8 (d, JC-F = 240 Hz), 144.5 (d, JC-F 
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= 20 Hz), 138.6 (d, JC-F = 10 Hz), 123.7 (d, JC-F = 10 Hz), 118.7 (d, JC-F = 10 Hz), 115.2 (d, 
JC-F = 20 Hz), 42.8, 42.1, 35.3 ppm. 
 
 
 
 
 
 
4-(4-(Benzyloxy)-3-fluorophenyl)cyclohexan-1-one (3.34).  To a solution of 3.33 (0.205 
g, 0.984 mmol) in DMF (10 mL), was added benzyl bromide (0.219 g, 0.15 mL, 1.28 mmol) 
and potassium carbonate (0.177 g, 1.28 mmol) and the mixture was heated at reflux for 6 
h.  After cooling to room temperature, the mixture was poured into ice-cold water.  The 
mixture was extracted with ethyl acetate (2 x 15 mL) and the combined extracts were 
washed with brine (15 mL), dried (Na2SO4), and concentrated.  Purification of the residue 
by column chromatography (SiO2, hexanes-ethyl acetate = 90:10) gave 3.34 (0.232 g, 79 
%) as a colorless solid.  mp 81-87 °C.  1H NMR (400 MHz, CDCl3) 7.49-7.29 (m, 5H), 
7.02-6.88 (m, 3H), 5.11(s, 2H), 2.95 (tt, J = 12.2, 6.9 Hz, 1H), 2.51-2.43 (m, 3H), 2.22-
2.13 (m, 2H), 1.92-1.79 (m, 2H) ppm.  13C NMR (100 MHz, CDCl3) δ 211.0, 152.9 (d, JC-
F = 240 Hz), 145.3 (d, JC-F = 10 Hz), 138.7 (d, JC-F = 10 Hz), 136.7, 128.7, 128.2, 127.5, 
122.3 (d, JC-F = 10 Hz), 115.9, 114.7 (d, JC-F = 20 Hz), 71.6, 41.8, 41.3, 34.0 ppm 
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1-(Benzyloxy)-2-fluoro-4-(4-methylenecyclohexyl)benzene (3.35).  A solution of 
nbutyllithium in hexane (2.5 M, 0.47 mL, 1.17 mmol) was slowly added to a solution of 
methyltriphenylphosphonium bromide (0.556 g, 1.56 mmol) in dry THF (20 mL) at -10 
°C.  After 20 min, a solution of 3.34 (0.232 g, 0.778 mmol) in dry THF (10 mL) was added 
dropwise.  The reaction mixture was slowly warmed to room temperature and stirred 
overnight.  The mixture was diluted with water (10 mL), extracted with ethyl acetate (2 
×25 mL), dried (Na2SO4) and concentrated.  The crude residue was purified by column 
chromatography (SiO2, hexanes-ethyl acetate = 90:10) to give 3.35 (0.165 g, 72 %) as a 
colorless solid.  1H NMR (400 MHz, CDCl3) 7.56-7.29 (m, 5H), 7.02-6.83 (m, 3H), 5.13 
(s, 2H), 4.71 (s, 2H), 2.63 (tt, J = 12.2, 3.3 Hz, 1H), 2.49-2.37 (m, 2H), 2.27-2.12 (m, 2H), 
2.04-1.92 (m, 2H), 1.57-1.43 (m, 2H) ppm.  13C NMR (100 MHz, CDCl3) δ 153.0 (d, JC-F 
= 250 Hz), 148.6, 144.9, 141.0, 137.0, 133.9 (d, JC-F = 20 Hz), 128.7, 128.2, 127.6, 122.3, 
115.8, 114.9 (d, JC-F = 20 Hz), 107.8, 71.7, 43.3, 35.7, 35.2 ppm. 
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(4-(4-(Benzyloxy)-3-fluorophenyl)cyclohexyl)methanol (3.36).  A solution of 9-BBN in 
THF (0.5 M, 1.46 mL, 0.729 mmol) was added to a solution of 3.35 (0.108 g, 0.364 mmol) 
in THF (15 mL) at 0 °C.  The reaction mixture was slowly warmed to room temperature 
and stirred for 20 h.  The mixture was cooled to 0 °C hydrogen peroxide solution (30% in 
water, 0.20 mL) and 1N NaOH solution (0.50 mL) was sequentially added.  The resulting 
mixture was warmed to room temperature, stirred for 15 min and extracted with ethyl 
acetate (2 ×20 mL). The combined organic extracts were dried (Na2SO4), and concentrated.  
The residue was purified by column chromatography (SiO2, hexanes-ethyl acetate = 60:40) 
to give 3.36 (0.025 g, 22%) as a colorless solid.  This was determined to be a 1:2 mixture 
of cis- and trans-stereoisomers by 1H NMR integration.  1H NMR (400 MHz, CDCl3) 7.50-
7.28 (m, 5H), 7.01-6.80 (m, 3H), 5.11 (s, 2H), 3.67 (d, J = 7.9 Hz, 0.7H), 3.50 (d, J = 6.2 
Hz, 1.3H), 2.60-2.50 (m, 0.3H), 2.47-2.36 (m, 0.7H), 1.98-1.33 (m, 8H), 1.17-1.03 (m, 1H) 
ppm.  13C NMR (100 MHz, CDCl3) δ 154.2, 151.8, 144.8, 141.6, 137.0, 128.8, 128.2, 
127.6, 122.4, 122.3, 115.9, 115.1, 114.9, 114.7, 71.8, 68.7, 64.6, 43.7, 42.2, 40.2, 36.2, 
33.9, 29.8, 29.3, 26.8 ppm. 
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2-Fluoro-4-(4-(hydroxymethyl)cyclohexyl)phenol (3.37).  To a solution of 3.36 (0.050 
g, 0.159 mmol) in ethyl acetate (10 mL) was added 10% Pd/C (0.017 g, 10 mol %) and 
mixture was stirred under a balloon of H2 at room temperature for 12 h.  The reaction 
mixture was filtered through a pad of celite, concentrated, and the residue was purified by 
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to give 3.37 (0.018 g, 51%) 
as a colorless solid.  This was determined to be a 1:2 mixture of cis- and trans-stereoisomers 
by 1H NMR integration.  1H NMR (400 MHz, CD3OD) 6.92-6.85 (m, 1H), 6.84-6.76 (m, 
2H), 3.60 (d, J = 7.4 Hz, 0.7H), 3.39 (d, J = 6.5 Hz, 1.3H), 2.55-2.33 (m, 1H), 1.94-1.34 
(m, 8H), 1.15-1.01 (m, 1H) ppm.  13C NMR (100 MHz, CD3OD) δ 154.0, 151.6, 143.9, 
141.1, 123.5, 118.5, 115.0, 68.8, 64.4, 45.0, 41.3, 37.1, 35.2, 31.0, 30.4, 29.5, 27.8 ppm. 
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2-Fluoro-4-(4-hydroxycyclohexyl)phenol (3.38).  To a solution of 3.33 (0.033 g, 0.159 
mmol) in anhydrous methanol (10 mL) was added NaBH4 (0.090 g, 2.38 mmol).  The 
mixture was stirred at room temperature for 2 h and then diluted with water.  The resulting 
mixture was extracted with ethyl acetate (2× 15 mL), combined extracts were dried 
(Na2SO4) and concentrated.  Purification of the crude material by column chromatography 
(SiO2, hexanes-ethyl acetate = 65:35) gave the 3.38 (0.020 g, 61%) as a colorless solid.  mp 
179-186 °C.  1H NMR (400 MHz, CD3OD) δ 6.91-6.85 (m, 1H), 6.83-6.74 (m, 2H), 3.60-
3.52 (m, 1H), 2.39 (tt, J = 12.0, 3.1 Hz, 1H), 2.05-1.96 (m, 2H), 1.88-1.79 (m, 2H), 1.52-
1.20 (m, 4H) ppm.  13C NMR (100 MHz, CD3OD) δ 152.8 (d, JC-F = 240 Hz), 144.0 (d, JC-
F = 10 Hz), 140.3, 123.6, 118.5, 115.1 (d, JC-F = 10 Hz), 71.1, 44.0, 36.6, 33.8 ppm. 
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5-(4-Methoxyphenyl)-1,2-cycloheptanediol (2.5b).  Epoxide 2.5a (0.103 g, 0.469 mmol) 
was dissolved in 0.5 M sulfuric acid solution (50 mL) and heated to reflux for 24 h.  The 
organic oil turned to a brown color and the mixture was allowed to cool and extracted with 
ether (3 × 30 mL).  The combined ethereal extracts were washed with water (2 × 20 mL), 
dried (MgSO4) and concentrated to give a crude residue. The residue was purified by 
column chromatography (SiO2, ethyl acetate = 100%) to give 2.5b (0.064g, 65%) as a 
colorless solid. mp 66-70 ˚C.  1H NMR (400 MHz, CDCl3)  7.08 and 6.82 (AA’BB’, JAB 
= 8.5 Hz, 4H), 3.79 (s, 3H), 3.67-3.51 (m, 2H), 2.92 (s, 2H), 2.69-2.60 (m, 1H), 2.02-1.77 
(m, 6H), 1.68-1.54 (m, 2H) ppm. 13C NMR (400 MHz, CDCl3)  157.8, 141.0, 127.4, 113.8, 
78.5, 77.2, 55.3, 44.1, 33.2, 31.9, 30.8, 29.8 ppm 
 
 
 
 
 
 
4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cyclohexane-1-carboxaldehyde (3.7-I).  To 
a solution of 3.7 (0.315 g, 0.983 mmol) in CH2Cl2 (15 mL) at room temperature, was added 
Dess–Martin periodinane (0.625 g, 1.47 mmol) and water (10 drops) and mixture was 
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stirred at room temperature for 6 h.  The mixture was quenched with 1:1 sodium 
thiosulfate:sodium bicarbonate solution.  The resulting mixture was stirred at room 
temperature for 30 min, and extracted with ethyl acetate (2 x 20 mL), dried (MgSO4), and 
concentrated to give the product 3.7-I (0.282 g, 90%) as a mixture of stereoisomers.  1H 
NMR (400 MHz, CDCl3) δ 9.78 and 9.67 (2 x s, 1H total), 7.10-6.97 (m, 2H), 6.80-6.71 
(m, 2H), 2.56-1.32 (m, 10H), 0.97 (s, 9H), 0.18 (s, 6H) ppm.   13C NMR (100 MHz, CDCl3) 
δ 205.9, 153.9, 139.9, 127.8, 119.9, 46.5, 42.9, 42.8, 41.6, 33.6, 33.3, 31.1, 30.8, 29.4, 27.6, 
26.6, 25.9, 25.2, 18.4, -4.2 ppm. 
 
 
 
 
 
 
4-(4-(((tert-Butyldimethylsilyl)oxy)methyl)cyclohexyl)phenol (3.4a-I).  To a solution of 
4-(4-(hydroxymethyl)cyclohexyl)phenol 3.4a (0.225 g, 1.09 mmol) in dry CH2Cl2 (30 ml) 
at 0 °C, was added imidazole (0.223 g, 3.27 mmol) and the mixture was stirred for a 30 
min.  A solution of t- butyldimethylsilyl chloride (0.115 g, 0.764 mmol) was added, and 
the mixture was slowly warmed to room temperature and stirred for 8 h.  The mixture was 
diluted with water (20 mL) and extracted with CH2Cl2 (2 × 20 mL).  The combined organic 
extracts were washed with brine, dried (Na2SO4), and concentrated.  The residue was 
purified by column chromatography (SiO2, hexanes-ethyl acetate = 90: 10) to give the 
product 3.4a-I (0.090 g, 26%) as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 7.14-7.04 
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(m, 2H), 6.82-6.73 (m, 2H), 5.14 (s, 1H), 3.67 (d, J = 7.6 Hz, 1.2 H), 3.49 (d, J = 6.2 Hz, 
0.8H), 2.60-2.48 (m, 0.6 H), 2.41 (br t, J = 11.5 Hz, 0.4 H), 1.96-1.34 (m, 9H), 0.94 (s, 9H), 
0.10 (s, 6H) ppm.  13C NMR (100 MHz, CDCl3) δ 153.8, 140.0, 139.6, 128.1, 115.3, 69.1, 
64.9, 43.9, 42.5, 40.2, 35.8, 34.2, 30.1, 29.6, 26.9, 26.2, 18.6, -5.0 ppm. 
 
 
 
 
 
 
4-(4-(((tert-Butyldiphenylsilyl)oxy)methyl)cycloheptyl)phenol (2.10-I).  To a solution 
of 4-(4-(hydroxymethyl)cycloheptyl)phenol 2.10 (0.158 g, 0.717 mmol) in dry CH2Cl2 (15 
ml) at 0 °C, was added imidazole (0.122 g, 1.79 mmol).  The mixture was stirred for 30 
min and then a solution of t-butyldiphenylsilyl chloride (0.15 mL, 0.574 mmol) in CH2Cl2 
(2 mL) was added.  The mixture was slowly warmed to room temperature and stirred 
overnight.  The mixture was diluted with brine (20 mL) and extracted with CH2Cl2 (2 × 20 
mL).  The combined organic extracts were dried (Na2SO4), and concentrated.  The residue 
was purified by column chromatography (SiO2, hexanes-ethyl acetate = 80: 20) to give the 
product 2.10-I (0.135 g, 41%) as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 7.79-7.68 
(m, 4H), 7.51-7.38 (m, 6H), 7.13-7.04 (m, 2H), 6.82-6.74 (m, 2H), 5.05 (s, 1H), 3.53 (s, 
2H), 2.75-2.50 (m, 1H), 2.02-1.42 (m, 11H), 1.12 (s, 9H) ppm.  13C NMR (100 MHz, 
CDCl3) δ 153.4, 142.1, 135.8, 134.2, 129.7, 127.8, 115.3, 69.3, 69.1, 47.4, 46.2, 42.0, 41.1, 
39.0, 36.9, 36.5, 33.0, 31.5, 30.6, 30.0, 28.5, 27.4, 24.3, 19.5 ppm.    
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Table 1 Crystal data and structure refinement for ISP163-PK1 
Identification code ISP163PK-1 (don2e) 
Empirical formula C14H20O2 
Formula weight 220.30 
Temperature/K 99.90(14) 
Crystal system orthorhombic 
Space group P212121 
a/Å 9.9579(5) 
b/Å 10.1803(8) 
c/Å 24.0251(12) 
α/° 90.00 
β/° 90.00 
γ/° 90.00 
Volume/Å3 2435.5(3) 
Z 8 
ρcalcg/cm3 1.202 
μ/mm-1 0.617 
F(000) 960.0 
Crystal size/mm3 0.3986 × 0.202 × 0.0143 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 7.36 to 148.1 
Index ranges -9 ≤ h ≤ 12, -10 ≤ k ≤ 12, -29 ≤ l ≤ 27 
Reflections collected 12560 
Independent reflections 4845 [Rint = 0.0642, Rsigma = 0.0740] 
Data/restraints/parameters 4845/0/293 
Goodness-of-fit on F2 1.052 
Final R indexes [I>=2σ (I)] R1 = 0.0807, wR2 = 0.1991 
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Final R indexes [all data] R1 = 0.1259, wR2 = 0.2335 
Largest diff. peak/hole / e Å-3 0.34/-0.31 
Flack parameter -1.1(5) 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for don2e. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 1257(4) 1630(3) 813.4(12) 52.5(8) 
O2 3907(3) 358(4) 5117.3(13) 59.1(9) 
C1 1195(4) 854(4) 2522.1(16) 37.3(9) 
C2 1216(4) 2128(5) 2308.6(18) 44.1(10) 
C3 1228(4) 2376(5) 1742.0(18) 44.4(10) 
C4 1263(4) 1325(5) 1370.9(17) 43(1) 
C5 1255(5) 56(5) 1570.3(18) 47.4(10) 
C6 1227(4) -190(5) 2138.3(17) 42.8(9) 
C7 1205(4) 595(5) 3144.6(17) 40.8(9) 
C8 2613(4) 837(6) 3378.8(19) 50.9(12) 
C9 2777(4) 415(6) 3985.6(19) 51.3(12) 
C10 2505(5) 1489(6) 4415(2) 55.6(13) 
C11 1114(6) 2141(7) 4353(2) 72.2(17) 
C12 21(5) 1331(6) 4067(2) 59.9(14) 
C13 73(4) 1388(6) 3436.0(18) 51.2(12) 
C14 2660(4) 1019(6) 5005(2) 57.4(13) 
O1A 3775(3) 5782(4) 587.8(12) 50.2(8) 
O2A 2794(4) 6197(4) 5279.3(14) 63(1) 
C1A 3762(4) 6250(4) 2321.7(17) 40.8(9) 
C2A 3683(4) 4998(5) 2084.0(18) 43.2(10) 
C3A 3678(4) 4818(5) 1513.4(17) 41.2(9) 
C4A 3766(4) 5923(4) 1159.4(18) 41.8(9) 
C5A 3875(5) 7157(5) 1385(2) 47.8(10) 
C6A 3867(5) 7312(5) 1957(2) 46.3(10) 
C7A 3723(4) 6485(5) 2944.2(18) 46.8(10) 
C8A 2439(5) 6014(11) 3195(2) 109(3) 
C9A 2148(5) 6604(11) 3763(2) 127(4) 
C10A 2678(5) 5945(7) 4266(2) 71.9(18) 
C11A 4048(7) 5372(7) 4195(3) 80(2) 
C12A 5045(4) 6139(9) 3868(2) 82(2) 
C13A 4968(4) 6014(8) 3225(2) 69.7(19) 
C14A 2565(6) 6837(7) 4755(2) 73.8(18) 
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Table 3 Anisotropic Displacement Parameters (Å2×103) for don2e. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
O1 49.1(16) 69(2) 39.9(16) -0.5(15) 3.0(14) -11.0(18) 
O2 39.9(15) 87(3) 50.0(19) 11.3(18) -3.4(14) -4.1(18) 
C1 26.1(15) 41(2) 45(2) -4.6(17) 0.6(16) -6.3(18) 
C2 31.1(17) 52(3) 49(2) -8(2) 1.0(19) -6(2) 
C3 34.3(18) 45(2) 54(3) 2(2) 1.5(19) -2(2) 
C4 26.5(16) 55(3) 47(2) -2(2) 2.1(17) -7(2) 
C5 38.2(19) 52(3) 52(3) -8(2) 7(2) -3(2) 
C6 37.2(18) 44(2) 48(2) -4.4(19) 3.5(19) 1(2) 
C7 28.4(16) 48(2) 46(2) -2.7(18) -1.1(17) 1.2(19) 
C8 27.0(18) 76(4) 49(3) -5(2) -0.6(17) 2(2) 
C9 32.5(18) 69(3) 53(3) -3(2) -6.2(18) 9(2) 
C10 48(2) 68(4) 50(3) -7(2) -9(2) -5(2) 
C11 68(3) 92(4) 57(3) -20(3) -16(3) 26(4) 
C12 39(2) 81(4) 59(3) -3(3) 5(2) 14(2) 
C13 26.2(17) 80(4) 47(3) 0(2) 1.8(17) 6(2) 
C14 41(2) 85(4) 46(3) -3(3) -2.3(19) 4(2) 
O1A 41.1(14) 66(2) 43.4(17) 2.6(14) 0.9(13) -11.1(17) 
O2A 73(2) 73(3) 43.3(19) 1.9(17) -2.3(16) -24(2) 
C1A 30.4(16) 42(2) 50(2) -2.5(19) -1.4(17) 1.5(19) 
C2A 31.2(18) 53(3) 45(2) 5.8(19) 4.1(17) -4.0(19) 
C3A 32.4(18) 41(2) 50(2) -1.7(19) 0.9(17) 0.3(18) 
C4A 26.3(15) 50(3) 50(2) 6.7(19) -1.6(17) -5.7(19) 
C5A 39(2) 45(3) 60(3) 11(2) -4(2) -7(2) 
C6A 39(2) 36(2) 65(3) -2(2) -7(2) 0(2) 
C7A 35.7(19) 58(3) 46(2) -8(2) -5.8(18) 5(2) 
C8A 36(2) 253(11) 39(3) -31(4) 3(2) -25(4) 
C9A 38(2) 303(14) 40(3) -34(5) -10(2) 42(5) 
C10A 59(3) 111(5) 46(3) -21(3) 18(2) -36(3) 
C11A 107(5) 69(4) 63(4) 12(3) 4(3) 31(4) 
C12A 30(2) 170(7) 46(3) 18(4) -8(2) -8(3) 
C13A 30(2) 138(6) 42(3) 3(3) 0.8(18) 4(3) 
C14A 75(4) 111(5) 35(3) -7(3) -8(2) 21(3) 
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Table 4 Bond Lengths for don2e. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C4 1.375(5)   O1A C4A 1.381(5) 
O2 C14 1.437(6)   O2A C14A 1.436(7) 
C1 C2 1.395(7)   C1A C2A 1.398(6) 
C1 C6 1.408(6)   C1A C6A 1.395(6) 
C1 C7 1.519(6)   C1A C7A 1.515(6) 
C2 C3 1.384(6)   C2A C3A 1.383(6) 
C3 C4 1.393(6)   C3A C4A 1.413(6) 
C4 C5 1.378(7)   C4A C5A 1.372(7) 
C5 C6 1.388(6)   C5A C6A 1.384(7) 
C7 C8 1.530(5)   C7A C8A 1.493(7) 
C7 C13 1.553(6)   C7A C13A 1.490(6) 
C8 C9 1.529(7)   C8A C9A 1.519(8) 
C9 C10 1.528(7)   C9A C10A 1.479(10) 
C10 C11 1.544(7)   C10A C11A 1.494(8) 
C10 C14 1.505(7)   C10A C14A 1.490(8) 
C11 C12 1.528(8)   C11A C12A 1.489(9) 
C12 C13 1.517(7)   C12A C13A 1.551(7) 
  
Table 5 Bond Angles for don2e. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 C1 C6 117.4(4)   C2A C1A C7A 123.1(4) 
C2 C1 C7 121.6(4)   C6A C1A C2A 117.0(4) 
C6 C1 C7 120.9(4)   C6A C1A C7A 119.9(4) 
C3 C2 C1 122.1(4)   C3A C2A C1A 121.7(4) 
C2 C3 C4 119.3(4)   C2A C3A C4A 119.4(4) 
O1 C4 C3 116.7(4)   O1A C4A C3A 121.1(4) 
O1 C4 C5 123.4(4)   C5A C4A O1A 119.2(4) 
C5 C4 C3 119.8(4)   C5A C4A C3A 119.7(4) 
C4 C5 C6 120.7(4)   C4A C5A C6A 119.8(4) 
C5 C6 C1 120.6(4)   C5A C6A C1A 122.4(4) 
C1 C7 C8 109.9(3)   C8A C7A C1A 111.7(4) 
C1 C7 C13 110.4(4)   C13A C7A C1A 112.0(4) 
C8 C7 C13 114.6(4)   C13A C7A C8A 115.2(5) 
C9 C8 C7 113.8(4)   C7A C8A C9A 113.5(6) 
C10 C9 C8 115.1(5)   C10A C9A C8A 119.2(8) 
C9 C10 C11 113.6(4)   C9A C10A C11A 114.1(4) 
C14 C10 C9 113.0(5)   C9A C10A C14A 109.9(6) 
C14 C10 C11 108.7(4)   C14A C10A C11A 113.4(5) 
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C12 C11 C10 116.8(5)   C12A C11A C10A 117.7(6) 
C13 C12 C11 113.9(5)   C11A C12A C13A 116.7(6) 
C12 C13 C7 117.1(4)   C7A C13A C12A 117.8(4) 
O2 C14 C10 114.4(4)   O2A C14A C10A 113.7(6) 
  
Table 6 Hydrogen Bonds for don2e. 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O1 H1 O21 0.84 1.80 2.631(5) 167.6 
O2 H2 O1A2 0.84 2.11 2.896(5) 156.0 
O1A H1A O2A3 0.84 1.82 2.655(5) 175.7 
O2A H2AA O14 0.84 1.93 2.726(5) 158.1 
11/2-X,-Y,-1/2+Z; 21-X,-1/2+Y,1/2-Z; 31/2-X,1-Y,-1/2+Z; 41/2-X,1-Y,1/2+Z 
  
Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for don2e. 
Atom x y z U(eq) 
H1 1276 935 625 79 
H2 4412 420 4839 89 
H2A 1221 2849 2560 53 
H3 1213 3254 1608 53 
H5 1270 -659 1316 57 
H6 1229 -1071 2269 51 
H7 999 -357 3199 49 
H8A 3273 354 3148 61 
H8B 2822 1785 3348 61 
H9A 2160 -328 4059 62 
H9B 3705 90 4039 62 
H10 3193 2191 4355 67 
H11A 789 2380 4729 87 
H11B 1230 2967 4141 87 
H12A 107 404 4186 72 
H12B -868 1652 4192 72 
H13A 164 2320 3325 61 
H13B -800 1072 3291 61 
H14A 2584 1783 5258 69 
H14B 1911 413 5092 69 
H1A 3305 5130 498 75 
H2AA 3190 6716 5496 95 
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H2AB 3632 4252 2321 52 
H3A 3615 3960 1361 49 
H5A 3956 7902 1150 57 
H6A 3935 8172 2108 56 
H7A 3721 7461 2992 56 
H8AA 2474 5046 3230 131 
H8AB 1690 6234 2940 131 
H9AA 2497 7514 3763 153 
H9AB 1161 6662 3804 153 
H10A 2063 5189 4342 86 
H11C 4429 5219 4570 96 
H11D 3947 4502 4015 96 
H12C 5955 5867 3987 98 
H12D 4941 7078 3966 98 
H13C 5737 6500 3065 84 
H13D 5091 5076 3129 84 
H14C 3221 7560 4713 89 
H14D 1656 7231 4759 89 
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Table 1 Crystal data and structure refinement for ISP163-PK3. 
Identification code ISP163-PK3 (don2d) 
Empirical formula C14H20O2 
Formula weight 220.30 
Temperature/K 100.00(10) 
Crystal system monoclinic 
Space group P21 
a/Å 10.0103(7) 
b/Å 10.1468(8) 
c/Å 12.2271(9) 
α/° 90.00 
β/° 103.012(8) 
γ/° 90.00 
Volume/Å3 1210.05(16) 
Z 4 
ρcalcg/cm3 1.209 
μ/mm-1 0.621 
F(000) 480.0 
Crystal size/mm3 0.2462 × 0.1633 × 0.0221 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 7.42 to 148.44 
Index ranges -12 ≤ h ≤ 11, -12 ≤ k ≤ 12, -14 ≤ l ≤ 15 
Reflections collected 15025 
Independent reflections 4596 [Rint = 0.0583, Rsigma = 0.0618] 
Data/restraints/parameters 4596/1/305 
Goodness-of-fit on F2 1.029 
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for don2d. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 3964(2) 4063(2) 1458.7(16) 30.5(4) 
O2 7030(2) 6822(2) 10051.0(17) 33.9(5) 
C1 5101(3) 4152(3) 4982(2) 26.6(5) 
C2 3716(3) 4102(3) 4424(2) 29.8(6) 
C3 3325(3) 4072(3) 3253(2) 28.0(6) 
C4 4309(3) 4102(3) 2620(2) 25.5(5) 
C5 5691(3) 4153(3) 3157(2) 28.8(6) 
C6 6061(3) 4162(3) 4325(2) 28.4(6) 
C7 5523(3) 4186(3) 6257(2) 26.7(6) 
C8 4760(3) 5290(3) 6723(2) 33.7(7) 
C9 5481(3) 5899(3) 7855(2) 31.7(6) 
C10 6122(3) 4950(3) 8812(2) 27.5(6) 
C11 5385(3) 3632(3) 8797(2) 31.3(6) 
C12 5806(4) 2622(3) 8006(3) 34.2(7) 
C13 5262(3) 2835(3) 6748(2) 32.1(6) 
C14 6212(3) 5645(3) 9938(2) 32.9(7) 
O1A -429(2) 6584(2) 1371.8(17) 33.8(5) 
O2A 1553(2) 5163(3) 10642.6(17) 41.3(6) 
C1A -226(3) 6766(3) 4824(2) 27.8(6) 
C2A 954(3) 6672(3) 4404(2) 30.8(6) 
C3A 872(3) 6620(3) 3249(2) 32.7(6) 
C4A -399(3) 6647(3) 2508(2) 28.2(6) 
C5A -1590(3) 6727(3) 2902(2) 30.6(6) 
C6A -1484(3) 6790(3) 4059(2) 29.8(6) 
C7A -183(3) 6805(3) 6074(2) 30.4(6) 
C8A 32(3) 5426(3) 6601(2) 31.3(6) 
C9A -555(3) 5270(4) 7643(2) 35.8(7) 
C10A 261(3) 5862(3) 8769(2) 29.9(6) 
C11A 1373(3) 6864(4) 8679(2) 34.3(6) 
C12A 863(4) 8053(3) 7923(3) 36.7(7) 
C13A 820(4) 7856(4) 6671(3) 38.7(7) 
C14A 866(4) 4736(4) 9545(2) 37.8(7) 
Final R indexes [I>=2σ (I)] R1 = 0.0528, wR2 = 0.1256 
Final R indexes [all data] R1 = 0.0730, wR2 = 0.1399 
Largest diff. peak/hole / e Å-3 0.28/-0.25 
Flack parameter 0.0(3) 
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Table 3 Anisotropic Displacement Parameters (Å2×103) for don2d. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
O1 34.0(11) 26.7(12) 27(1) 2.2(9) -0.8(8) 5.1(9) 
O2 39.7(11) 22.1(11) 34.2(10) -0.4(9) -3.4(9) -1.1(9) 
C1 29.8(13) 17.6(13) 30.1(12) -0.3(11) 1.7(10) -1.7(11) 
C2 29.6(13) 26.9(15) 32.4(14) -1.0(13) 6.1(11) -3.7(12) 
C3 24.3(12) 22.4(14) 32.7(14) 3.2(12) -3.1(10) -1.1(11) 
C4 30.6(13) 16.3(13) 26.7(12) -1.0(11) 0.4(10) 0.8(11) 
C5 31.7(14) 21.9(14) 31.3(13) 0.4(12) 3.6(11) 2.0(12) 
C6 24.2(12) 22.1(14) 35.2(14) -0.5(13) -1.4(11) -0.2(11) 
C7 31.2(14) 21.0(14) 26.2(13) -0.7(11) 3.0(11) -0.7(11) 
C8 39.1(16) 27.0(17) 29.4(14) -3.0(12) -4.2(12) 6.6(13) 
C9 40.8(16) 23.6(15) 27.7(15) -0.5(12) 1.5(12) 1.4(13) 
C10 29.3(14) 22.8(15) 28.7(13) -1.0(11) 3.1(11) -1.4(11) 
C11 39.4(15) 22.5(15) 31.3(14) -0.7(12) 6.8(12) -7.5(12) 
C12 48.4(18) 18.6(15) 33.5(16) 0.5(11) 4.5(13) -1.9(12) 
C13 41.8(16) 21.5(15) 30.7(15) 0.0(12) 3.7(12) -1.8(12) 
C14 40.4(16) 26.6(17) 29.9(15) -0.9(11) 4.3(12) -2.6(12) 
O1A 38.3(12) 37.7(14) 23.8(10) 1.8(9) 3.7(9) 5.7(10) 
O2A 44.2(13) 47.9(15) 27(1) 1.1(10) -2.4(9) 16.2(11) 
C1A 33.8(14) 22.7(14) 25.4(13) -0.6(12) 3.3(11) -1.0(12) 
C2A 26.3(13) 30.9(16) 30.6(13) 0.5(12) -3.4(10) -1.4(12) 
C3A 30.0(14) 37.0(19) 31.0(14) 1.8(13) 7.1(11) -0.4(13) 
C4A 34.8(14) 21.9(15) 26.1(13) 1.1(11) 3.4(11) 1.0(12) 
C5A 27.2(13) 30.5(16) 30.5(14) 0.3(13) -1(1) 1.4(12) 
C6A 29.4(13) 28.7(16) 30.7(13) -1.3(12) 5.5(11) 0.3(12) 
C7A 31.8(13) 31.4(17) 25.9(13) -3.5(12) 2.4(11) 1.5(13) 
C8A 36.8(15) 28.8(16) 26.7(13) -2.4(12) 3.5(11) -3.5(12) 
C9A 37.0(15) 38.0(19) 29.7(14) -0.4(13) 1.5(12) -10.9(14) 
C10A 31.0(14) 31.6(17) 24.8(13) -0.9(11) 1.4(11) 2.2(13) 
C11A 32.6(14) 36.4(18) 29.9(14) -2.6(13) -1.2(11) -4.7(14) 
C12A 50.0(19) 27.0(17) 30.9(15) -8.0(12) 4.4(13) -9.9(14) 
C13A 54.3(19) 27.5(17) 33.1(16) -3.2(13) 7.3(14) -9.9(15) 
C14A 45.1(18) 37.3(19) 28.1(15) -1.3(13) 2.3(13) 7.5(14) 
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Table 4 Bond Lengths for don2d. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C4 1.384(3)   O1A C4A 1.384(3) 
O2 C14 1.438(4)   O2A C14A 1.430(4) 
C1 C2 1.402(4)   C1A C2A 1.394(4) 
C1 C6 1.384(4)   C1A C6A 1.389(4) 
C1 C7 1.521(4)   C1A C7A 1.520(4) 
C2 C3 1.397(4)   C2A C3A 1.396(4) 
C3 C4 1.384(4)   C3A C4A 1.387(4) 
C4 C5 1.392(4)   C4A C5A 1.384(4) 
C5 C6 1.393(4)   C5A C6A 1.397(4) 
C7 C8 1.537(4)   C7A C8A 1.535(5) 
C7 C13 1.542(4)   C7A C13A 1.532(4) 
C8 C9 1.539(4)   C8A C9A 1.527(4) 
C9 C10 1.539(4)   C9A C10A 1.555(4) 
C10 C11 1.526(4)   C10A C11A 1.530(4) 
C10 C14 1.531(4)   C10A C14A 1.521(4) 
C11 C12 1.532(4)   C11A C12A 1.536(5) 
C12 C13 1.528(4)   C12A C13A 1.535(4) 
  
Table 5 Bond Angles for don2d. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 C1 C7 121.0(3)   C2A C1A C7A 122.5(2) 
C6 C1 C2 117.2(3)   C6A C1A C2A 117.9(2) 
C6 C1 C7 121.7(3)   C6A C1A C7A 119.5(2) 
C3 C2 C1 121.2(3)   C1A C2A C3A 120.9(3) 
C4 C3 C2 120.1(2)   C4A C3A C2A 119.8(3) 
O1 C4 C5 118.5(2)   O1A C4A C3A 117.7(3) 
C3 C4 O1 121.9(2)   C5A C4A O1A 121.7(3) 
C3 C4 C5 119.6(2)   C5A C4A C3A 120.6(2) 
C4 C5 C6 119.4(3)   C4A C5A C6A 118.7(3) 
C1 C6 C5 122.4(3)   C1A C6A C5A 122.1(3) 
C1 C7 C8 110.5(2)   C1A C7A C8A 111.6(3) 
C1 C7 C13 110.3(2)   C1A C7A C13A 111.4(3) 
C8 C7 C13 111.2(2)   C13A C7A C8A 114.8(3) 
C7 C8 C9 117.0(2)   C9A C8A C7A 113.6(3) 
C8 C9 C10 117.6(3)   C8A C9A C10A 118.4(3) 
C11 C10 C9 114.9(3)   C11A C10A C9A 116.0(2) 
C11 C10 C14 110.1(2)   C14A C10A C9A 108.6(3) 
C14 C10 C9 109.0(2)   C14A C10A C11A 110.5(3) 
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C10 C11 C12 113.1(2)   C10A C11A C12A 114.6(2) 
C13 C12 C11 117.0(3)   C13A C12A C11A 115.4(3) 
C12 C13 C7 117.7(2)   C7A C13A C12A 115.7(3) 
O2 C14 C10 112.7(2)   O2A C14A C10A 113.4(3) 
  
Table 6 Torsion Angles for don2d. 
A B C D Angle/˚   A B C D Angle/˚ 
O1 C4 C5 C6 -178.6(3)   O1A C4A C5A C6A -179.9(3) 
C1 C2 C3 C4 -0.5(5)   C1A C2A C3A C4A -0.7(5) 
C1 C7 C8 C9 -152.1(3)   C1A C7A C8A C9A -153.1(2) 
C1 C7 C13 C12 171.7(3)   C1A C7A C13A C12A 175.5(3) 
C2 C1 C6 C5 1.4(5)   C2A C1A C6A C5A -0.2(5) 
C2 C1 C7 C8 -52.0(4)   C2A C1A C7A C8A -78.5(4) 
C2 C1 C7 C13 71.3(4)   C2A C1A C7A C13A 51.2(4) 
C2 C3 C4 O1 179.4(3)   C2A C3A C4A O1A -179.6(3) 
C2 C3 C4 C5 0.4(5)   C2A C3A C4A C5A 0.1(5) 
C3 C4 C5 C6 0.5(5)   C3A C4A C5A C6A 0.4(5) 
C4 C5 C6 C1 -1.5(5)   C4A C5A C6A C1A -0.4(5) 
C6 C1 C2 C3 -0.4(5)   C6A C1A C2A C3A 0.8(5) 
C6 C1 C7 C8 128.3(3)   C6A C1A C7A C8A 99.7(3) 
C6 C1 C7 C13 -108.4(3)   C6A C1A C7A C13A -130.5(3) 
C7 C1 C2 C3 179.9(3)   C7A C1A C2A C3A 179.0(3) 
C7 C1 C6 C5 -178.9(3)   C7A C1A C6A C5A -178.5(3) 
C7 C8 C9 C10 -46.7(4)   C7A C8A C9A C10A -77.5(4) 
C8 C7 C13 C12 -65.4(3)   C8A C7A C13A C12A -56.5(4) 
C8 C9 C10 C11 -31.4(4)   C8A C9A C10A C11A 16.0(4) 
C8 C9 C10 C14 -155.6(3)   C8A C9A C10A C14A -109.1(3) 
C9 C10 C11 C12 83.1(3)   C9A C10A C11A C12A 56.6(4) 
C9 C10 C14 O2 -59.6(3)   C9A C10A C14A O2A -175.4(3) 
C10 C11 C12 C13 -73.8(4)   C10A C11A C12A C13A -86.4(3) 
C11 C10 C14 O2 173.4(2)   C11A C10A C14A O2A 56.3(3) 
C11 C12 C13 C7 53.9(4)   C11A C12A C13A C7A 64.3(4) 
C13 C7 C8 C9 85.1(3)   C13A C7A C8A C9A 79.0(3) 
C14 C10 C11 C12 -153.3(3)   C14A C10A C11A C12A -179.3(3) 
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Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for don2d. 
Atom x y z U(eq) 
H1 3290(40) 4440(40) 1220(30) 23(9) 
H2 6610(40) 7460(50) 9600(40) 52(12) 
H2A 3031 4088 4850 36 
H3 2381 4032 2890 34 
H5 6375 4181 2730 35 
H6 7007 4176 4685 34 
H7 6529 4375 6479 32 
H8A 3864 4938 6802 40 
H8B 4570 6006 6159 40 
H9A 4807 6457 8120 38 
H9B 6215 6488 7719 38 
H10 7081 4760 8744 33 
H11A 4383 3781 8563 38 
H11B 5582 3266 9567 38 
H12A 6820 2605 8158 41 
H12B 5502 1741 8200 41 
H13A 4259 2685 6576 38 
H13B 5667 2149 6346 38 
H14A 5275 5874 10012 39 
H14B 6610 5030 10554 39 
H1A -1140(50) 6720(50) 1020(30) 57(13) 
H2AA 900(50) 5610(60) 10900(40) 79(16) 
H2AB 1826 6643 4910 37 
H3A 1685 6566 2973 39 
H5A -2461 6739 2394 37 
H6A -2298 6850 4332 36 
H7A -1115 7095 6145 36 
H8AA -403 4768 6034 38 
H8AB 1027 5235 6806 38 
H9AA -674 4316 7761 43 
H9AB -1481 5671 7476 43 
H10A -415 6324 9125 36 
H11C 2095 6410 8387 41 
H11D 1798 7189 9442 41 
H12C -71 8281 8005 44 
H12D 1464 8815 8196 44 
H13C 577 8707 6282 46 
H13D 1752 7618 6592 46 
H14C 120 4122 9614 45 
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H14D 1523 4245 9203 45 
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Table 1 Crystal data and structure refinement for ISP163-PK4. 
Identification code ISP163-PK4 (don2c) 
Empirical formula C14H20O2 
Formula weight 220.30 
Temperature/K 99.90(14) 
Crystal system monoclinic 
Space group P21 
a/Å 10.0043(3) 
b/Å 10.1405(4) 
c/Å 12.2188(3) 
α/° 90.00 
β/° 103.121(3) 
γ/° 90.00 
Volume/Å3 1207.22(6) 
Z 4 
ρcalcg/cm3 1.212 
μ/mm-1 0.623 
F(000) 480.0 
Crystal size/mm3 0.8254 × 0.4513 × 0.0546 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 7.42 to 148.64 
Index ranges -12 ≤ h ≤ 12, -12 ≤ k ≤ 12, -15 ≤ l ≤ 14 
Reflections collected 7992 
Independent reflections 7992 [Rint = 0.0000, Rsigma = 0.0091] 
Data/restraints/parameters 7992/1/306 
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for don2c. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 6036.6(17) 5934.1(17) 8540.7(12) 24.9(3) 
O2 2970.2(16) 3174.2(18) -54.6(13) 27.7(4) 
C1 4897(2) 5849(2) 5011.7(18) 21.2(4) 
C2 6281(2) 5899(2) 5572.3(18) 23.3(4) 
C3 6675(2) 5927(2) 6742.1(18) 23.8(4) 
C4 5689(2) 5899(2) 7383.4(17) 21.3(4) 
C5 4305(2) 5854(2) 6841.0(17) 23.2(4) 
C6 3924(2) 5837(2) 5673.1(18) 23.1(4) 
C7 4475(2) 5811(2) 3739.4(17) 21.4(4) 
C8 5250(3) 4704(3) 3278.6(19) 28.7(5) 
C9 4522(2) 4099(2) 2145.5(19) 26.1(5) 
C10 3877(2) 5049(2) 1185.7(18) 22.2(4) 
C11 4614(2) 6376(2) 1204.0(19) 26.3(5) 
C12 4188(3) 7377(2) 1996(2) 28.6(5) 
C13 4737(3) 7167(2) 3257.9(19) 26.8(5) 
C14 3795(2) 4357(2) 61.7(18) 25.3(5) 
O1A 426.7(18) 3417.3(18) 8623.7(13) 27.1(4) 
O2A -1557(2) 4841(2) -642.8(14) 34.3(4) 
C1A 231(2) 3231(2) 5173.3(17) 22.8(4) 
C2A -958(2) 3335(3) 5590.8(18) 26.2(5) 
C3A -870(2) 3392(3) 6746.1(18) 25.5(5) 
C4A 402(2) 3353(2) 7495.6(18) 23.4(4) 
C5A 1600(2) 3268(3) 7099.3(18) 25.3(5) 
C6A 1490(2) 3208(2) 5941.9(19) 24.6(5) 
C7A 195(2) 3181(2) 3924.1(18) 24.2(5) 
C8A -34(2) 4575(2) 3395.9(17) 24.6(5) 
C9A 555(2) 4725(3) 2352.1(18) 27.8(5) 
C10A -258(2) 4136(3) 1229.4(18) 25.9(5) 
C11A -1378(2) 3137(3) 1319.4(19) 29.3(5) 
C12A -863(3) 1944(3) 2073.4(19) 30.9(5) 
C13A -837(3) 2150(3) 3320.6(19) 30.7(5) 
C14A -863(3) 5270(3) 452.9(19) 30.9(5) 
Goodness-of-fit on F2 1.062 
Final R indexes [I>=2σ (I)] R1 = 0.0688, wR2 = 0.1938 
Final R indexes [all data] R1 = 0.0696, wR2 = 0.1948 
Largest diff. peak/hole / e Å-3 0.48/-0.25 
Flack parameter -0.1(2) 
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Table 3 Anisotropic Displacement Parameters (Å2×103) for don2c. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
O1 31.0(8) 18.9(9) 22.6(7) 0.7(6) 1.2(6) 2.3(7) 
O2 33.2(8) 16.8(9) 28.5(8) -1.0(6) -2.3(6) -2.8(7) 
C1 26.4(10) 11.0(9) 23.4(9) 0.3(8) 0.0(7) -2.0(8) 
C2 25.4(10) 16.9(11) 26.8(10) 1.1(9) 4.1(8) -1.3(9) 
C3 22.6(10) 17.9(12) 27.6(10) 0.8(9) -1.2(8) -2.1(9) 
C4 28.4(11) 9.7(10) 23.4(9) 0.1(8) 0.9(8) 1.3(8) 
C5 26.5(10) 16.0(11) 26.5(10) 1.1(9) 4.9(8) 0.3(9) 
C6 21.7(10) 16.3(11) 28.6(10) 1.2(9) 0.6(8) 0.5(8) 
C7 24.6(10) 14.6(10) 22.2(9) -0.7(8) -0.6(7) -1.7(8) 
C8 37.4(13) 19.3(12) 25.3(10) -1.5(9) -1.6(9) 4.4(10) 
C9 34.8(12) 14.6(12) 26.4(10) -0.4(9) 2.0(8) 2.6(10) 
C10 25.3(10) 16.5(12) 23.9(9) 0.2(8) 3.5(8) -1.2(8) 
C11 35.2(11) 16.5(11) 26.7(10) 0.5(8) 6.3(9) -5.4(10) 
C12 44.0(14) 12.9(12) 26.9(11) 2.3(8) 4(1) 0.8(10) 
C13 38.0(12) 15.0(11) 25.2(10) 0.1(8) 2.6(9) -0.9(9) 
C14 32.5(12) 17.6(12) 24.1(10) -0.6(8) 2.8(8) -3.7(9) 
O1A 31.3(9) 27.7(10) 21.2(7) 0.4(7) 3.8(6) 4.3(7) 
O2A 37.8(10) 37.4(11) 23.4(8) -1.3(7) -2.0(7) 14.4(9) 
C1A 29.6(11) 14.5(11) 22.7(10) 0.1(8) 2.5(8) -0.1(9) 
C2A 25(1) 22.9(12) 27.6(10) 1.2(9) -0.2(8) 1.3(9) 
C3A 24.6(11) 24.2(13) 27.3(10) 1.4(10) 5.2(8) 2.6(9) 
C4A 29.4(11) 16.3(11) 23.5(10) -0.1(9) 4.2(8) 1.7(9) 
C5A 26.1(10) 21.6(12) 26.2(10) -1.7(9) 1.6(8) 1.4(9) 
C6A 25.1(10) 21.1(12) 27(1) -1.1(9) 4.4(8) 0.1(9) 
C7A 27.5(10) 20.4(12) 23.3(10) -1.0(8) 2.6(8) 0.1(9) 
C8A 29.4(11) 19.3(12) 22.6(9) -1.1(8) 0.9(8) -2.1(9) 
C9A 30.3(11) 27.9(13) 22.5(9) 0.9(9) 0.4(8) -6.7(10) 
C10A 29.0(11) 25.1(13) 21.4(9) -1.4(9) 1.2(8) 0.3(10) 
C11A 29.1(11) 29.2(14) 26.3(10) -3.2(10) -0.8(8) -4.9(10) 
C12A 43.7(14) 20.7(13) 26.2(10) -4.3(9) 3.3(9) -7.3(10) 
C13A 43.7(13) 20.1(12) 27.3(11) -1.9(9) 6.1(9) -6.4(10) 
C14A 41.6(13) 25.0(13) 22.8(10) 0.7(9) 0.8(9) 6.6(11) 
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Table 4 Bond Lengths for don2c. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C4 1.378(2)   O1A C4A 1.374(3) 
O2 C14 1.445(3)   O2A C14A 1.429(3) 
C1 C2 1.399(3)   C1A C2A 1.400(3) 
C1 C6 1.399(3)   C1A C6A 1.390(3) 
C1 C7 1.516(3)   C1A C7A 1.519(3) 
C2 C3 1.394(3)   C2A C3A 1.395(3) 
C3 C4 1.392(3)   C3A C4A 1.389(3) 
C4 C5 1.394(3)   C4A C5A 1.394(3) 
C5 C6 1.391(3)   C5A C6A 1.395(3) 
C7 C8 1.541(3)   C7A C8A 1.549(3) 
C7 C13 1.542(3)   C7A C13A 1.535(3) 
C8 C9 1.539(3)   C8A C9A 1.529(3) 
C9 C10 1.542(3)   C9A C10A 1.547(3) 
C10 C11 1.532(3)   C10A C11A 1.533(3) 
C10 C14 1.528(3)   C10A C14A 1.526(3) 
C11 C12 1.529(3)   C11A C12A 1.537(4) 
C12 C13 1.530(3)   C12A C13A 1.533(3) 
  
Table 5 Bond Angles for don2c. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 C1 C6 117.27(19)   C2A C1A C7A 122.69(18) 
C2 C1 C7 121.2(2)   C6A C1A C2A 118.0(2) 
C6 C1 C7 121.6(2)   C6A C1A C7A 119.3(2) 
C3 C2 C1 121.4(2)   C3A C2A C1A 120.51(19) 
C4 C3 C2 120.35(19)   C4A C3A C2A 120.3(2) 
O1 C4 C3 122.08(19)   O1A C4A C3A 117.7(2) 
O1 C4 C5 118.74(19)   O1A C4A C5A 122.00(19) 
C3 C4 C5 119.17(19)   C3A C4A C5A 120.2(2) 
C6 C5 C4 119.9(2)   C4A C5A C6A 118.6(2) 
C5 C6 C1 121.9(2)   C1A C6A C5A 122.3(2) 
C1 C7 C8 110.28(19)   C1A C7A C8A 110.80(19) 
C1 C7 C13 109.68(18)   C1A C7A C13A 111.45(19) 
C8 C7 C13 111.50(19)   C13A C7A C8A 113.69(19) 
C9 C8 C7 116.41(19)   C9A C8A C7A 113.0(2) 
C8 C9 C10 117.8(2)   C8A C9A C10A 118.4(2) 
C11 C10 C9 114.86(19)   C11A C10A C9A 115.93(19) 
C14 C10 C9 108.95(19)   C14A C10A C9A 108.4(2) 
C14 C10 C11 110.07(18)   C14A C10A C11A 110.43(19) 
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C12 C11 C10 112.95(19)   C10A C11A C12A 114.32(19) 
C11 C12 C13 117.2(2)   C13A C12A C11A 114.6(2) 
C12 C13 C7 117.11(19)   C12A C13A C7A 115.3(2) 
O2 C14 C10 112.46(18)   O2A C14A C10A 113.1(2) 
  
Table 6 Hydrogen Bonds for don2c. 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O1 H1 O2A1 0.90(4) 1.74(4) 2.632(2) 172(3) 
O2 H2 O12 0.91(4) 2.08(4) 2.955(2) 161(4) 
O1A H1A O23 0.79(4) 1.91(4) 2.698(2) 172(5) 
O2A H2AB O1A4 0.80(4) 1.96(5) 2.763(3) 177(4) 
11+X,+Y,1+Z; 21-X,-1/2+Y,1-Z; 3+X,+Y,1+Z; 4+X,+Y,-1+Z 
  
Table 7 Torsion Angles for don2c. 
A B C D Angle/˚   A B C D Angle/˚ 
O1 C4 C5 C6 179.0(2)   O1A C4A C5A C6A -179.9(2) 
C1 C2 C3 C4 0.3(4)   C1A C2A C3A C4A 0.3(4) 
C1 C7 C8 C9 152.3(2)   C1A C7A C8A C9A 153.47(19) 
C1 C7 C13 C12 -171.6(2)   C1A C7A C13A C12A -175.2(2) 
C2 C1 C6 C5 -1.0(3)   C2A C1A C6A C5A 0.8(4) 
C2 C1 C7 C8 51.7(3)   C2A C1A C7A C8A 77.9(3) 
C2 C1 C7 C13 -71.5(3)   C2A C1A C7A C13A -49.8(3) 
C2 C3 C4 O1 -179.5(2)   C2A C3A C4A O1A 179.8(2) 
C2 C3 C4 C5 -0.6(3)   C2A C3A C4A C5A 0.6(4) 
C3 C4 C5 C6 0.0(3)   C3A C4A C5A C6A -0.7(4) 
C4 C5 C6 C1 0.8(4)   C4A C5A C6A C1A 0.0(4) 
C6 C1 C2 C3 0.4(4)   C6A C1A C2A C3A -0.9(4) 
C6 C1 C7 C8 -128.5(2)   C6A C1A C7A C8A -100.5(3) 
C6 C1 C7 C13 108.4(2)   C6A C1A C7A C13A 131.8(3) 
C7 C1 C2 C3 -179.7(2)   C7A C1A C2A C3A -179.3(2) 
C7 C1 C6 C5 179.1(2)   C7A C1A C6A C5A 179.2(2) 
C7 C8 C9 C10 46.8(3)   C7A C8A C9A C10A 77.8(3) 
C8 C7 C13 C12 65.9(3)   C8A C7A C13A C12A 58.7(3) 
C8 C9 C10 C11 31.0(3)   C8A C9A C10A C11A -15.9(3) 
C8 C9 C10 C14 155.0(2)   C8A C9A C10A C14A 108.9(3) 
C9 C10 C11 C12 -83.0(2)   C9A C10A C11A C12A -57.1(3) 
C9 C10 C14 O2 60.0(2)   C9A C10A C14A O2A 175.8(2) 
C10 C11 C12 C13 74.1(3)   C10A C11A C12A C13A 87.4(3) 
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C11 C10 C14 O2 
-
173.22(18) 
  C11A C10A C14A O2A -56.2(3) 
C11 C12 C13 C7 -54.2(3)   C11A C12A C13A C7A -66.4(3) 
C13 C7 C8 C9 -85.6(3)   C13A C7A C8A C9A -80.1(3) 
C14 C10 C11 C12 153.6(2)   C14A C10A C11A C12A 179.2(2) 
  
Table 8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for don2c. 
Atom x y z U(eq) 
H1 6860(40) 5540(40) 8760(30) 39(9) 
H2 3360(40) 2640(40) 530(30) 48(10) 
H2A 6966 5915 5147 28 
H3 7621 5966 7104 29 
H5 3621 5834 7269 28 
H6 2977 5818 5314 28 
H7 3469 5619 3514 26 
H8A 6145 5059 3200 34 
H8B 5441 3989 3844 34 
H9A 3787 3510 2282 31 
H9B 5194 3539 1879 31 
H10 2916 5235 1250 27 
H11A 5617 6229 1440 32 
H11B 4415 6744 434 32 
H12A 3173 7386 1844 34 
H12B 4483 8262 1802 34 
H13A 4330 7850 3661 32 
H13B 5741 7319 3432 32 
H14A 3400 4972 -556 30 
H14B 4734 4127 -8 30 
H1A 1180(40) 3290(50) 8980(40) 61(12) 
H2AB -970(40) 4420(50) -830(30) 59(12) 
H2AA -1831 3365 5084 31 
H3A -1682 3458 7021 31 
H5A 2473 3251 7607 30 
H6A 2305 3150 5669 30 
H7A 1124 2884 3851 29 
H8AA -1031 4762 3190 29 
H8AB 400 5235 3963 29 
H9AA 1481 4322 2521 33 
H9AB 677 5679 2233 33 
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H10A 417 3671 874 31 
H11C -1810 2815 556 35 
H11D -2096 3594 1617 35 
H12C -1457 1178 1797 37 
H12D 77 1724 2000 37 
H13C -625 1295 3713 37 
H13D -1767 2416 3388 37 
H14C -1517 5764 797 37 
H14D -115 5881 382 37 
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Table 1 Crystal data and structure refinement for ISP358-2. 
Identification code ISP358-2 (don2f) 
Empirical formula C13H18O2 
Formula weight 206.27 
Temperature/K 100.00(10) 
Crystal system orthorhombic 
Space group Pbca 
a/Å 12.0669(2) 
b/Å 8.09601(18) 
c/Å 22.4321(4) 
α/° 90.00 
β/° 90.00 
γ/° 90.00 
Volume/Å3 2191.46(7) 
Z 8 
ρcalcg/cm3 1.250 
μ/mm-1 0.653 
F(000) 896.0 
Crystal size/mm3 0.25 × 0.15 × 0.01 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 7.88 to 148.36 
Index ranges -10 ≤ h ≤ 14, -9 ≤ k ≤ 8, -19 ≤ l ≤ 27 
Reflections collected 9115 
Independent reflections 2181 [Rint = 0.0318, Rsigma = 0.0235] 
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Data/restraints/parameters 2181/0/138 
Goodness-of-fit on F2 1.043 
Final R indexes [I>=2σ (I)] R1 = 0.0414, wR2 = 0.1109 
Final R indexes [all data] R1 = 0.0503, wR2 = 0.1190 
Largest diff. peak/hole / e Å-3 0.23/-0.20 
 
 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for don2f. Ueq is defined as 1/3 of of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 6398.2(8) 5568.4(12) 5152.2(4) 27.0(2) 
O2 6894.3(8) 2635.2(13) 9776.1(4) 30.9(3) 
C1 6163.1(10) 5414.5(15) 7017.2(5) 21.2(3) 
C2 6978.5(11) 6355.0(17) 6734.5(6) 25.2(3) 
C3 7075.8(11) 6425.1(17) 6119.5(6) 25.5(3) 
C4 6335.5(11) 5541.8(15) 5766.6(6) 22.5(3) 
C5 5517.3(11) 4598.7(16) 6031.9(6) 24.9(3) 
C6 5437.1(11) 4537.3(16) 6652.7(6) 24.0(3) 
C7 6135.1(10) 5371.5(15) 7694.9(5) 21.4(3) 
C8 7066.4(11) 4283.3(17) 7941.1(6) 24.6(3) 
C9 7105.2(11) 4268.6(17) 8619.6(5) 23.8(3) 
C10 5996.7(11) 3692.7(16) 8874.8(6) 23.5(3) 
C11 5066.9(11) 4813.0(18) 8648.1(6) 26.6(3) 
C12 5026.6(10) 4848.1(18) 7965.8(6) 25.7(3) 
C13 6009.6(12) 3638.7(18) 9550.2(6) 28.0(3) 
 
Table 3 Anisotropic Displacement Parameters (Å2×103) for don2f. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
O1 30.6(5) 30.7(5) 19.9(5) -1.3(4) -0.7(4) -3.2(4) 
O2 37.5(6) 28.1(5) 27.0(5) 5.6(4) -5.5(4) -3.4(4) 
C1 20.6(6) 20.6(6) 22.4(6) -0.1(5) -0.7(5) 2.8(5) 
C2 24.5(6) 27.4(7) 23.7(7) -2.7(5) -2.6(5) -5.7(5) 
C3 25.5(6) 26.7(7) 24.4(7) 0.5(5) 1.3(5) -4.5(5) 
C4 25.0(6) 22.4(6) 20.0(6) -1.6(5) -1.5(5) 4.8(5) 
C5 25.0(7) 23.8(6) 26.1(7) -2.6(5) -4.4(5) -1.7(5) 
C6 22.1(6) 23.7(6) 26.1(7) 1.1(5) -0.9(5) -1.3(5) 
C7 20.0(6) 22.9(6) 21.2(6) -0.1(5) -0.7(5) -1.3(5) 
C8 21.9(6) 29.4(7) 22.6(6) 1.0(5) 2.4(5) 4.0(5) 
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Table 4 Bond Lengths for don2f. 
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C4 1.3805(15)   C5 C6 1.3967(18) 
O2 C13 1.4340(17)   C7 C8 1.5310(17) 
C1 C2 1.3964(18)   C7 C12 1.5291(17) 
C1 C6 1.3931(18)   C8 C9 1.5226(17) 
C1 C7 1.5209(16)   C9 C10 1.5279(18) 
C2 C3 1.3858(18)   C10 C11 1.5297(18) 
C3 C4 1.3915(18)   C10 C13 1.5159(17) 
C4 C5 1.3827(19)   C11 C12 1.5315(17) 
 
Table 5 Bond Angles for don2f. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C2 C1 C7 118.82(11)   C1 C7 C12 115.03(11) 
C6 C1 C2 117.03(12)   C12 C7 C8 109.83(10) 
C6 C1 C7 124.13(12)   C9 C8 C7 112.81(10) 
C3 C2 C1 122.29(12)   C8 C9 C10 110.49(11) 
C2 C3 C4 119.40(12)   C9 C10 C11 109.67(11) 
O1 C4 C3 121.65(12)   C13 C10 C9 111.98(11) 
O1 C4 C5 118.52(11)   C13 C10 C11 110.91(11) 
C5 C4 C3 119.83(12)   C10 C11 C12 111.50(11) 
C4 C5 C6 119.88(12)   C7 C12 C11 111.99(11) 
C1 C6 C5 121.57(12)   O2 C13 C10 112.15(11) 
C1 C7 C8 110.94(10)           
 
Table 6 Hydrogen Bonds for don2f. 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O1 H1 O21 0.84 1.82 2.6594(14) 172.7 
O2 H2 O12 0.84 1.97 2.7924(14) 165.1 
13/2-X,1-Y,-1/2+Z; 2+X,1/2-Y,1/2+Z 
C9 22.7(6) 26.6(7) 22.1(6) 1.8(5) -1.7(5) 1.8(5) 
C10 26.2(7) 22.2(6) 22.2(6) -0.7(5) 0.4(5) -2.5(5) 
C11 22.9(7) 31.3(7) 25.5(7) 0.9(5) 3.4(5) -0.7(5) 
C12 19.7(6) 32.2(7) 25.1(7) 1.5(5) -0.5(5) -0.4(5) 
C13 30.4(7) 29.3(7) 24.1(7) 0.5(5) 1.4(5) -2.6(6) 
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Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for don2f. 
Atom x y z U(eq) 
H1 6910 6208 5046 41 
H2 6660 1674 9839 46 
H2A 7484 6968 6972 30 
H3 7643 7070 5940 31 
H5 5011 3994 5792 30 
H6 4874 3882 6830 29 
H7 6284 6522 7836 26 
H8A 6962 3139 7796 30 
H8B 7785 4688 7786 30 
H9A 7274 5393 8768 29 
H9B 7702 3519 8755 29 
H10 5852 2549 8726 28 
H11A 5184 5948 8800 32 
H11B 4348 4412 8804 32 
H12A 4828 3736 7816 31 
H12B 4442 5627 7836 31 
H13A 6090 4776 9707 34 
H13B 5294 3195 9695 34 
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